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Acrocentric chromosomes:  Chromosomes lacking the short arm. The human acro-
centric chromosomes are 13, 14, 15, 21, and 22.
Congenital malformation: A physical defect present in the newborn.
Copy number:   The number of copies of a given chromosomal locus. 
Copy number variation:  Alteration of a copy number of a certain DNA sequence 
in relation to the normal situation. 
  with phenotypic trait: variation with clinical consequences.
  without phenotypic trait:   variation without obvious clinical consequences (also 
called Polymorphic CNVs).
Deletion: Loss of a DNA sequence.
Duplication: An extra copy of a DNA sequence.
Duplicon:  Duplicon or segmental duplication has been defined as 
sequences of DNA greater than 1 Kb in size sharing a 
homology of at least 90 %.  
False positive result: An incorrect positive result of a test.
False negative result:  A result that appears negative but fails to reveal an al-
teration.
Gene: Coding sequence.
Gene desert:  Region in the human genome that does not contain 
genes.
Genomic disorders:  The clinical condition that results from a dosage altera-
tion of gene(s) located within a rearranged segment of 
the genome.
Mendelian inheritance:  Several inheritable traits or congenital conditions in hu-
mans are classical examples of Mendelian inheritance: 
Their presence is controlled by a single gene that can 
either be of the autosomal-dominant or -recessive type. 
People that inherited at least one dominant gene from 
either parent usually present with the dominant form 
of the trait. Only those that received the recessive gene 
from both parents present with the recessive phenotype 
(Wikipedia).
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Mental retardation (MR) classification:  Mild MR (intelligent quotient (IQ) between
  50 and 70), moderate MR (IQ between 35 and 50), 
severe MR (IQ between 20 and 35) and profound MR 
(IQ below 20).
Polymorphic CNVs:   CNVs (deletions as well as duplications) that are not re-
lated to a clinical phenotype (also called CNVs without 
phenotypic trait).
Phenotypic trait:   Any (abnormal) clinical feature, such as mental retarda-
tion, congenital malformations, dysmorphologies.
Translocations:  Exchange of genetic material between two different 
chromosomes.
Robertsonian translocations:  These translocations are produced by exchange in proxi-
mal short arms of the acrocentric chromosomes. Both 
centromeres are present, however, they function as one 
unit. This translocation is named after W.R.B. Robert-
son who described fusion of acrocentric chromosomes 
in insects. 
Reciprocal translocations:  A translocation where part of one chromosome is ex-
changed with a part of a separate non-homologous 
chromosome.
Transposition:  Transfer of a segment of DNA to a new position on the 
same or another chromosome.
Uniparental disomy:  A euploid cell in which one of the chromosome pairs 
have been inherited exclusively from one parent. If two 
identical homologues are inherited this called isodiso-
my; if non-identical homologues are inherited the term 
heterodisomy is used. This occurs when non-disjunc-
tion during meiosis in one parent leads to formation 
of a disomic gamete. A trisomic zygote is formed and 
trisomic rescue with loss of the chromosome from the 
other parent occurs. UPD is of particular relevance in 




BAC Bacterial Artificial Chromosome
CGH Comparitive Genome Hybridisation
CM Congenital Malformation
CNVs Copy Number Variation
COBRA COmbined Binary RAtio 
DD Development Delay
DNA Deoxyribonucleic acid
DOP-PCR  Degenerate Oligonucleotide Primed Polymerase Chain 
Reaction
FISH Fluorescent in Situ Hybridisation
I.Q. Intelligence Quotient
K Kilo 
Kb Kilo base (one thousand base pairs)
LCR Low Copy Repeat
MAPH Multiplex Amplifiable Probe Hybridisation
Mb Mega base (one million base pairs)
M-FISH Multi-colour FISH
MLPA Multiplex Ligation-dependent Probe Amplification
MR Mental Retardation
NAHR Non Allelic Homologous Recombination
Nt Nucleotide
PAC P1 derived Artificial Chromosome (PAC)
PCR Polymerase Chain Reaction
PFGE PulseField Gel Electrophoresis
RFLP Restriction Fragment Length Polymorphism
SKY Spectral Karyotyping
SNP Single Nucleotide Polymorphism
UPD Uniparental Disomy







i-1. the Plasticity of the human genome
Many authors have discussed the significance of gene and whole genome duplication in 
evolution (these publications are reviewed in (Taylor and Raes 2004)). Indeed, Ohno 
(1970) (in Evolution by gene duplication. New York: Springler-Verlag) stated that du-
plications of the genetic material were the most important factor driving evolution. Re-
cently, projects using genome sequencing have shown that large scale gene duplications 
have contributed to the creation and expansion of gene families. Whether a duplication is 
passed onto future generations depends on whether the change is beneficial for survival. 
One example is the olfactory gene family. These (pseudo)genes create a redundancy of se-
quences contributing to the ability to smell, which appears to be beneficial for mammali-
an survival. A more recent example was published by Perry et al. (2007). They found that 
the copy number of the AMY1 gene is positively correlated with the amount of starch in 
a diet. We have also learned that the susceptibility of developing a disease is influenced by 
changes in CNVs. It has been shown that altered copy number of the CCL3L1 and FC-
GR3B genes influence susceptibility to HIV infection and systemic lupus erythematosus 
(SLE), respectively (Gonzalez et al. 2005; Aitman et al. 2006). These examples indicate 
that selection may operate on copy number variants containing sequences that are coding 
or regulating functions involved in survival. 
 A substantial proportion of (partial) gene duplications are gathered in segmental du-
plications (chapter II-1). Segmental duplications presumably originated from the du-
plication and subsequent transposition (and / or inversion) of genomic blocks (Eichler 
2001a) from one chromosomal region to another some tens of million years ago (Bailey 
et al. 2002b; Armengol et al. 2003). It appears that these segmental duplications are often 
present at (breakpoint) loci where the human genome differs from that of the great apes 
(Samonte and Eichler 2002a) (Stankiewicz et al. 2001; Locke et al. 2003) and other spe-
cies, such as mice (Armengol et al. 2003).
 Besides duplications of existing sequences, another frequent form of variation in the 
human genome is deletion of unique sequences. In fact, it has been shown that these 
deletions are quite common in the human genome, with each individual having at least 
30-50 deletions larger than 5 kb (Conrad et al. 2006). Van Ommen (2005) estimated 
that one in eight live births may have a de novo deletion. Some of these may enhance 
adaptation to environmental changes and might therefore be beneficial for survival. It is 
assumed that these deletion polymorphisms are exposed to more strict selection than 
Single Nucleotide Polymorphisms (SNPs), based on the fact that the X-chromosome
contains less deletion polymorphisms compared to SNPs (Conrad et al. 2006).
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 In contrast to their potentially positive role in evolution, duplications and deletions 
(e.g. copy number variations = CNVs) (figure 1 A&B) in the human genome can also be 
related to inherited disease, mental retardation (MR), and congenital malformations 
(CM). For decades, it has been clear that numerical chromosome aberrations (e.g. triso-
my 13, 18 and 21) and large CNVs have enormous influence on embryonic develop-
ment and can lead to malformation syndromes or intra-uterine death. More recently, a 
systematic search for submicroscopic CNVs leading to MR and CM was initiated by 
Flint et al. (1995). These authors focused on the chromosome ends (also called the sub-
telomeres) and they found the percentage of alterations in their MR study population to 
be around 6%. Since that time, many different screening tools have been successfully 
implemented to find such cryptic (subtelomeric) CNVs (table 1). Detecting small CNVs 
on a genome-wide scale has only recently become possible with the development of mi-
cro-arrays. First results indicate that many CNVs are detected in patients with MR and 
CM (CNVs with phenotypic trait) as well as in healthy individuals (CNVs without an 
obvious phenotypic trait). In the most comprehensive CNV study to date no less than 
12% of the human genome showed variations among healthy individuals (Redon et al. 
2006). Consequently, our main challenge is currently to determine whether a variation is 
related to a phenotypic trait or not. This will remain so in the near future until the com-
plete plasticity of the human genome has been fully mapped.
 In short, copy number variations (CNVs) in the human genome are inherent in both 
evolutionary progression as well as the etiology of disease. The introduction of this thesis 
will review CNVs that appear to be neutral as well as CNVs that appear to be related to 
a phenotypic trait. This will be followed by a review of the many different technical ap-
proaches that can be used for detecting genomic rearrangements. 
 The articles (chapter II & III) describe several studies that have applied the rapidly 
evolving techniques for CNV detection to the clinical problem of unexplained MR and 
CM. The availability of the new diagnostic tools will greatly increase our understanding 
of the genetic causes of MR and CM, and might one day lead to therapeutic interven-
tions in some cases.
i-2. cnVs with no obVious PhenotyPic trait
2.1. Neutral CNVs 
Copy number variants have been identified since the start of the cloning era, however, 
the full extent of the variability and plasticity of the human genome has only recently 
14
Chapter I
been appreciated (Iafrate et al. 2004; Sebat et al. 2004; Fredman et al. 2004). Sebat et al. 
(2004) presented the first study assessing the frequency of CNVs in the healthy popula-
tion using genome-wide screening tools. CNVs were shown to be frequent and, although 
they are present all over the human genome, loci enriched for structural rearrangements 
are not randomly distributed. Regions within or flanked by segmental duplications show 
a higher frequency of CNVs compared to regions outside these duplications. Further-
more, the genes that show enrichment in CNVs are also not random. Genes associated 
with immunity-, defence, cancer susceptibility, drug detoxification, signal transduction 
and sex hormone metabolism frequently show variations (Eichler 2006), including null-
alleles. McCarroll et al. (2006) showed these variations to result in expression level dif-
ferences, indicating that these variants are related to adaptation. On the other hand, the 
A. Part of the long arm of the right chromosome is missing. The loss of genomic material is called a deletion. 
B.  A part of the short arm of the chromosome is present twice (right). This extra material is called a duplication. As 
the duplicated region is localised within the chromosome, this duplication is called an interstitial duplication.
C.  The amount of genetic material in part C of this picture is similar to the unaffected left chromosome. However, 
a part of the chromosome is inverted. As the centromere is localised within the invertion, this situation is called a 
pericentromeric inversion.
D.  Again the amount of genetic material is normal, however, a part of the information of the dark grey chromosome 
has been transported to the light grey chromosome and vice versa. This is called a balanced translocation.
[See appendix: colour figures.]
Figure 1. Deletion, duplication, inversion and balanced translocation.
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majority of deletions found thus far were located in so called gene-deserts (Conrad et al. 
2006) and may therefore be neutral variants or have modest regulatory effects due to the 
presence of microRNA, noncoding RNA and other highly conserved regions.
 Nearly half of all CNVs seem to be complex events, formed by more than one event 
(for example an inversion (figure 1C) and a deletion, or a deletion combined with a 
duplication) (Eichler unpublished data). 
2.2 Segmental duplications
2.2.1. Characteristics of segmental duplications
Segmental duplications have been defined as sequences of DNA greater than 1 
Kb in size sharing a homology of at least 90 % (She et al. 2006). Previous studies 
Figure 2. Non-allelic homologous recombination and insertions.
A.  Non allelic homologous recombination. The two alleles of a chromosome contain regions that are highly homolo-
gous (e.g. segmental duplications, low copy repeats or duplicons). The presence of these segmental duplications 
can result in misalignment of these regions and subsequently in non allelic homologous recombination. The green 
arrow shows the origin of a duplication of the region present between two highly homologous regions, whereas the 
red arrow indicates the origin of a deletion.
B. In this situation a part of the left chromosome is inserted in another chromosome. This is called an insertion.




indicate that at least 5% (154 Mb) of the human genome is composed of such 
duplications (Bailey et al. 2002a; Cheung et al. 2003b; She et al. 2004; Zhang et al. 
2005), also called Low Copy Repeats (LCRs) or duplicons. Duplicons can have ei-
ther a simple or a complex structure (Ji et al. 2000) and contain genes, pseudogenes, 
gene fragments, repeat gene clusters (Ford and Fried 1986) and other chromosomal 
segments (Eichler et al. 1996; Samonte and Eichler 2002b; Horvath, Schwartz, 
and Eichler 2000). Especially the pericentromeric regions consist of a mosaic of 
different genomic segments (Horvath, Schwartz, and Eichler 2000). Compared to 
the chimpanzee and baboon, the human genome is particularly enriched for the 
number and the length of mainly Alu repeats (Liu et al. 2003). Also, the degree of 
genome sequence identity is higher in humans compared to other vertebrates (She 
et al. 2006).
 Misalignment between segmental duplications followed by Non Allelic Homolo-
gous Recombination can result in a duplication and reciprocal deletion of the sequence 
flanked by these duplicons (figure 2A). However, the high degree of sequence homol-
ogy between segmental duplications alone is not sufficient for providing ‘repetitive 
breakpoints events’, and therefore additional conditions are needed before recombina-
tion occurs. These include minimum length of 100% homology required for recom-
bination in human mitosis and meiosis (minimal region of homology was estimated 
to be 220 – 300bp and 300 – 500 bp, respectively) (Lupski et al. 1992; Waldman and 
Liskay 1988), AT-rich sequences (Peoples et al. 2000), for example those present on 
both sites of a recombination hotspot in Smith Magenis Syndrome (Bi et al. 2003) and 
enrichment of Alu repeats near or within the junctions present in segmental duplica-
tions (Stoppa-Lyonnet et al. 1990; Potocki et al. 2000; Bailey, Liu, and Eichler 2003). 
 Segmental duplications are also largely responsible for the fact that a part of the hu-
man genome sequence working draft contains gaps or is misassembled. The higher the 
sequence similarity the more difficult it is to distinguish and correctly assemble LCRs 
(Eichler 2001b). 
2.2.2. Intra- and interchromosomal segmental duplications
Segmental duplications can be divided in two categories, interchromosomal and intra-
chromosomal. Interchromosomal segmental duplications are based on the transposi-
tion of DNA sequences towards other chromosomes, whereas intrachromosomal seg-
mental duplications originated from a sequence that is transported to another region 
within the same chromosome. The prevalence of intrachromosomal segmental dupli-
cations in humans is higher than interchromosomal segmental duplications (3.97%, 
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113.66 Mb versus 2.37 %, 67.86 Mb)(Samonte and Eichler 2002b; Cheung et al. 
2003a; She et al. 2006). 
 Interchromosomal segmental duplications are frequently found at pericentromeric 
and subtelomeric sites (Cheung et al. 2001). An example is the pericentromeric region 
of the short arm of chromosome 16, which contains four different segmental duplica-
tions that were duplicated and subsequently transposed from Xq28, 15q13, 2p11 and 
14q32 (Ji et al. 2000) towards 16p11.
 While studying the olfactory gene family, which is spread over several chromo-
somes, (Trask et al. 1998) found that there are differences in subtelomeric segmental 
duplications between different ethnic groups, suggesting that such rearrangements are 
still ongoing. 
i-3. cnVs with PhenotyPic trait: genomic disorders
3.1. Genomic disorders
Genomic disorders were defined in 1998 (Lupski 1998) as the clinical condition, all 
types of phenotypic features included, that result from the dosage alteration of gene(s) 
located within a rearranged segment of the genome. It was estimated that about 0.7-1 / 
1000 live births suffer from a genomic disorder (Ji et al. 2000). Different types of CNV 
are involved in genomic disorders, e.g whole, and partial chromosome alterations (see 
section 4). These alterations include deletions, duplications, inversions, insertions and 
translocations (see figure 1 and figure 2). Three clinical conditions frequently arising 
from such CNVs are discussed below.
3.2. Mental retardation (MR)
MR or developmental delay (DD) is defined as a significant impairment of cognitive 
and adaptive functions (Battaglia and Carey 2003). It is a clinically important condi-
tion as it affects about 1:30 – 1:50 people. MR can be categorised into four degrees 
of severity (WHO 1980, International classification of Impairments, disabilities and 
handicaps. Geneve: World Health Organisation, 1980): Mild MR (intelligent quo-
tient (IQ) between 50 and 70), moderate MR (IQ between 35 and 50), severe MR 
(IQ between 20 and 35) and profound MR (IQ below 20). 
 Both genetic - and environmental factors can contribute to the origin of mental 
retardation. Environmental factors can involve pre- peri- and postnatal events, such 
as oxygen deprivation (perinatal event), infection (prenatal, postnatal), teratogenic 
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influences (prenatal) (Hamel 1999. X-linked MR. A clinical and molecular study 
(Alkmaar: Dekave)). 
 Genetic causes for mental retardation include (1) chromosomal causes such as 
aneuploidies, chromosome end rearrangements, rearrangements in regions related 
to microdeletion syndromes and other interstitial rearrangements, (2) complex dis-
orders (caused by mutations in multiple genes) and (3) monogenic disorders (sec-
tion 4.2.). A substantial number of point mutations have been identified in isolated 
genes that play an important role in early development (Petrij et al. 1995), such as 
mutations in the RAI1 (Slager et al. 2003) causing Smith Magenis syndrome, mu-
tations in the CREBBP gene (responsible for Rubinstein Taybi syndrome) and the 
CTG expansion of the FMR-gene which accounts for about 1:4000 – 1:6000 male 
cases of mental retardation (Fragile X syndrome) (Murray et al. 1996; Turner et al. 
1996; De Vries et al. 1997) (section 4.2.). 
 It is known that the causes of mental retardation vary with the severity of the 
condition. Large CNVs are more frequently associated with severe cases. Chromo-
somal and genetic disorders account for 30%- 50% of moderate to severe mental 
retardation (I.Q.< 50); environmental insults explain a further 10%-30% (Gustav-
son, Holmgren, and Blomquist 1987; McDonald 1973; Elwood and Darragh 1981; 
Flint and Wilkie 1996). In mild mental retardation cases (I.Q. between 50 and 70), 
approximately equal proportions of genetic and environmental causes are diagnosed, 
about 10-30% each (Lamont and Dennis 1988; Bundey, Thake, and Todd 1989; 
Einfeld 1984).
 The cause of MR remains unclear in about 40-50% of cases, indicating that, 
despite its high prevalence, the pathogenesis of MR is poorly understood. It is ex-
pected, however, that this rather high percentage will decline with the use of recently 
developed high-resolution genome analysis (see section 6.2. and 6.3.).
3.3. Congenital Malformation (CM)
Along with mental retardation, CNVs in the human genome may also result in a 
wide range of congenital malformations, such as organ and skeletal defects. These 
clinical features are already present at birth, before the mental retardation becomes 
apparent, so these entities can be the first indication of a genetic defect. The pres-
ence of more than one CM in a newborn that lacks a characteristic pattern of a 




i-4. cnVs with PhenotyPic trait: different tyPes of Variations
4.1. Whole chromosome variations
Since it was shown that an extra chromosome 21 causes Down syndrome (LEJEUNE, 
TURPIN, and GAUTIER 1959; Jacobs et al. 1959), it became clear that aneuploidy 
has significant influence on early development as well as on the intellectual capacities 
of an individual. Moreover, the severity of congenital malformations associated with 
trisomy 13 or 18 is such that only a small percentage of these fetuses will be viable with 
a drastically reduced life expectancy. Complete aneusomies of the remaining autosomal 
chromosomes have not been reported among live births, indicating that these are not 
compatible with life. Studies on material from spontaneous abortions support this 
statement (Carr 1971; Lauritsen et al. 1972; Boue and Boue 1977).
 The fact that cells use one copy of the X chromosome while inactivating extra cop-
ies, combined with the small number of genes on the Y chromosome results in the less 
severe impact of sex chromosomes aneuploidies on the development of the embryo. 
Karyotypes such as 45,X, 47,XXX, 47,XXY, 47,XYY constitute the most common 
class of chromosome abnormality in humans (Hall, Hunt, and Hassold 2006). 
 Incomplete aneusomies of autosomal and sex chromosomes (chromosomal mo-
saicisms) are also known to be present in both affected and healthy individuals. The 
phenotypic consequence of a chromosomal mosaicism depends on the chromosome 
involved, the percentage of abnormal cells and the tissue(s) that contain cells with an 
abnormal chromosomal constitution.
 Some of the whole chromosome variations originate from Robertsonian transloca-
tions in one of the parent of the affected fetuses / newborn. The frequency of Robert-
sonian translocations is 1:1000 (Shaffer and Lupski 2000).
4.1. Partial chromosome variations
4.1.1. Subtelomeric CNVs
The subtelomeric regions are localized proximal to the telomere proper, which consists 
of short repetitive sequences that cap the end of the chromosome. The subtelomeric re-
gions from different chromosomes are highly variable, with some having a simple pat-
tern and little similarity to other chromosome ends, whereas others contain complex 
and extensive patterns of homology. A good example regarding similarity of two sub-
telomeric regions is 4q and 10q, both encompassing repeats that share >98% sequence 
homology (van Overveld et al. 2000; van Geel et al. 2002). The subtelomeres are 
particularly dynamic regions, due to repeat-rich sequences that have a high frequency 
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Table 1.  Overview of subtelomeric screening studies in chronological order. Based on 
Rooms et al. (2004a) with addition of more recent publications.
Reference Method of analysis Number of cases Detection rate
Flint et al. (1995) VNTR marker analysis 99 3%
Knight et al. (1999) Multiprobe FISH 284 moderate/severe 7.4%
    182 mild 0.5%
Slavotinek et al. (1999) Microsatellitemarker analysis 27 7.5%
Bonifacio et al. (2001) PRINS 65 3.1%
Borgione et al. (2001) Microsatellitemarker analysis 60 6.6%
Colleaux et al. (2001) Microsatellitemarker analysis 29 6.9%
Fan et al. (2001) Multiprobe FISH 150 4%
Riegel et al. (2001) Multiprobe FISH 254 5%
Rosenberg et al. (2001) Microsatellitemarker analysis 120 4.1%
Rossi et al. (2001) Multiprobe FISH 200 6%
Sismani et al. (2001) Multiprobe FISH / MAPH 70 1.4%
Anderlid et al. (2002)  Multiprobe FISH 111 9%
Baker et al. (2002) Multiprobe FISH 53 isolated MR 1.9%
197 MR and dysmorphic 
features/malformations
4.1%
Clarkson et al. (2002) Multiprobe FISH/ SKY 50 6%
Dawson et al. (2002) Multiprobe FISH 40 10%
Hélias-Rodzewicz et al. (2002) Multiprobe FISH 33 9%
Hollox et al. (2002) MAPH 37 13.5%
Popp et al. (2002) M-TEL 30 13.3%
Rio et al. (2002) Microsatellitemarker analysis 150 10%
Van Karnebeek et al. (2002) Multiprobe FISH 184 0.5%
Hulley et al. (2003) Multiprobe FISH 13 7.7%
Jalal et al. (2003) Multiprobe FISH 372 6.8%
Bocian et al. (2004) Multiprobe FISH 59 moderate-severe 10%
 24 mild 12.5%
Harada et al. (2004) Array CGH 69 5.8%
Koolen et al. (2004) MLPA 210 6.7%
Kriek et al. (2004) MAPH 184 4.3%
Pickard et al. (2004) MAPH / FISH 69 mild 1.5%
Rodriguez-Revenga et al. (2004) Multiprobe FISH 8 moderate-severe 12.5%
22 mild 4.5%
Rooms et al. (2004b) Microsatellitemarker analysis 70  -
Rooms et al. (2004a) MLPA 75  5.2%
Walter et al. (2004) Multiprobe FISH 50 10%
Novelli et al. (2004) Multiprobe FISH 92 16.3%
Li and Zhao (2004) Multiprobe FISH 46 4.4%
Rooms et al. (2006) MLPA 275 4.4%
Lam et al. (2006) MLPA / multprobe FISH 20 15%
Palomares et al. (2006) MLPA 50 10%
Multiprobe FISH 50 10%
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of recombination. They are also gene- rich, and the plasticity of these chromosomal 
regions may be one of the factors responsible for phenotypic diversity (Mefford and 
Trask 2002). 
 CNVs near the chromosome ends are a significant cause of idiopathic mental re-
tardation (Flint et al. 1995; Knight et al. 1999; Flint and Knight 2003). Flint et al. 
(1995) demonstrated that ~6% of the patients with idiopathic mental retardation have 
a rearrangement in a subtelomeric region. These findings were verified by observations 
in many other studies. Biesecker (2002) and later Rooms et al. (2004a) summarized 
subtelomeric aneusomy screening studies using various detection methods (table 1). 
In our study, (chapter II-1) 4.3% subtelomeric alterations were found among 184 
idiopathic mild to severe MR patients.
 The percentage of aberrations detected varies considerably between different stud-
ies. This is due to the different criteria for the selection of patients, different techniques 
used, and, in smaller patient groups, by stochastic factors. It seems that the number of 
CNVs detected goes up with increasing complexity and severity of the clinical prob-
lems of the patients. 
 A proportion of the subtelomeric imbalances originate from reciprocal transloca-
tions in one of the parents. The frequency of reciprocal translocations is 1:625 (Shaffer 
and Lupski 2000). All chromosomes seem to participate in reciprocal translocations 
and most of the breakpoints are family-specific, however some breakpoints are re-
current, such as t(11;22)(q23-q11.2) and t(4;8)(p16;p23) (Giglio et al. 2002). These 
common and recurrent breakpoints originate from misalignment between interchro-
mosomal duplicons, which can lead to crossing over between non homologous chro-
mosomes (Kurahashi et al. 2000; Kurahashi et al. 2003).
 Gribble et al. (2005) studied a group of patients with a phenotypic trait and who 
had initially been diagnosed to have a balanced translocation based on the outcome 
of karyotyping. The majority of these apparent balanced translocations appeared to 
consist of several complex rearrangements often combined with the presence of one or 
more imbalances. To gain more insight in different ‘balanced’ translocations and their 
consequences, Danish investigators started to collect and characterize large numbers of 
balanced chromosomal rearrangements (Bugge et al. 2000).
4.1.2. CNVs in microdeletion syndromes regions
Microdeletion syndromes result from the loss of several genes (contiguous gene syn-
drome) or may result from the loss of a single gene. The majority of the microdeletion 
related regions are localised between intrachromosomal segmental duplications. These 
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Table 2.  Characteristics of syndromes flanked by duplicons (recombination hotspots) 
of which the reciprocal alteration has also been identified to have clinical 
consequences. 








17p12 Del Hereditary Neuropathy 
with liability to Pressure 
Palsy
24 1.5 1:20000 Reiter et al. (1996); Reiter 




1:2500 Valentijn et al. (1992); 
Pentao et al. (1992);
Lupski et al. 1992; Lupski 
et al. (1991)
22q11 Del DiGeorge - / Velo-
CardioFacial Syndrome
200 3 1: 4000 Shaikh et al. (2000); 
Edelmann, Pandita, and 
Morrow (1999)




Yobb et al. (2005) 
Ensenauer et al. (2003)
7p11.2 Del Smith Magenis syndrome 250 - 400 5.0 1:25000 Bi et al. (2003); Slager et al. 
(2003)
Shaw, Bi, and Lupski 
(2002)
Dup Potocki-Lupski syndrome Probably 
equal
Chen et al. (1997) Potocki 
et al. (2000); Bi et al. 2003; 
Potocki et al. (2007)
7q11.23 Del Williams syndrome 320 1.6 1:20000-
50000
Bayes et al. (2003); Peoples 
et al. (2000)
Urban et al. (1996); 
Francke (1999)




Somerville et al. (2005); 
Kriek et al. (2006)
As reciprocal duplications have only been discovered recently, the frequency cannot be determined based on literature. 
Based on Non Allelic Homologous Recombination one can assume that the frequency of reciprocal duplication is equal 
to that of the corresponding deletion, although there is no reason to assume that the consequence of a deletion or dupli-
cation would be the same. Nevertheless, it seems that the frequency of HNPP is an underestimation. In addition to the 
duplication of the region involved in DiGeorge/VCF syndrome, tetrasomy of this 22q11 region has also been described 
in Cat eye syndrome. Del = deletion, dup =duplication, Freq. = frequency, CNV = Copy Number Variation. 
This table was based on table 3 of Shaffer and Lupski (2000).
homologous regions facilitate unequal crossing over, resulting in deletions as well as 
duplications (Chance et al. 1994). This indicates that the frequency of reciprocal du-
plications of such regions is in principle equal to that of the corresponding deletions. 
In general, clinical phenotypes of these duplications are milder compared to the dele-
tion of the same region (for references see right column of table 2), and some of these 
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duplications might not even result in MR. In addition, duplications used to be more 
difficult to detect compared to deletions. This explains the lower frequency of publica-
tions regarding micro- duplications within such regions. Examples of microdeletion 
syndromes that are flanked by duplicons include Hereditary Neuropathy with liability 
to Pressure Palsy (HNPP), Williams-Beuren syndrome, DiGeorge- / Velocardiofacial 
syndrome, Smith Magenis syndrome (see table 2), Angelman - /Prader Willi syndrome 
(Miller, Dykes, and Polesky 1988; Amos-Landgraf et al. 1999) (see table 2). Up to 
now microdeletion syndromes have been recognised by their distinctive clinical phe-
notypes, using targeted fluorescence in situ hybridisation (FISH) to detect the dele-
tion in patients selected by a dysmorphologist. Recently, the genome-wide array-CGH 
method revealed additional microdeletions among MR patients that at first sight ap-
peared to lack salient and distinct features. A recent example of such a microdeletion is 
the 17q21.31 microdeletion syndrome that is associated with parental inversion of this 
region (Shaw-Smith et al. 2006; Koolen et al. 2006; Sharp et al. 2006). After identifica-
tion of the deletion, dysmorphologists do see common features in a series of patients, 
possibly enabling the recognition of these patients in the clinic.
4.1.3. Other interstitial CNVs 
Several CNVs localised outside the subtelomeres and microdeletion related regions 
have been identified as being involved in the etiology of MR/CM. 
 Bailey et al. (2002) described a bioinformatic approach to analyse the human 
genome sequence, and identified nearly two hundred potential hotspots for CNVs, 
e.g. regions flanked by segmental duplications (Bailey et al. 2002a). Some of these 
regions appear to be related to genomic disorders. 130 of these regions were subse-
quently tested for rearrangements among 47 healthy individuals using a segmental 
duplicon BAC microarray (Sharp et al. 2005). 79 of the 130 potential CNV hotspots 
showed no alteration among this study population, supporting the hypothesis that 
alterations within these regions could be related to disease. Chapter II-2 summarizes 
our results of screening for CNVs of regions flanked by intrachromosomal duplicons 
among 105 MR/CM patients. As expected, the rearrangement frequency per unit of 
DNA is much higher in regions flanked by duplicons compared to regions without 
known duplicons nearby, supporting the statement that regions flanked by duplicons 
are enriched for copy number variations. Of course, pathogenic CNVs outside du-
plicon-flanked regions have also been identified, for example the interstitial deletion 
of chromosome band 2p16p21 (Sanders et al. 2003; Lucci-Cordisco et al. 2005) (see 
chapter III-4) and the DMD gene (Blonden et al. 1991; Nobile et al. 2002). 
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4.2. Other variations 
Several microdeletion syndromes are in fact caused by the inactivation of a single gene. 
An example is the Rubinstein Taybi Syndrome (RTS). After two reciprocal transloca-
tions with a breakpoint in the short arm of chromosome 16 had been described in 
RTS patients, submicroscopic deletions were detected in six of a series of 25 patients 
with the syndrome (Breuning et al. 1993). Subsequent mutation detection using the 
protein truncation test identified two point mutations in the CREBBP gene in 16p 
(Petrij et al. 1995), indicating that RTS was not, as previously thought, a contiguous 
gene syndrome, but due to haplo-insufficiency of a single gene. Similarly, Smith Ma-
genis syndrome was initially found to be caused by a microdeletion of chromosome 
band 17p11.2. Subsequently mutations in the RAI1 gene were shown to be responsible 
for the vast majority of the clinical features associated with the syndrome (Slager et al. 
2003). More recent examples of variants within a single gene that are found to related 
to a syndrome or a sequence include the gene for CHARGE sequence (Vissers et al. 
2004) and the gene involved in Cornelia de Lange syndrome (Krantz et al. 2004). In 
2006, the gene linked to Peters Plus syndrome was identified after finding two splice 
donor site mutations within the B3GALTL gene (chapter III-2). This year, Zweier et 
al. revealed that haplo-insufficiency of TCF4 is responsible for the Pitt Hopkins syn-
drome (Zweier et al. 2007).
i-5. considerations regarding Pathogenicity of cnVs 
The vast majority of the large CNVs related to genomic disorders are thought to be 
de novo (except for CNVs with an X-linked or autosomal recessive inheritance), as 
affected patients often have a severe phenotype and are unable to have offspring. How-
ever, for some microdeletion syndromes an autosomal dominant transmission has been 
documented (Leana-Cox et al. 1996; Morris, Thomas, and Greenberg 1993), empha-
sizing that even CNVs that are known to cause genomic disorders can demonstrate 
phenotypic variability. The pathogenicity of familial CNVs is often hard to interpret, 
as variable expression of the remaining allele and incomplete penetrance can influence 
the clinical consequences in different family members. An example is the phenotypic 
variability associated with a duplication of the DiGeorge- / Velocardiofacial syndrome 
region. Edelmann et al. (1999) described an individual with this duplication who was 
affected by failure to thrive, marked hypotonia, sleep apnoea and seizure-like episodes. 
The healthy mother and grandmother however also carried the same duplication. Ad-
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ditional reports verified that this specific alteration, despite showing a very wide range 
of clinical features, is not a benign genomic variant (Ensenauer et al. 2003; Yobb et 
al. 2005). A second example includes the 1.5 Mb duplication of chromosome band 
16p13.1 that has been recently found among four severe autistic male patients. The 
same duplication was detected among less affected and unaffected family members 
(Ullmann et al. 2007).
 In general, the presence of a particular CNV in a patient as well as in family mem-
bers does not exclude a causal relation with the clinical problem, since autosomal reces-
sive, digenic, complex or multifactorial inheritance can apply. The identification of the 
gene responsible for Peters’ plus syndrome (chapter III-2) is the perfect example to 
Figure 3. Current standard cytogenetic diagnostic tools and their characteristics.
[See appendix: colour figures.]
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underline the presence of an autosomal recessive inherited disorder. This syndrome was 
suspected to be an autosomal recessive disorder, although cryptic unbalanced translo-
cations could not be excluded based on the presence of multiple spontaneous miscar-
riages in several families. We identified an interstitial deletion in two affected brothers 
that was also present in the mother and the maternal grandmother. The latest two were 
both suffering from breastcancer. Additional investigation of the brothers identified a 
mutation in the B3GLTL gene from the same region on the paternal allele.
 A de novo variant is often assumed to be causative, however, since many CNVs are 
(neutral) polymorphisms, de novo variations can also be inconsequential. Van Ommen 
(2005) discussed the frequency of de novo deletions and duplications. He estimated 
a frequency of 1 in 8 for deletions, and 1 in 50 for duplications comprising random 
events in human newborns. It was noted that these are likely to be underestimates 
as, in addition, segmental duplicons cause recurrent non-random variations. Given, 
therefore, that de novo CNV is relatively frequent and not in all cases linked to genomic 
disorders, the finding of a de novo variation in a patient is not sufficient to conclude 
that this CNV is causally related to the clinical phenotype. 
 Recent initiatives, such as those of the Sanger Institute (www.sanger.ac.uk/Post-
Genomics/decipher/) and Ecaruca, to create platforms for collecting and comparing 
molecular cytogenetic data from many clinical genetic centers in relation to the human 
genome sequence, will assist in giving a better understanding of the role of CNVs in 
MR, CM and other genetic diseases. 
i-6. detection of cnVs
6.1. (Standard) Cytogenetic tools (figure 3)
6.1.1. Karyotyping
Analysis of chromosomes using the light microscope has been the gold standard for 
chromosome analysis during the past five decades. The banding technique, developed 
in the 1970s, enables the identification of specific chromosomes and large rearrange-
ments (Caspersson, Lomakka, and Zech 1972; Yunis 1976). Using this technique, it 
became clear that chromosomes from healthy individuals are not completely similar. 
For each and every chromosome, microscopically visible variations not related to any 
phenotypic trait have been identified (Wyandt HE, Tonk VS (eds), 2004. Atlas of 




 Karyotyping has been implemented worldwide in a diagnostic setting, as it is very 
specific and reproducible in detecting large chromosomal variations among different 
groups of patients. 
 Even with optimal quality, however, it is not possible to identify structural imbal-
ances smaller that 3-5 Mb (figure 3). 
 The implementation of the high-resolution banding (more than 800-band level) may 
not always resolve the resolution problem, as it can result in both false positive and false 
negative results (Kuwano et al. 1992; Delach et al. 1994; Butler 1995). An example of 
this was published by Francke et al. (1985). They described a patient suffering from 
Duchenne muscular dystrophy, chronic granulomatous disease associated with cyto-
chrome b deficiency and with the McLeod phenotype in the Kell red cell antigen system 
and retinitis pigmentosa due to an interstitial deletion of part of band Xp21. This dele-
tion could be identified by standard resolution chromosome banding. However, using 
higher resolution chromosomes, the loss of genetic material was very hard to appreciate. 
Flint and Knight (2003) also found a negative correlation between the resolution of the 
banding and the number of chromosomal alterations found. This phenomenon may be 
explained by the fact that high resolution banding uses chromosomes that are in the pro-
metaphase stage. At this stage the condensation of the chromatids is incomplete, result-
ing in elongated chromosomes. Since the condensation process is ongoing and variable 
during pro-metaphase, apparent differences in length may be due to unequal condensa-
tion instead of a “real” difference caused by a gain or loss of genetic material. 
6.1.2. Fluorescent in Situ Hybridisation (FISH) analysis
FISH analysis (Prooijen-Knegt et al. 1982; Landegent et al. 1985; Ried et al. 1990) 
(figure 3) is based on the hybridisation of a fluorescently labelled probe containing a 
sequence of several tens (cosmids) to hundreds of kilobases (Bacterial Artificial Chro-
mosomes (BACs)/ P1 derived Artificial Chromosomes (PACs)) that is complementary 
to the region of interest. The fluorescently labelled sequences will bind to the genomic 
DNA, which is subsequently visualised under a microscope. The two types of FISH 
analysis commonly used in diagnostic procedures are (1) metaphase FISH, that uses 
cultured cells for analysis, and (2) interphase FISH, that does not require culturing 
of cells. The advantage of interphase FISH analysis is that it has a higher resolution, 
allowing the detection of small tandem duplications, whereas FISH using metaphase 
cells will often miss such duplications as the extra signal is overlapping the original sig-
nal. Furthermore, interphase FISH can be used for the detection of low-level mosaics 
as large numbers of cells can be scored. On the other hand, the advantage of metaphase 
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FISH analysis is that individual chromosomes are visible, providing positional infor-
mation of the CNV. 
 Detecting CNVs using FISH analysis is only possible if the following criteria are 
fulfilled: (1) The CNV must be characterized by a specific phenotype, (2) this phe-
notype must be recognized by a specialist (for example clinical geneticist) and (3) a 
specific diagnostic FISH test must be available.
6.1.3. Fiber FISH 
Fiber FISH refers to the analysis of extended chromatin fibers. It provides a higher 
resolution than conventional FISH, because the chromosomes are analysed as distinct 
single threads under the microscope. Fiber FISH can also be used to resolve complex 
rearrangements. The principal drawback of this approach is that it is technically chal-
lenging and time consuming (Wiegant et al. 1992; Florijn et al. 1995; Rosenberg et al. 
1995; Giles et al. 1997; Raap et al. 1996).
6.1.4. Multi-probe FISH (M-FISH) and SKY (Spectral Karyotyping)
Multiple color FISH was first described in the late eighties (Nederlof et al. 1989; 
Nederlof et al. 1990; Dauwerse et al. 1992). In general, Multiprobe FISH and SKY 
(Schrock et al. 1997) provide recognition of many chromosomes simultaneously by la-
belling them with a distinct combination of fluorochromes (Fan et al. 2000; Speicher, 
Gwyn, and Ward 1996). By pooling cloned DNA fragments of a particular (part of a) 
chromosome, the FISH probe can ‘paint’ the chromosome or a region of interest. By 
combining different fluorophores in different proportions, chromosome specific colors 
can be generated (Tanke et al. 1999; Raap and Tanke 2006). This COmBined RAtio 
labelling or COBRA–FISH is particularly useful for the detection of balanced translo-
cations or to determine the content of a marker chromosome. As shown in figure 3, the 
resolution of tools is better than that of karyotyping. COBRA-FISH was used for the 
screening of subtelomeres (Engels et al. 2003). By applying the subtelomeric COBRA-
FISH method, it was possible to screen 41 subtelomeres (except for the p-arms of the 
acrocentric chromosomes), with BACs/PACs localised approximately 230 Kb from the 
telomeres, using only two hybridisations and four fluorochromes. 
 Knight et al. (1997) developed a multi-hybridisation protocol, using a slide divided 
into 24 small hybridisation chambers. By applying different dyes to label each chromo-
some arm, the slide can be used to perform FISH analysis for all subtelomeres in one 
assay (Flint and Knight 2003). As this approach is quite laborious and consequently 
the throughput is very limited, it is currently not used on a wide scale.
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coding for the alpha and beta chain of haemoglobin were found to frequently undergo 
gross rearrangements, showing deletions as well as duplications. Some, but certainly 
not all, of the deletions appear to be related to crossing-over between repeat elements 
as described by Higgs et al. (1984). Herrmann, Barlow, and Lehrach (1987) were the 
first to identify a molecular basis for recombination across a large inverted duplication 
that resulted in duplicated and deleted regions. For their study, which was published 
in 1987, restriction fragment length polymorphisms of cloned regions combined with 
pulse field gel electrophoresis were applied. 
 Studying another gene cluster, using hybridisation analysis of labelled cosmid clone 
fragments, Groot et al. (1990) hypothesized that unequal intrachromosomal crossing-
over might be a frequent event leading to multiple and variable copies of the amylase 
genes. This model was recently confirmed using array and Fiber FISH analysis (Iafrate 
et al. 2004).
 This section will briefly describe several techniques used for the detection of 
CNVs.
6.2.2. Restriction fragment length polymorphisms 
Restriction fragment length polymorphisms (RFLP) are detected by digestion of (am-
plified) DNA using endonucleases, which only cut in the presence of specific DNA 
sequences (the restriction sites). The restriction fragments are then separated according 
to length by agarose gel electrophoresis. Depending on changes within these sequenc-
es, the length of the fragments and thus the position of the corresponding gel bands 
differ between individuals. The result of RFLP may be enhanced by Southern blotting 
(see 6.2.3). Using RFLP analysis, it was possible to identify duplications or deletions 
of a certain region of the genome. For example, RFLP analysis was applied within the 
first series of randomly cloned DNA fragments for the detection of probes showing 
non-Mendelian segregation. Both missing and extra alleles were identified (E. Bakker, 
personal communications, 1983).
6.2. High resolution tools (not genome-wide)
6.2.1. History
As stated previously, the phenomenon of copy number variation has been recognised 
since the earliest days of human gene cloning. The first gene clusters cloned, those
  By applying karyotyping and (different applications of) FISH analysis, a signifi-
cant number of chromosomal anomalies remain undetected. Therefore, there is a 




For many years, Southern blot analysis followed by densitometry was the main assay 
that was utilized for the detection of CNVs in clinical molecular genetic laboratories. It 
was the first technique to analyse human DNA on a wider scale. The Southern blotting 
procedure (Southern 1975) could show differences in length of restriction fragments and 
was used to study single copy, as well as low copy repeat sequences. Quantitative analysis 
was also possible on a very limited scale. Presence or absence of a sequence was of course 
no problem, but even the difference between one or two copies of a fragment with similar 
length required optimal experimentation. In some cases a rearrangement within a gene 
could be visualised by finding a new junction fragment. Since the technique required the 
use of radioactive labels and is very laborious, it has become less popular and has been 
largely replaced by quantitative PCR- based techniques, such as Q-PCR and Multiplex 
Ligation dependent Probe Amplification (MLPA) (Schouten et al. 2002). 
6.2.4. Pulse field gel electrophoresis (PFGE)
This technique (van Ommen et al. 1986; Den Dunnen et al. 1987) extends Southern 
blotting to include detection of very large DNA molecules (20 kb to several Mb in 
length) that are too large to be separated using normal agarose gel electrophoresis. 
It can be used to detect a rearrangement-specific junction fragment. Shearing of the 
genomic DNA is prevented by preservation and enzymatic digestion in solid agarose. 
The agarose-embedded DNA is cut by a rare-cutting restriction endonuclease and 
subsequently separated by an electrical current. During electrophoresis, the relative 
orientation of the electric field is periodically altered (Strachan and Read, Human Mo-
lecular Genetics, third edition, chapter 6.2). Fragments of different sizes will migrate 
at different speeds through the gel, and consequently PFGE is capable of detecting 
structural rearrangements. 
 Despite being technically challenging, is still used to study large repeat arrays e.g. 
FSHD (Buzhov et al. 2005).
6.2.5. Microsatellites for detecting CNVs
Microsatellites are sequences containing variable number of tandem repeats (hence are 
also known as variable number of tandem repeat markers (VNTRs). The number of re-
peat units for a given locus may differ between individuals, resulting in alleles of varying 
lengths. The differences in repeat length can be visualised either by using a nearby single 
copy probe on a Southern blot or by PCR-based methods. Allelic variation, the number 
of repeats, and allelic frequencies are available for thousands of markers across numerous 
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organisms. These polymorphisms can be used for the identification of CNVs by observ-
ing abnormal inheritance of parental alleles (figure 4), such as uniparental disomy. The 
limitation of this type of genetic marker for the detection of imbalances is that its success 
depends on the availability of parental DNA (Wilke, Duman, and Horst 2000). 
  All techniques described above have major disadvantages. They are either techni-
cally demanding, expensive, slow, require fresh samples, or have a low throughput 
(Heath, Day, and Humphries 2000). The major limitation is the small number of 
loci that can be tested in one experiment. The development of PCR based tech-
niques, such as Multiplex Amplifiable Probe Hybridisation (MAPH) and Multi-
plex Ligation-dependent Probe Amplification (MLPA) allowed more widespread 















Figure 4. Identification of the parental origin of an allele. 
A. Different VNTR lengths in both parents present on a specific region in the human genome.
B.  One of the children has the identical combination of VNTR lengths as one of its parents. Uniparental disomy (of 
genetic material from the parent with identical VNTR lengths) or a deletion present at the allele inherited from 
the ‘other’ parent should be considered. Picture derived from www.geninfo.no.
[See appendix: colour figures.]
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6.2.6. Quantitative real-time Polymerase Chain Reaction (Q-PCR) 
This method is independent of the availability of informative markers in the region of 
interest. Quantitation of input DNA is achieved by using dyes or dual-labelled probes, 
and a fluorescence scanner to monitor the amount of product generated during the 
amplification process. The method was originally designed to facilitate quantification 
of RNA, but it can also be used to quantify the copy number of a genomic sequence. 
The combination of real-time PCR and TaqMan TM fluorescent probes for the detec-
tion of CNVs has been described by Wilke, Duman, and Horst (2000) and Lauren-
deau et al. (1999). In this case, one only needs the amplification of one reference locus 
to measure the copy number of the test loci, instead of using different diluted DNA 
fragments for standardisation.
6.2.7. Towards MAPH and MLPA
In 1995, a PCR method was described which simplifies quantitative multiplex PCR 
(Shuber, Grondin, and Klinger 1995) where gene specific primers were tagged at the 
5’end with an unrelated 20 nucleotide universal primer binding site. Based on this 
method, new applications of multiplex-PCR were designed such as quantitative fluo-
rescent multiplex PCR (QFM-PCR) (Heath, Day, and Humphries 2000) that was 
published in the same year as Armour published another application, called Multi-
plex Amplifiable Probe Hybridisation, MAPH (see below). QFM-PCR, MAPH (sec-
tion 6.2.6), MLPA (section 6.2.7.) are all useful, effective and reliable methods for 
the detection of both deletions and duplications in the same assay.
6.2.8. MAPH
MAPH was first described by Armour et al. (2000). MAPH is a PCR-based method 
for simultaneously determining the copy number of a set of up to 50 different chro-
mosomal loci (White et al. 2002). The probes, usually exons from candidate genes, 
are individually cloned such that all can be amplified using one pair of primers. To 
detect copy number changes, the probes are hybridised to denatured genomic DNA 
that has been immobilised and cross-linked on numbered nylon filters. After stringent 
washing, only the probes that hybridise specifically to the complementary sequence 
on the genomic DNA will remain bound. These hybridised probes are recovered off 
the filters, quantitatively amplified using PCR and analysed. The initial publication 
used a radioactively labelled primer followed by separation on a slab gel. This was then 
exposed to a film, with the resulting bands being measured using densitometry. White 
et al. (2002) simplified the procedure by using a fluorescently labelled primer followed 
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by analysis using a 96 capillary sequencer. The yield, represented by peak height and 
area, is determined for each probe. Changes in probe yield correspond to changes in 
copy number of the sequence analysed, i.e. a deletion or duplication. 
 The first report of subtelomere screening in patients with MR using MAPH was 
from Sismani et al. (2001). In their study, a group of 70 mentally retarded individuals 
was screened, using multiprobe telomeric FISH assay and MAPH. One subtelomeric 
deletion was found and confirmed with an independent technique. It has to be men-
tioned, however, that not all the subtelomeric probes were informative.
 It has been calculated previously (Hollox et al. 2002), that about 0.12% of the 
mentally retarded patients were reported to have false positive results (that is, MAPH 
analysis detected an alteration that could not be verified using an independent tech-
nique), using MAPH based screening of subtelomeres, suggesting that this technique 
is reliable for the detection of CNVs. Obviously, the percentage depends highly on 
thresholds applied in a certain study.
6.2.9. MLPA
MLPA is based on the ligation of two adjacently annealing oligonucleotides, fol-
lowed by the quantitative PCR amplification of the ligated products (Schouten 
et al. 2002). The left half-probe is chemically synthesised. It consists of a unique 
sequence complementary to the locus of interest along with a sequence containing 
the primer-binding site common to all probes. The other half-probes consist of 
three parts. In addition to the parts present in the left half-probe, this right half-
probe also contains a spacer sequence, responsible for the difference in length of 
the MLPA probes. As the size of the right-sided half-probe initially was designed 
up to 440 nt, it was not possible to synthesize this oligonucleotide. Therefore, 
M13 vectors were used carrying the spacer sequences. However, generating a right 
half-probe with a spacer requires a laborious and time consuming cloning step. 
Therefore, a modified protocol for designing probes was implemented (White et 
al. 2004). Using this protocol, the right half probe is also chemically synthesised 
followed by 5’phosphorylation. Each probe was designed to be of unique size, en-
abling easy differentiation. This alternative MLPA protocol significantly reduces 
the time necessary for MLPA probe design, however, the number of loci that can be 
tested by MLPA using one fluorescent dye is limited. A second (and even a third) 
dye can be used by designing probes with another primer binding sequence (White 
et al. 2004; Harteveld et al. 2005). In this way, it is possible to screen up to 60 loci 
in nearly 100 patients in one assay.
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6.2.10. Data analysis of MLPA and MAPH
Several methods for data analysis have been described (Hollox et al. 2002; White et al. 
2002) and analysis protocols are available at www.mlpa.com.
 Besides analysing the result of MLPA and MAPH using either a polyacrylamide 
gel or through polymer-filled capillaries, both techniques can be adapted for an ar-
ray- or bead based read out. This will increase the number of loci than can be tested 
simultaneously in one patient (Gibbons et al. 2006). To detect the amplified frag-
ments, universal arrays can be designed using specific zip codes. These are spotted on 
the array, with the complementary sequences being incorporated into the probes. An 
added advantage of this approach is that the half probes used can have identical sizes, 
facilitating uniform amplification. Using the 3-Dimensional, Flow-Through Microar-
ray Platform from PamGene, hybridisation time of the amplified fragments to their 
target sequences can be reduced to minutes. This technique has been used for the rapid 
detection of aneusomies, resulting in a gain in time of more than 60 hours compared 
to karyotyping (Kalf et al. in preparation).
  The advantage of MAPH and MLPA compared to other techniques, including 
(multi-probe) FISH and array-CGH, is that the resolution of detection is limited 
only by the size of the probes used (100-500 bp). In addition, using specific probe 
design, it is even possible to detect point mutations using MLPA analysis. 
  Both MAPH and MLPA facilitate the parallel screening of large numbers of pa-
tients at many different loci in one experiment with rather cheap consumables. 
  A disadvantage of these methods is that they are not suitable for genome-wide 
screening.
6.3 Whole genome (high resolution) screening tools; recent genome approaches
6.3.1. Overview
Affordable, high-resolution, genome-wide approaches for DNA copy number analysis 
have been available for less than five years. In contrast to FISH, where small fragments 
of DNA are labelled and hybridised to genomic DNA (in the form of chromosome 
spreads), array-based approaches label the genomic DNA, which is then hybridised to 
small fragments of DNA. 
 Currently, there are two main formats, array-CGH and SNP-based arrays. Both 
are discussed in more detail below. For array-CGH, the probes used are (3K – 30K) 
genomic clones or up to 400K 60-mer oligonucleotides, with the size and number 
determining the resolution of analysis. 
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 SNP arrays, containing 10K–1000K loci have recently proven to facilitate, in ad-
dition to genome-wide association studies, the detection of deletions and duplications 
(see section 6.3.4.). The resolution of the SNP arrays depends on the number of SNP 
loci present and on their coverage across the genome. 
 The coverage of the genome of all genome-wide mapping platforms is rapidly im-
proving. 
 It should be noted that these tools can not be used to detect copy-neutral rearrange-
ments like translocations, insertions and inversions.
6.3.2. Array-CGH using BAC clones
High-resolution comparative genomic hybridisation (CGH)-based micro-arrays (Soli-
nas-Toldo et al. 1997; Pinkel et al. 1998; Snijders et al. 2001) were developed to increase 
the resolution of chromosome studies. The technique is based on immobilised DNA 
isolated from Bacterial Artificial Chromosome (BAC) clones that were amplified by ei-
ther DOP-PCR (Telenius et al. 1992) or ligation-mediated PCR (Snijders et al. 2001). 
The amplified DNA, spotted on coated microscope slides by an arrayer, is usually present 
in triplicate enabling internal standardisation. Test and reference DNA are differently 
labelled by random priming to incorporate fluorescently labelled nucleotides, and subse-
quently mixed with Cot –1 DNA to block repetitive DNA sequences. After hybridisation 
for 16-24 hours, images of hybridised fluorochromes can be obtained. The resolution ob-
tained with BAC-arrays depends on the genomic distance between the BACs spotted on 
the array and the size of the BACs (Snijders, Pinkel, and Albertson 2003).
 Clinical applications of array-CGH using different subsets of the human genome 
have been published by several groups (Veltman et al. 2002; Rauen et al. 2002; 
Bruder et al. 2001; Rosenberg et al. 2006). Veltman et al. (2002) estimated, based on 
their results obtained by screening 20 patients with known cytogenetic abnormali-
ties, that the incorrect positive result of the 3500 BAC-array is approximately 0.4%, 
whereas no abnormality was missed. Many papers have been published regarding 
findings of screening MR patients using BAC-array of ~3500 BAC DNA probes 
spaced at ~1 Mb density over the full genome (3K array) (table 3). De Vries et al. 
(2005), Vissers et al. (2005) and Koolen et al. (2006) presented the results of screen-
ing using a BAC array with 10 fold higher resolution (33000 BACs). BAC arrays are 
also widely used in cancer diagnostics (Snijders et al. 2003; Weiss et al. 2003). The 
genomic variation among 55 healthy individuals was also tested using array-CGH 
(Iafrate et al. 2004). This study found as many as 255 alterations that were suspected 
to be neutral variants. 
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  BAC-based array-CGH has been very important for the initiation of genome-
wide screening at high resolution.  It has proven to be a reliable and reproducible 
technique. Recently, oligonucleotide-based arrays have become available. These 
arrays come in two types, 60-mer oligos (see section 6.3.3.) for the detection of 
small CNVs and shorter 25-mer oligos for SNP (see section 6.3.4.) detection. 
  In their latest versions, these arrays have an effective resolution below 10 kilo-
bases. A disadvantage of array-based methods is that they are currently still rather 
expensive.  
6.3.3. Array-CGH using long oligos 
Examples of these arrays include Nimblegen and Agilent. The 60 nucleotide is longer 
than the sequence that is spotted on the SNP array. As a result, these oligo based ar-
rays are not suitable for SNP analysis, however, they do give stronger signal intensity. 
Therefore, CNVs can be detected using solely the signal intensity.
 In addition, as the location of the oligos is not limited to known SNPs, it is possible 
to analyse regions of the genome where no validated SNPs are available. This can be 
particularly important when looking at duplicated regions. The most recent Agilent 
micro array contains ~244.000 spots on the array. 
6.3.4. SNP based arrays
The 25-mer probe arrays were originally designed to detect SNPs to be used in genome 
wide linkage and association studies. However, they were quickly used to estimate 
copy number changes by using both signal strength and allele scoring. Initial studies 
used the Affymetrix 10K array, which demonstrated the principle that the arrays could 
provide quantitative data (Herr et al. 2005). Subsequent work has taken advantage of 
higher resolution chips, currently up to 500-1000K (Komura et al. 2006). In practice, 
these arrays have an effective resolution below 10 kilobases, meaning that much smaller 
rearrangements can be detected compared to previous genome-wide technologies. 
6.3.5. Comparing cross platform
Currently, there is no golden standard available to determine which platform, CGH-
based or SNP-based, is the most accurate. It might be argued that high density SNP ge-
notyping would be the most appropriate to implement for screening for copy number 
alterations, as this tool offers the simultaneous measurement of copy number changes 
and copy-neutral loss of heterozygosity (i.e uniparental disomy). On the other hand, 
SNP arrays have been selected based on criteria such as heterozygosity, being in Hardy-
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Weinberg equilibrium. Although these features are important for association studies, 
where SNPs need to be informative, they are less critical for copy number analysis 
where even spacing is more important. Indeed, many regions prone to rearrangements 
(e.g. duplicons) are lacking or underrepresented on these arrays, as the associated SNPs 
did not meet the required quality criteria. This is in contrast to array-CGH in which 
the location of the oligonucleotides is not limited to known SNPs, and, therefore, it 
is possible to analyse regions of the genome where no validated SNPs are available. 
Indeed, the study of Redon et al. (2006) shows that in addition to the SNP-arrays, 
arrayCGH analysis is required to cover all CNV regions in the human genome, other-
wise at least one third of the CNVs will be missed. New arrays of both Affymetrix and 
Illumina now close this gap by combining SNP- and non-SNP probes on one array.
 Chapter III-4 attempts to compare different whole genome screening tools by ap-
plying them to four unrelated patients suffering from overlapping interstitial 2p dele-
tions. Comparing cross-platform, we found that the localisation of both proximal and 
distal breakpoints was largely in agreement. 
There have been few studies published screening MR patients with the new oligo-array 
platforms (table 3). Most studies described to date looked at either CNVs in healthy in-
dividuals (table 4) or the validation of techniques for detecting CNVs in patient popula-
tions. Using the 10K genechip of Affymetrix, seven known alterations with a size between 
0.2-3.7Mb were not detectable due to insufficient SNP density in the regions involved 
(Rauch et al. 2004). Slater et al. (2005) were able to find all known alterations previously 
found by karyotyping, FISH or MLPA analysis using a ten-fold higher density (>110 K) 
SNP chip of Affymetrix, except for one duplication at the end of chromosome 9q. The 
same mapping tool was successfully validated by another group (Ting et al. 2006). The 
utility of the beadchip (SNP) array of Illumina, assaying 109,000 and 317,000 SNP loci, 
to detect chromosomal aberrations in samples bearing constitutional aberrations as well 
tumor samples at sub-100 kb effective resolution has also been described (Peiffer et al. 
2006). In addition, summaries of different whole genome high resolution mapping tools 
have been published recently (Veltman 2006; Coe et al. 2007). 
i-7. scoPe of this thesis
The main aim of this thesis was to assess several new techniques for the detection of 
genomic rearrangements in patients with MR and / or CMs. In quick succession, 
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MAPH, followed by MLPA, and MLPA in combination with array-CGH, have been 
implemented to expand the possibilities for diagnostic screening for deletions and 
duplications. By applying these high-resolution techniques, new regions and genes 
involved in the etiology of MR/CM were identified, resulting in an increased number 
of patients with a known cause for their developmental disorders. Currently, using the 
new genome-wide high(er) resolution techniques, such as the oligo based array, the 
number of variations detected in the human genome will increase even further. At this 















Vissers et al. 
(2003)
BAC arrays 3,500 BACs 20 MR patients 3 (2 ) 2 (1) 0 25% (15%)
Schoumans et 
al. (2005)
BAC array 2,600 BACs 41 MR patients + 
dysm. features
4 (4) 0 0 9.8% (9.8%)
Tyson et al. 
(2005)
BAC array 3,000 BACs 22 MR patients 1 (1) 2 (1) 0 14% (9%)
De Vries et al. 
(2005)
BAC array 33,000 BACs 100 MR patients Many (7) Many (3) 0 10% (10%)
Menten et al. 
(2006)
BAC array 3,500 BACs 140 MR patients 18 (11) 7 (3) 3 20% (10%)
Miyake et al 
(2006)
BAC array 2,173 BACs 30 MR patients 3 (1) 1 (1) 1(1*) 17% (10%)
Rosenberg et al. 
(2006)
BAC array 3,500 BACs 80 MR patients 12 (5) 6 (2) 2 (1*) 25% (10%)
Shaw-Smith et 
al. (2006)
BAC array 3,500 BACs 50 MR patients + 
dysm. features
7 (6) 5 (1) 0 24% (14%)




100K SNPs 10 MCA patients 2(2) 0 0 20% (20%)




100 K SNPs 100 MR patients 8 (8) (3) (1 was a 
mosaic)
0 11 (11%)
Sebat et al. 
(2007)
ROMA 85,000 oligos 195 autistic patients 12 (12) 3 (3) 0 7,7% (7,7%)
This table summarizes the eight studies screening MR patients using BAC arrays, and three studies screening a MR or autistic study 
population using oligo based arrays. Based on the data presented in this table, it shows that, independent of the sample size tested, the 
number of de novo alterations detected using whole genome screening tools is around 10%. It is noteworthy that although the number 
of loci tested using a BAC-array is increased significantly compared to the initial BAC-arrays, the number of de novo alterations detected 
remains 10%. The same holds true for the implementation of the 100K SNP array.
*: one of the parents is a carrier of a balanced translocation. Affy: SNP array designed by Affymetrix, ROMA: representational oligo-
nucleotide microarray analysis, dels: deletion, U.T.: unbalanced translocation, dysm.: dysmorphic
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moment, the consequence of the detection of a CNV in an affected individual is not 
always clear. Therefore, the main challenge will be determining whether a variation is 
related to disease or one of the many neutral polymorphisms. 
i-8. in summary 
The following two chapters contain seven papers. Chapter II includes three studies 
where groups of patients were tested for CNVs. The frequency of subtelomeric altera-
tions as well as interstitial variations in and outside duplicons were determined among 
different groups of mentally retarded patients. We were able to report the second pa-
tient with the reciprocal duplication of the Williams syndrome critical region and a 
previously undescribed duplication within the 16p13.1 region. In addition, based on 
our findings using parallel testing of both MLPA- and array based analysis, an alterna-
tive, cost effective approach is recommended for screening mentally retarded patients.
Chapter III is comprised of four studies using small numbers of patients and a case 
report. The first report describes a complex rearrangement on both copies of chromo-
some 22. Different characteristics of the rearrangements were defined using different 
diagnostic tools. We found that haplo-insufficiency of the Cat eye critical region is 
probably not related to a clinical phenotype. The phenotypic variability in relation 
Table 4.  The results of screening for CNVs among healthy individuals using different 
whole genome screening tools.
References Methods of Analysis Genome Coverage Sample size
Total No 
of CNVs
Iafrate et al. (2004) BAC array 5,264 BACs 55 healthy 
individuals
255
Sebat et al. (2004) Oligo based array
(ROMA)
85,000 oligo nt 20 healthy 
individuals
221





Mc Carrol et al. (2006) Clustered genotype & Men-
delian errors (Hapmap data)





Komura et al. (2006) Affymetrix gene chip 500 K 270 healthy 
individuals
1,203









to the size of the deletion of patients having the ATR-16 (a-thalassemia retardation-
16) syndrome was explored in the next paper. It was concluded that in MR patients 
showing microcytic (= small cell) hypochromatic anemia, the presence of ATR-16 syn-
drome should be excluded. 
 Thirdly, we were able to unravel the etiology of the Peters Plus syndrome, an auto-
somal recessive inheritable disorder, using a genome-wide screening tool. Finally, four 
high resolution genome-wide mapping tools were compared using four patients with 
an overlapping interstitial 2p deletion.
Chapter II
 Screening ‘large’ patient groups 
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Introduction: It has been estimated that cytogenetically visible rearrangements are pres-
ent in ~1% of newborns. These chromosomal changes can cause a wide range of del-
eterious developmental effects, including mental retardation (MR). It is assumed that 
many other cases exist where the cause is a submicroscopic deletion or duplication. To 
facilitate the detection of such cases, different techniques have been developed, which 
have differing efficiency as to the number of loci and patients that can be tested. 
Methods: We implemented multiplex amplifiable probe hybridisation (MAPH) to test 
areas known to be rearranged in MR patients (for example, subtelomeric/pericentro-
meric regions and those affected in microdeletion syndromes) and to look for new 
regions that might be related to MR. 
Results: In this study, over 30 000 screens for duplications and deletions were carried 
out; 162 different loci tested in each of 188 developmentally delayed patients. The 
analysis resulted in the detection of 19 rearrangements, of which ~65% would not have 
been detected by conventional cytogenetic analysis. A significant fraction (46%) of the 
rearrangements found were interstitial, despite the fact that only a limited number of 
these loci have so far been tested. 
Discussion: Our results strengthen the arguments for whole genome screening with-
in this population, as it can be assumed that many more interstitial rearrangements 
would be detected. The strengths of MAPH for this analysis are the simplicity, the high 
throughput potential, and the high resolution of analysis. This combination should 
help in the future identification of the specific genes that are responsible for MR. 
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introduction
The evolution of the human genome has resulted in mixture of large and small inter-
spersed and tandem segmental duplications throughout the genome. Such duplications 
provide substrates for homologous recombination, and consequently, the intervening 
regions show considerable rate of rearrangement.1–3 Many of these rearrangements oc-
cur in regions where a change in gene dosage does not affect human health. However, 
after the description by Lejeune of trisomy 21 in Down’s syndrome,4 and the many 
subsequent publications on different aneuploidies, it became clear that the genome 
contains many loci for which the correct copy number is critical for normal develop-
ment. Change in genetic dosage of one or more genes is one of the most common 
causes of mental retardation (MR). Examples of known important loci include the 
subtelomeric regions and the areas involved in microdeletion syndromes. 
 The subtelomeric regions, localised proximal to the telomeres, have been found to 
be especially susceptible to copy number changes, owing to repeat rich sequences that 
show a high frequency of recombination.1 It has been hypothesised that about 6% 
of the patients with idiopathic MR will have a subtelomeric rearrangement,5 a figure 
confirmed in several studies that have reported a frequency of 2–9% of cryptic rear-
rangements in MR patients.67 
 The cause for MR is only established in approximately 50% of cases, limiting the 
efficiency of genetic counselling, detection of carriers, and prenatal diagnosis in these 
families. This rather low percentage of diagnosis may have several explanations. A rou-
tine cytogenetic analysis gives a minimum resolution of only 4–10 Mb. Fluorescent in 
situ hybridisation (FISH) largely overcomes this limitation of resolution; however, it can 
only be applied to simultaneously test a limited number of chromosome regions. FISH 
is therefore mostly used to confirm well recognised microdeletion syndromes in patients 
who present a suggestive phenotype. Another potential explanation is that the genome 
contains undiscovered loci that are involved in the aetiology of MR. New technologies, 
such as multiplex amplifiable probe hybridisation (MAPH),8 multiplex ligation depen-
dent probe amplification (MLPA),9 and array based comparative genomic hybridisation 
(array CGH),10 have recently been developed to search for such undiscovered regions. 
We chose to implement a high resolution, high throughput, rapid, and simple method, 
MAPH,8 which allows the simultaneous screening at the exon level for copy number 
changes of 40–50 different chromosomal loci in up to 96 patients in one assay. Hollox 
et al.11 previously described subtelomeric screening using MAPH of patients with a de-
velopmental delay. In our study, we screened loci known to be involved in MR (subtelo-
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meric/pericentromeric regions and genes involved in microdeletion syndromes) as well 
as interstitial genes randomly spaced throughout the genome. A total of 30 000 gene 
dosage screens were performed from 188 cases with unexplained developmental delay 
that were each scanned for copy number changes at 162 loci. We were able to detect 
subtelomeric, pericentromeric, and interstitial rearrangements in a group of patients 
with MR and dysmorphic features and/or multiple congenital abnormalities, as well as 
in patients selected solely on the basis of developmental delay. 
subjects and methods
Probe design and MAPH
The probe design has been previously described,12 using unique sequences only. The 
primers of the chosen sequences were designed using Prophet (http://www.basic.nwu.
edu/ biotools/prophet.html), and supplied by Invitrogen Life Technologies. Products 
were amplified from genomic DNA by PCR and cloned into the pGEM-T easy vec-
tor (Promega). The correct insert was confirmed by sequencing with the BigDye 
Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) at the Leiden 
Genome Technology Center, using an ABI 3700 Sequencer (Applied Biosystems). 
 MAPH was performed as described by White et al.12 (see also Leiden Muscular 
Dystrophy Pages (http://www.dmd.nl/ DMD_MAPH.html)). 
Study population 
The DNA of 188 patients (110 males and 78 females) from the Center for Human and 
Clinical Genetics Leiden (a DNA diagnostic laboratory) was analysed. The patients had 
been seen by a clinical geneticist or a paediatrician and diagnosed with developmental 
delay. The study population was divided into two groups. The first group contained 123 
coded patients who had been referred for fragile X screening. Before testing, information 
about the results of additional tests, such as karyotyping, was not known to the investiga-
tors. The second study group (n = 65) was known to have a normal karyotype and had 
tested negative for fragile X screening. All patients had (multiple) congenital malforma-
tions or dysmorphic features in addition to psychological developmental delay. 
Data analysis 
The data were analysed with GeneScan Analysis and Genotyper Software (Applied 
Biosystems). These programs provide information about the length, peak height, 
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and peak area of the DNA fragments. Peaks were not used for analysis if they were 
outside predefined thresholds (upper and lower limits of 12 000 and 150 units, 
respectively). To obtain a ratio, the height of a given peak was divided by the sum 
of the heights of the four nearest peaks. As it is not likely that all four probes from 
diverse regions of the genome are altered in one patient, adding unrelated standards 
was not necessary in most of the probe sets. For the chromosome 22 probe set, how-
ever, unrelated probes, containing sequences from other chromosomes, were used as 
references. 
 The median ratio for each probe within a single hybridisation (minimum number 
of samples 8; maximum number 12) was determined and used to calculate a nor-
malised ratio for each patient. Within each patient, initial ‘‘normal’’ thresholds were 
set as 0.75 and 1.25. The standard deviation from the ratios within these limits was 
calculated, and three times this standard deviation was used as the threshold for any 
given patient. Any probe that was outside these limits was retested, and samples that 
showed an apparent copy number change in duplicate were examined further using 
other techniques. Samples that showed a standard deviation of .10% over probes with-
in the normal thresholds were retested. 
Verifying the MAPH results 
Copy number changes detected by MAPH were verified using another technique, pri-
marily FISH with a bacterial artificial chromosome (BAC) or cosmid probe covering 
the appropriate genomic region. The BACs used were designed by Flint,13 or supplied 
by Vysis Abbott Laboratories (TV, Telvysion, LSI, locus specific identifiers) or selected 
from the RPCI human BAC library. The FISH experiments were performed following 
standard operating procedures as described in Dauwerse et al.14 Some MAPH results 
were verified using MLPA.9 
results
Genotyping 
We designed several probe sets covering both the subtelomeric/pericentromeric and 
interstitial regions, including genes involved in microdeletion syndromes, genes on 
chromosome 22, and genes spread across all chromosomes (table A, supplemental). 
The subtelomeric probe set is composed of probes corresponding to the 41 subtelo-
meric regions, preferably an exon of a gene within 1 Mb from the telomere, five genes 
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near the centromere on the q arm of the acrocentric chromosomes, a sequence in the 
pseudoautosomal region of chromosome Xq and Yq, and an exon of a Yp specific 
gene. The microdeletion probe set was made up of 27 probes from 21 different genes 
involved in microdeletion syndromes (Williams, Prader Willi, Angelman, Smith-
Magenis, Sotos, 22q11, Alagille, and Wolf-Hirschhorn syndromes). The chromosome 
22 probe set included 19 probes from genes on chromosome 22 with approximately 
1 Mb spacing. Finally, we used two probe sets containing a total of 68 interstitial 
genes spread throughout the genome. 
 We applied these probe sets following two methods of validation. Firstly, a probe 
was considered to be reliable when the standard deviation over 12 unaffected samples 
(one hybridisation) was <15%. Secondly, where possible, we verified the unique and 
correct localisation of the probes using DNA from patients with known aberrations 
(42% of the subtelomeric probes, 70% of the microdeletion probes). 
 Overall, 188 patients were screened for deletions and duplications at 162 loci, re-
sulting in the detection of 19 copy number changes. Of these, four aberrations turned 
out to be cytogenetically visible, namely an isochromosome 18p (karyotype 47, XY, 
+i(18p)), a marker chromosome (karyotype 47, XY, +mar.ish der(22)t(8;22)(q24.1;q
11.2)), a triple X female (karyotype 47, XXX) and a Turner syndrome (karyotype 45, 
X), because the outcome of additional investigations had not been made known to 
the investigators before testing. These patients and their corresponding aberrations 
were not included in the calculation of the percentage of rearrangements found by 
MAPH; however, they emphasise the usefulness of MAPH for detecting copy number 
changes. 
 In total, eight subtelomeric/pericentromeric rearrangements were found (table 1; 
upper part). Five of these mutations were detected in the group of MR patients with 
additional dysmorphic features or additional congenital malformations (5/65 = 7.7%) 
and the remaining three subtelomeric aneusomies were diagnosed in the group selected 
on the basis of developmental delay only (3/123 = 2.4%). The smallest mutation found 
was a deletion of 110 kb maximum present in chromosome band 7p22.3 (table 1, F; 
and data not shown). Seven rearrangements were interstitial mutations. These are sum-
marised in the lower part of table 1. Where possible, the DNA of both parents of these 
patients was tested; 75% (9/12) were shown to be de novo. The duplication of 14q11.2 
(table 1, O) and the 7ptel deletion (table 1, F) were also found in the parental DNA, 
and one of the parents of patient E was a balanced translocation carrier. 
 As the number of cytogenetically detectable aberrations is highly dependent on 
the banding resolution, the karyograms of all 15 patients with a MAPH detected rear-
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rangement were re-examined. At a resolution of 500–550 bands per haploid set, the 
karyograms showed that two subtelomeric copy number changes should have been 
detected cytogenetically (table 1; A, C). The detection of a 1ptel deletion (table 1, H) 
was doubtful; however, the duplication of 1ptel (table 1, H) was picked up. This im-
plies that although the presence of the copy number change was known, 63% (12/19) 
of these genomic changes found in this study were cytogenetically undetectable using 
karyotyping at a resolution of 500–550 bands. 
Case descriptions 
Case 1 
This 15 year old girl was diagnosed with total anomalous pulmonary venous return, 
hearing loss in combination with a narrow external auditory meatus, and MR. Physical 
examination at the age of 14 years showed a short stature (–3 SD) and some facial 
dysmorphic features (small palpebrae, broad mouth, thin upper lip). Karyotyping at 
a resolution of 400 bands and FISH studies of the 22q11 region did not detect any 
rearrangements. MAPH study showed a de novo deletion of the subtelomeric region of 
18q, which was confirmed by FISH using probe TV18q. The clinical features of this 
patient are consistent with those of the 18q syndrome phenotype.15 
Case 2 
A male patient, who had previously tested negative for Williams syndrome, was di-
agnosed with a de novo deletion of 16ptel by MAPH. FISH analysis confirmed this 
finding and limited the proximal breakpoint to chromosome band 16p13.3, distal to 
the PKD1–TSC2 (LocusLink 5310–7249) gene cluster16 using probe COS15A. As ex-
pected, owing to the location of the alphaglobin gene (HBA1; LocusLink 3039) in this 
region (16p13.3),17 further investigation showed that this patient had mild anaemia 
(alpha thalassaemia heterozygosity) in addition to his moderate mental handicap and 
dysmorphic features. 
Case 3 
This boy was seen by a clinical specialist at the age of 2.5 years for his psychomotor 
retardation and joint hyper-flexibility. Physical examination showed few dysmorphic 
features (a tent shaped mouth), hypotonia, and hypermobility. MAPH analysis re-
vealed a de novo deletion within chromosome band 17p11.2 corresponding to the 
Smith-Magenis syndrome (SMS) region, using a probe for the DRG2 gene (LocusLink: 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This boy was seen by a clinical specialist at the age of
2.5 years for his psychomotor retardation and joint hyper-
flexibility. Physical examination showed few dysmorphic
features (a tent shaped mouth), hypotonia, and hypermobi-
lity. MAPH analysis revealed a de novo deletion within
chromosome band 17p11.2 corresponding to the Smith-
Magenis syndrome (SMS) region, using a probe for the DRG2
gene (LocusLink: 1819). The more distally located COPS3 gene
(LocusLink: 8533) showed two copies (fig 1a). Additional
MLPA testing showed that the RAI1 gene (LocusLink: 10743)
was also deleted in this patient (fig 1b), and FISH analysis
(probe LSI-SMS) verified the deletion of part of chromosome
band 17p11.2 (fig 1c). Recently, three dominant frameshift
mutations in RAI1 have been identified in three patients with
phenotypic characteristics of SMS but no cytogenetically
detectable deletion of chromosome band 17p11.2.18 The
authors argue that mutations in RAI1 are responsible for
most of the characteristic features of SMS and that further
variation is caused by hemizygosity of the other genes in the
chromosome region.
Case 4
This male patient showed at the age of 12 years a mild
learning disability, a low voice, a disproportionally short
stature (height 22 SD, span 23 SD for height, sitting height
20.5 SD, head circumference 22 SD), limited elbow
extension, a permanently extended, inflexible fifth digit of
both hands with a ram’s horn shaped nail and hypotrophy of
the hypothenar muscles (fig 2), and a short broad great toe
on both feet. The hand x ray revealed short metacarpals I and
V, short distal phalange V, and a delay of bone maturation. In
this patient, a de novo deletion of 4q34.1 was detected and
confirmed by FISH (probe RP11-475B2). Analysis with a
more distally located MAPH probe at chromosome band
4q35.1 showed that this latter region was still present,
indicating an interstitial rearrangement. Additional FISH
experiments using different BAC probes limited the deletion
to a maximum of 3 Mb (data not shown).
Patients with an interstitial 4q deletion have been
described with a range of features, depending on the
proximal and distal breakpoints of the deletion.19 As it is
known that fifth finger anomalies and short stature are
found in patients with an interstitial deletion of 4q including
4q34,20 as well as in patients with a terminal deletion of 4q, it
is possible that the genes responsible for these features are
located within this region.
Figure 1 The plots correspond to the MAPH results showing (A) a
deletion of the DRG2 gene, two normal copies of COPS3A (RAI1 not
present), and the MLPA results; and (B) a deletion of RAI1, a deletion of
DRG2, and a normal ratio of COPS3A. (C) The additional FISH analysis
using the LSI-SMS probe specific for the Smith Magenis chromosomal
region shows a normal signal on the short arm of only one copy of
chromosome 17.
Figure 2 The right hand of case 4 showing a short, inflexible fifth digit
with a ram’s horn shaped nail and hypotrophy of the hypothenar
muscles.
252 Kriek, White, Bouma, et al
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Figure 1.  Results of case 3. 
The plots correspond to the MAPH results showing (A) a deletion of the DRG2 gene, two normal copies of COPS3A 
(RAI1 not present), and the MLPA results; and (B) a deletion of RAI1, a deletion of DRG2, and a normal ratio of 
COPS3A. (C) The additional FISH analysis using the LSI-SMS probe specific for the Smith Magenis chromosomal 
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(fig 1a). Additional MLPA testing showed that the RAI1 gene (LocusLink: 10743) 
was also deleted in this patient (fig 1b), and FISH analysis (probe LSI-SMS) verified 
the deletion of part of chromosome band 17p11.2 (fig 1c). Recently, three dominant 
frameshift mutations in RAI1 have been identified in three patients with phenotypic 
characteristics of SMS but no cytogenetically detectable deletion of chromosome band 
17p11.2.18 The authors argue that mutations in RAI1 are responsible for most of the 
characteristic features of SMS and that further variation is caused by hemizygosity of 
the other genes in the chromosome region. 
Case 4 
This male patient showed at the age of 12 years a mild learning disability, a low voice, 
a disproportionally short stature (height –2 SD, span –3 SD for height, sitting height 
–0.5 SD, head circumference –2 SD), limited elbow extension, a permanently extend-
Figure 2.  The right hand of case 4 showing a short, inflexible fifth digit with a ram’s 
horn shaped nail and hypotrophy of the hypothenar muscles. 
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ed, inflexible fifth digit of both hands with a ram’s horn shaped nail and hypotrophy 
of the hypothenar muscles (fig 2), and a short broad great toe on both feet. The hand 
x ray revealed short metacarpals I and V, short distal phalange V, and a delay of bone 
maturation. In this patient, a de novo deletion of 4q34.1 was detected and confirmed 
by FISH (probe RP11-475B2). Analysis with a more distally located MAPH probe at 
chromosome band 4q35.1 showed that this latter region was still present, indicating an 
interstitial rearrangement. Additional FISH experiments using different BAC probes 
limited the deletion to a maximum of 3 Mb (data not shown). 
 Patients with an interstitial 4q deletion have been described with a range of fea-
tures, depending on the proximal and distal breakpoints of the deletion.19 As it is 
known that fifth finger anomalies and short stature are found in patients with an 
interstitial deletion of 4q including 4q34,20 as well as in patients with a terminal 
deletion of 4q, it is possible that the genes responsible for these features are located 
within this region. 
Figure 3. Facial dysmorphism of case 6. 
Note the microcephaly, ptosis of the left eye, flat philtrum, and thin upper lip. [See appendix: colour figures.]
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Case 5 
This mildly retarded man, with a de novo duplication within chromosome band 
20p12.2, containing the Jagged1 gene (JAG1; LocusLin: 182), died at the age of 
60 years from multiple myeloma. He had been institutionalised for over 40 years in 
a psychiatric hospital because of aggressive behaviour, and was diagnosed as schizo-
phrenic. To the best of our knowledge there has been only one previous report21 of a 
duplication of 20p11.21–p11.23, in four members of a family with clinical signs of 
Alagille syndrome. As our patient is not available for further investigation, it remains 
unclear whether he had such features. 
Case 6 
After 41 weeks of gestation, this child was born with a birth weight of 1995 g (<2.5 SD) 
and a head circumference of 28.5 cm (<2.5 SD). At the age of 25 months, her psycho-
motor development was severely delayed and she suffered from epilepsy. Physical exami-
nation showed growth retardation (length <2 SD; weight –6 SD), microcephaly (head 
circumference –6 SD), hypertonicity, dystonic movements, facial dysmorphisms (ptosis 
of the left eye, flat philtrum, thin upper lip; fig 3) ear pits, café au lait spots, and absence 
of the labia minora. Further investigation revealed corpus callosum hypoplasia and de-
formed gyri, the presence of only one kidney and mildly increased urinary glutaric acid. 
 Using the microdeletion probe set, a duplication of 22q11.2 was detected by 
MAPH, and FISH analysis in interphase nuclei confirmed this finding (LSI TUPLE1). 
The patient’s mother did not carry the duplication, and the father was unavailable for 
testing. We plan to use polymorphic markers to determine the parental origin of the 
aberrant chromosome 22. 
discussion 
Using MAPH analysis, we performed a high resolution duplication/deletion screening 
of 188 patients with a developmental delay; 162 loci per patient were tested, amount-
ing to over 30 000 typings. The MAPH probes designed for this study can be broadly 
divided into two groups: (a) subtelomeric and pericentromeric probes (n = 48) and (b) 
interstitial probes (n = 114), containing sequences located in regions previously found 
to be rearranged in mentally retarded individuals, and genes randomly spaced through 
out the genome. 
 We detected 4.3% (8/184) subtelomeric/pericentromeric rearrangements (six de-
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letions, one duplication, and one subtelomeric deletion/duplication in one patient), 
using 48 MAPH probes. A subdivision of subtelomeric aberrations over our two study 
populations agrees with the findings of Knight et al.22 and Yasseen et al.23 The percent-
age of subtelomeric mutations detected was higher in a group of MR patients with 
additional malformations (7.7%) than in a group selected on the basis of developmen-
tal delay only (2.5%). This supports the suggestion of De Vries et al. that pre-selec-
tion of patients for subtelomeric screening is worthwhile. However, pre-selection of 
these patients for subtelomeric rearrangements is difficult, as only two clinical features 
(perinatal onset growth retardation and a positive family history) differed significantly 
between patients with subtelomeric aneusomies and patients with idiopathic MR.24 
Our overall percentage is similar to that reported in a recent paper that summarised 
all previous subtelomeric publications.7 A total of 131 subtelomeric imbalances were 
found using several different methods among 2582 MR patients, resulting in an overall 
frequency of 5.1%. A review of the corresponding clinical aspects of these subtelomeric 
rearrangements has been published recently.25 After re-examining the karyogram of our 
patients at a banding resolution of 500–550 bands, it showed that five MAPH detected 
subtelomeric imbalances were not cytogenetically visible, despite the knowledge of a 
copy number change present. This means that the percentage of ‘‘true’’ submicroscopic 
subtelomeric/ pericentromeric findings is ~3% (5/184) in this study. 
 Previous reports by Sismani et al.26 and Hollox et al.11 had already shown the abil-
ity of MAPH to detect subtelomeric copy number changes. Hollox et al. found a copy 
number change in 5 of 37 male patients (13.5%) who had been referred for fragile X 
screening. The higher percentage of mutations found by this group may be due to dif-
ferences in selection criteria for fragile X screening. 
 We also screened the subtelomeric/pericentromeric regions in eight newborns suf-
fering multiple congenital abnormalities (MCA). Among these patients, one deletion 
of the subtelomeric region of chromosome 15 was detected and subsequently con-
firmed by FISH (data not shown).27 To determine whether it is worthwhile to test this 
group for submicroscopic mutations, more newborns with MCA should be examined. 
The ease and relatively low cost of the MAPH technique means that such analysis is 
feasible. Moreover, new techniques such as MAPH/MLPA and array CGH provide 
the possibility of genetic diagnosis at a younger age. As the suggestive phenotype for 
some microdeletion syndromes emerge only later in life, this diagnosis would be very 
important for providing appropriate healthcare. 
 In addition to the reports published by Sismani et al.25 and Hollox et al.,11 we also 
examined interstitially localised genes, including genes involved in several microdele-
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tion syndromes, genes on chromosome 22 (as this was the first chromosome to be com-
pletely sequenced), and genes that are spread throughout the genome and might be 
involved in cognitive development. Recently, Bailey et al.3 argued that regions between 
highly similar duplications (low copy repeats) are prone to recombination and conse-
quently, copy number changes occur at a higher frequency in these regions compared 
with other loci in the genome. Several of the areas described were also tested in this 
study, mostly corresponding to chromosomal regions involved in microdeletion syn-
dromes. In total, seven interstitial deletions and duplications were detected, of which 
five were diagnosed in three different regions known to be involved in the microde-
letion syndromes and flanked by segmental duplications. Three of these interstitial 
rearrangements detected include duplications of regions that are usually deleted (the 
chromosome regions of Smith Magenis (17p11.2), DiGeorge (22q11.2), and Alagille 
syndromes (20p12.2)). This observation supports the theory that the regions between 
low copy repeats can both be deleted and duplicated, and implies that the number of 
patients suffering from a microduplication syndrome is currently probably underesti-
mated. The phenotype (if any) of a microduplication syndrome might, however, be 
less severe, and under standard diagnostic conditions, the detection of duplications is 
more problematical. It should be noted that in the second study group, the cases with 
a distinctive phenotype for a specific microdeletion syndrome were not included. 
 As has been the case during the development of every new technique, the genomic 
variations detected can be divided into the following subclasses: (a) genetic changes 
that are clearly pathogenic, (b) rearrangements that may or may not be causal to the 
patient’s problem, and (c) polymorphic changes. In some cases, extensive clinical stud-
ies will be needed to determine to which category a newly detected aberration belongs. 
In two of our cases, we could detect the rearrangement in one of the parents (the 
duplication of chromosome band 14q11.2 and the deletion of 7ptel on chromosome 
band 7p22.3). One explanation is that these imbalances are polymorphic, and that the 
phenotype of the patient is not related to the copy number change. However, other 
explanations are possible: (a) the affected region is imprinted, and the parental origin 
of this region is critical in causing the deleterious phenotype;28 (b) allelic variation in 
the expression of the genes may influence the phenotype;29 and (c) low penetrance of 
the rearrangement–that is, a genetic defect does not always lead to a phenotypic ef-
fect. The detection of such rearrangements will increase as high resolution techniques 
are applied, and this will pose new problems for genetic counselling. Therefore, it is 
important to map these familial imbalances in further detail to allow a genotype–phe-
notype correlation in larger populations of individuals with the same copy number 
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change. In this way, the understanding of any clinical consequence of such a rearrange-
ment should be improved. 
 Based on previous publications, seven rearrangements found in this study were 
considered to be pathogenic (table 1). In the remaining cases, the data available in lit-
erature were insufficient to support a conclusion that the aneusomy detected is related 
to the phenotype of the patient. It should be noted that the fact that a rearrangement 
is de novo is not in itself proof that it is causally related to the deleterious phenotype. 
 Several different methologies have been described to identify changes using MAPH 
and MLPA. These include visual comparison of traces from controls and patients,30 the 
setting of arbitrary thresholds,26 and bivariate analysis.11 We observed that the standard 
deviations for each probe varied slightly between hybridisations, and could be nor-
malised only within a single hybridisation. The standard deviation of ‘‘normal’’ probes 
within each patient was calculated, with 3 times this figure defining the threshold for 
a potential rearrangement, thus minimising the effect of any genuine copy number 
changes on the analysis. As false negative results are, by definition, mutations that 
were not detected, it is difficult to determine the percentage. To gain an estimate as to 
the actual false negative rate, we looked at a number of samples where a mutation was 
previously known. We tested 30 samples that had aberrations at loci corresponding to 
39 of the probes used. The appropriate copy number changes were detected in all cases. 
Using the LaPlace formula p = (x+1)/(n+2) to provide a false negative rate from our 
data yields an expected value of ~2.5%. This figure suggests that the true false negative 
rate would be, at least for the 39 probes examined, comparable to the 2% theoretically 
predicted by Hollox et al.11 Of course, it would be desirable to test all the probes on 
known mutations in the future. 
 The number of interstitial aneusomies found in this report strengthens the argu-
ments for genomewide screening for copy number changes in developmentally delayed 
patients. In most clinical laboratories, deletions and duplications are detected by FISH. 
This usually focuses on only one region per hybridisation, and is therefore relatively 
slow and expensive. Several new technologies have emerged that facilitate large scale 
and genomewide screening of deletion and duplication mutations. For genomewide 
screening, array CGH currently seems to be the most attractive, with recent publica-
tions describing screening with approximately 2000 BAC-PAC clones at an average 
resolution of 1.5 Mb.31 32 This is impressive, but inherently means that 90% of the ge-
nome is not screened. In addition, probes in array CGH are 100–200 kb BAC clones, 
often covering more than one gene and thus able to pick up large multi-gene dele-
tions/duplications only–that is, those >100 kb, while it is probable that a significant 
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proportion of deletion/duplication mutations are smaller than this. In contrast, it is 
possible to detect rearrangements of only 100 bp using MAPH and MLPA technology. 
By applying a high resolution method, however, the percentage of the genome that can 
be screened using the same number of probes will be much less compared with array 
CGH. Using MAPH/MLPA, it is not possible to screen the whole genome for copy 
number changes at this moment, unless a very large number of probes are included. 
For this reason, a different approach is required. We consider array CGH to be an ex-
cellent tool for finding large regions in the genome where genes involved in particular 
diseases reside. As soon as these areas have been identified, targeted and much cheaper 
assays can be designed, zooming in on these regions only. For these reasons, we believe 
that gene specific screening is ultimately more attractive. With that in mind, MAPH/ 
MLPA have an important role in such analyses, as they are able to pick up both large 
and small deletions/duplications. 
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Duplicons, that is, DNA sequences with minimum length 10 kb and a high sequence 
similarity, are known to cause unequal homologous recombination, leading to deletions 
and the reciprocal duplications. In this study, we designed a Multiplex Amplifiable 
Probe Hybridisation (MAPH) assay containing 63 exon-specific single-copy sequences 
from within a selection of the 169 regions flanked by duplicons that were identified, at 
a first pass, in 2001. Subsequently, we determined the frequency of chromosomal rear-
rangements among patients with developmental delay (DD) and/or congenital mal-
formations (CM). In addition, we tried to identify new regions involved in DD/CM 
using the same assay. In 105 patients, six imbalances (5.8%) were detected and veri-
fied. Three of these were located in microdeletion-related regions, two alterations were 
polymorphic duplications and the effect of the last alteration is currently unknown. 
The same study population was tested for rearrangements in regions with no known 
duplicons nearby, using a set of probes derived from 58 function-selected genes. The 
latter screening revealed two alterations. As expected, the alteration frequency per unit 
of DNA is much higher in regions flanked by duplicons (fraction of the genome tested: 
5.2%) compared to regions without known duplicons nearby (fraction of the genome 
tested: 24.5–90.2%). We were able to detect three novel rearrangements, including the 
previously undescribed reciprocal duplication of the Williams Beuren critical region, 
a subduplicon alteration within this region and a duplication on chromosome band 
16p13.11. Our results support the hypothesis that regions flanked by duplicons are 
enriched for copy number variations. 
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Introduction 
Many genetic disorders are caused by changes in chromosomal structure. Deletions, 
duplications, inversions and translocations can all lead to changes in the effective dos-
age of one or more genes, often with pathological consequences. Large rearrangements 
affecting at least 5 Mb can be seen cytogenetically, and many disorders have been 
recognised and characterised based solely on microscopic analysis.1-4 
 It was shown in 1992 that the region duplicated in Charcot-Marie-Tooth (CMT) 
was flanked by highly similar (>98%) sequences.5 Unequal crossing over between these 
duplicons leads both to this duplication and the reciprocal deletion, which was lat-
er shown to cause hereditary neuropathy with liability to pressure palsies (HNPP).6 
Duplicons, also known as low copy repeats (LCRs), have since been implicated in 
many other disorders.7,8 It has been estimated that 5% of the human genome is com-
posed of such LCRs, which can be present both inter-and intrachromosomally.9,10 
 In 2002, Bailey et al.11 identified 169 unique regions of at least 10 kb in size, between 
intrachromosomal duplicons with >95% sequence identity. These data were based on the 
Human Working draft of August 2001. In all, 24 of these regions were already associ-
ated with known genetic disorders. It was hypothesised that these 169 regions are likely 
to undergo rearrangements more frequently compared to interstitial regions outside the 
defined regions, due to misaligned recombination between the LCRs, creating microde-
letions, microduplications and inversions of the segments involved. To assess this in more 
detail, we have designed a Multiplex Amplifiable Probe Hybridisation (MAPH) probe set 
containing 30% of these regions, including those related to microdeletion syndromes. In 
all, 105 unrelated patients with developmental delay (DD) and/or congenital malforma-
tions (CM) were tested using these probes. We compared the performance of this probe 
set with a set of probes located outside the thus far known duplicons. The second pur-
pose of this study was to identify new regions that are frequently altered in DD patients 
or patients with CM using the duplicon data of 2002. 
 The assay using sequences flanked by duplicons resulted in the detection of six 
duplications, of which three were located in regions related to known disorders. Two 
alterations were detected by screening regions outside known duplicons. These results 
show that in our study population the genetic variation within duplicon-flanked re-
gions was three times more common compared to the regions outside the duplicons. 
Among the rearrangements detected was the postulated, but until now unidentified, 
reciprocal duplication of the Williams Beuren critical region (WBCR) and a smaller 
subduplicon alteration within this region. 
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materials and methods 
Patients 
The DNA of 99 DD/CM patients and six individuals with CM only (64 males 
and 41 females) from the Center of Human and Clinical Genetics Leiden (DNA 
Diagnostic Laboratory) was analysed. Prior to MAPH analysis, all patients showed a 
normal karyotype and, where tested, had tested negative for Fragile X syndrome. This 
study cohort does not include any patient presenting with typical microdeletion char-
acteristics. These had been previously diagnosed by the cytogenetics department. 
 This study was approved by the Institutional Review Board of the Leiden University 
Medical Center, conforming to Dutch law. All subjects, or their representatives, gave 
informed consent for DNA studies. 
Multiplex Amplifiable Probe Hybridisation 
MAPH was performed as described by White et al.12 Ratios were obtained by divid-
ing the peak height of each probe by the sum of the peak heights of the four nearest 
probes. The probes with a normalised ratio between 0.75 and 1.25 (log(2) scale –0.42 
to +0.32) were considered to be present in two copies. The probes with a ratio outside 
these thresholds were considered to have a copy number alteration. All samples in 
which an alteration was found were screened at least in duplicate. 
 The different probe sets used contained respectively 63 probes from genes flanked 
by duplicons (see Appendix A) in 51 different regions, including those involved in 
Smith Magenis (SMS (MIM 182290)), William Beuren (WBS (MIM 194050)), 
DiGeorge (DGS (MIM 188400)), Cat eye (CES (MIM 115470)), Prader Willi (PWS 
(MIM 176270)), Angel-man syndrome (AS (MIM 105830)) and 58 probes contain-
ing function-selected genes outside the duplicons (Appendix B). 
Multiplex Ligation-dependent Probe Amplification 
A modified protocol of multiplex ligation-dependent probe amplification (MLPA)13 
was performed as described by White et al.14 In the current study, MLPA was performed 
to verify alterations obtained by MAPH analysis. The data analysis is identical with that 
applied for MAPH analysis. The MLPA probes used were derived from the sequences 
of RAI1 (GeneID: 10743), DRG2 (GeneID: 1819), COPS3 (GeneID: 8533), ELN 
(GeneID: 2006), CYLN2 (GeneID: 7461), FKBP6 (GeneID: 8468), TBL2 (GeneID: 
26608), FZD9 (GeneID: 8326), GTF2IRD1 (GeneID: 84163), GTF2I (GeneID: 
2969), HIP1 (GeneID:3092), AUTS2 (GeneID:26053), CALN1 (GeneID: 83698), 
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NUDE1 (GeneID: 54820), PYRR1, defender against cell death 1 (DAD1) gene 
(GeneID: 1603) and the diacylglycerol kinase iota (DGKI) gene (GeneID: 9162). 
Fluorescence In Situ Hybridisation 
The FISH experiments were performed following Standard Operating Procedures.15 
An FITC-labeled FISH clone LSI-ELN (Vysis) was used for the Williams critical 
Region. BAC clones RP11-14N9, RP11-M13, RP11-489O1 and RP11-72I8 were 
used to determine the extent of the rearrangement on chromosome band 16p13.3. 
Array comparative genomic hybridisation 
The array comparative genomic hybridisation (array-CGH) procedures were performed 
as described in Knijnenburg et al.16 using larger genomic insert clones retrieved from the 
Sanger Center (UK) (1 MB clone set). In silico data at the http://www.ensemble.org were 
used to determine the size of the duplications. 
results 
Considering that duplicon-flanked regions might be preferentially involved in copy 
number variation, we based our MAPH probe set to detect new regions involved in DD/ 
CM on a gene-enriched selection from the 169 regions published by Bailey et al.11 
 The MAPH probes were designed based on autosomal exon-specific single-copy 
sequence. Regions lacking known genes and/or single-copy sequence (62/169 or 37% 
of the defined regions) were excluded. Before the actual screening, the probe sets were 
validated using DNA samples derived from 50 anonymous healthy controls. Among 
those, we detected a pancreatic polypeptide receptor 1 (PPYR1) gene duplication 
that was verified using MLPA analysis. Probes showing inconsistent copy number 
variation within an individual (duplicate testing) were excluded (n = 9). The validated 
probe sets, targeting 63 unique sequences in 51 different regions (see Appendix A), 
were tested among a total of 105 unrelated patients (64 males, 41 females), includ-
ing 99 developmentally delayed (DD) patients (25 mild DD; 74 severe DD) and six 
individuals with CM. 
 Screening these 105 patients revealed six imbalances (5.8%), all duplications 
(Table 1). All rearrangements were verified using MLPA, array-CGH or FISH. Three 
of the rearrangements were located in areas known to be involved in microdeletion syn-
dromes, including two duplications within the WBCR on chromosome band 7q11.23 
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(see case reports), and a de novo duplication of the Smith Magenis Critical Region 
(SMCR) on chromosome band 17p11.2. The two 7q11.23 duplications, detected in 
two unrelated patients, differed in length, as one was found using four MAPH probes 
(containing sequences derived from the CYLN-2, ELN, FKBP6 and TBL2 genes) and 
the other with only one of these, the FKBP6 gene (Figure 1). Additional array-CGH 
analysis did not detect this alteration. The exact size of the duplication is difficult to 
define as the BACs flanking this region (RP11-450O3, RP4-771P4) partly colocalise 
with segmental duplicons in this region. Additional MLPA was performed using se-
quences of the GTF2I and GTF2IRD1 genes within the WBCR and HIP1, CALN1 
and AUTS2 genes localised just outside the telomeric and centromeric sides of the seg-
mental duplicon, respectively. This assay revealed that this duplication is the reciprocal 
duplication of the deletion causing Williams–Beuren syndrome. 
 To fine map the other duplications (case 2), additional MLPA probes were designed. 
Exon 4 and exon 8 (the last exon) of the FKBP6 gene were shown to be duplicated. 
We were unable to test the first three exons of this gene, as they contain large repeti-
tive sequences. The probe derived from the adjacent FZD9 gene showed no alteration. 
Testing the parents of the patients showed that in each case the duplication was present 
in one of the parents (data not shown). There appeared to be no parent of origin effect, 
as the large alteration was found in the patient’s father, and the small alteration in the 
mother of the other patient. 
Table 1. Alterations in regions flanked by duplicons.
Case Alteration Chrom. Band Gene(s) involved Size (Mb) de novo Confirmed by 
1 Duplication 7q11.23 CYLN2, ELN, 
FZD9, FKBP6, TBL2
1.4–1.7 No, present in 
father
MLPA/FISH 
2 Duplication 7q11.23 FKBP6 0.3–0.4 No, present in 
mother
MLPA 
3 Duplication 17p11.2 RAI1, DRG2, 
COPS3 
min. 3.5a Yes MLPA/FISH/array-CGH 
4 Duplication 16p13.11 NUDE1, MYH11 0.8–2.4 Yes MLPA/FISH/array-CGH 
5 Duplication 10q11.22 PPYR1 0.5–2.3 No, present in 
father
MLPA/array-CGH 
6 Duplication 10q11.22 PPYR1 max. 1.4 Unknownb MLPA/array-CGH 
Summary of results obtained by screening 105 DD/CM patients using 51 unique regions flanked by duplicons. The 
sizes of the different alterations were determined based on results of both MAPH/MLPA and array-CGH.
a)  As the regions near the centromere of chromosome 17 are not covered by array-CGH, the centromeric breakpoint 
of this duplication remains unknown.
b) The mother of case 6 did not carry the duplication. The father was not available for testing.
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 The duplication of the SMCR (case 3) was detected using three probes correspond-
ing to the RAI1, DRG2 and COPS3 gene. Array-CGH testing was performed to deter-
mine the length of the duplication on chromosome 17 (Table 1). This analysis exclud-
ed a duplication of chromosome band 17p12, which causes CMT disease (Figure 2). 
 Chromosome 16 contains many repeats, limiting the application of additional 
FISH analysis. Thus, it was not possible to determine the precise breakpoints of the 
imbalance in case 4, a de novo duplication of the NUDE1 gene on the short arm of 
chromosome 16p13.11. Two BACs (RP11-489O1, CTD-2504F3) overlapping the 
NUDE1 region were found amplified using array-CGH, indicating that the size of the 
duplication is between 0.8 and 2.4 Mb. We note that the dosage of the MYH11 gene 
(Locus Link: 4629) must also be doubled as this gene is transcribed from the reverse 
strand of the NUDE1 gene. 
 In two unrelated patients (cases 5 and 6), a duplication of a probe within the first 
exon of the PPYR1 gene on chromosome 10 was identified and subsequently verified 
using MLPA. Using array-CGH analysis, a nonoverlapping BAC (RP11-292F22) lo-
calised 0.5 Mb telomeric from the PPYR1 gene showed a duplication in only one of 
the patients, indicating a difference in the size of the regions duplicated. We were able 
to test both parents of the patient with the largest rearrangement (case 5); the father 
Figure 1.  The duplications within 7q11.23 (WBCR). 
The figure shows the length of the two duplications in the WBCR, detected in unrelated patients. Duplication 1 en-
compasses the whole critical area flanked by two large duplicons, whereas the other duplication involves only (a part 
of ) the FKBP6 gene. The diamonds represent the maximum size of both duplications. The AUTS2, CALN1 and HIP1 
genes localised just outside the duplicons were not altered. 
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Figure 2.  Results obtained in case 3. 
Results of the MAPH and array-CGH analysis revealing a duplication of the SMCR. (A) Log(2) ratio of MAPH probes 
showing a duplication of (a) the RAI1 gene, (b) the DRG2 gene and (c) the COPS3 gene. The remaining probes contained 
sequences localised on different chromosomes. The probes with a normalised ratio between –0.42 and +0.32 (log(2) scale) 
were considered to be present in two copies. The probes are ordered by probe length, not on their position on the genome. 
(B) Array-CGH testing showed that chromosome band 17p12 is not duplicated, excluding CMT syndrome (white ar-
row). The BACs showing amplification included RP11 –219A15, RP11–524F11, RP11 –189D22, RP1– 162E17, CTB 
–1187M2, RP11–78O7, RP5–836L9 and RP11–121A13. The distal breakpoint matches the common deletion break-
point of SMS.18 The proximal breakpoint is unknown, as the region near the centromere is not covered by BACs. 
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carried the same duplication. The mother of the other patient did not show the dupli-
cation, the father was not available for testing. 
 To determine whether the number of alterations obtained is significantly higher 
compared to copy number changes of regions outside the duplicons described in 2001, 
we have tested the same study population for genomic variation in a set of probes from 
regions not known to be flanked by duplicons. These probes were targeting function-
selected genes, such as genes involved in transcription, neuronal and brain maturity, 
with a potential function in mental development (Appendix B). This MAPH analysis 
comprised 58 validated probes (Appendix B) and resulted in the detection of two ge-
netic imbalances (1.9%), including a duplication of the DGKi gene on chromosome 
band 7q33 and a deletion of the DAD1 gene on chromosome band 14q11. Both 
alterations were verified by MLPA analysis. We were not able to test the parents of 
these patients. Despite their predicted function, these genes have not previously been 
causally linked to DD. 
Case reports 
Case 1 
This male patient was born after an uneventful pregnancy. In the perinatal period, 
he was diagnosed with trigonocephalic synostosis of the metopic ridge. At the age of 
1 year, he was examined by a clinical geneticist. He did not show any DD nor obvious 
dysmorphic features. Except for a mild aberrant shape of his skull (status after recon-
struction), no CM were present. 
 The family history of this patient included, in the father with a complete cutaneous 
III–IV syndactyly of the hand, a II–III syndactyly of the feet, and a carcinoma in situ 
of the testis that was diagnosed after infertility screening. The family members of both 
the father’s mother and father’s father showed syndactyly. Additional MAPH analysis 
showed a duplication of the WBCR present in the patient as well as in the father. The 
parents of the patient’s father did not carry the duplication. The parenthood of the 
father and his parents was proven using marker studies. 
Case 2 
In addition to synostosis of both the sutura lamboidea and the sutura coronalis, this 
4-year-old male patient with a normal mental development showed facial asymmetry, a 
severe heart malformation including two ventricular septum defects and a (sub)valvular 
pulmonal stenosis and a finger-like thumb. Except for craniosynostosis, these features 
are related to hemifacial microsomia. 
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The family history does not include individuals with dysmorphic features nor CM. 
Additional investigation showed a normal karyotype. MAPH analysis showed a dupli-
cation of a part of the FKBP6 gene that was also present in the unaffected mother and 
the unaffected maternal grandmother. 
discussion 
In this study, we have assessed the frequency of chromosomal rearrangements in DD 
and/or CM patients. The fraction of the genome that was localised between the de-
fined duplicons (as of 2001) and tested by at least one MAPH probe was 5.2% (see 
Appendix A). Within these regions, six alterations were detected. The fraction of the 
genome that was flanked by duplicons and not tested in this study was 4.6%, indicat-
ing that the majority of the genome fraction flanked by duplicons has been tested in 
this study. The total fraction of the genome that was flanked by duplicons identified 
at a first pass in 2001 is thus 9.8%. This percentage corresponds closely with the 
~328 Mb of sequence calculated by Bailey et al. 
 The fraction of the genome unflanked by duplicons (defined in 2001) is 90.2%. 
However, we have only tested 58 sequences (probes) localised outside the duplicons. We 
would argue that this number is not representative for 90.2% of the genome. Based on 
the calculation shown in Appendix B, the fraction of the non-duplicon regions tested was 
at least 24.5%. The real percentage tested is higher, as sequences located at the chromo-
some ends could not be included. In short, the fraction of the genome localised outside 
the duplicons and tested ranges between 24.5 and 90.2%. Two alterations were found 
within these regions. While the sample sizes are small, the aberration frequency per unit (= 
percentage of the total genome) of DNA in regions flanked by duplicons was higher com-
pared to the regions outside the duplicons, indicating that the regions between the dupli-
cons are indeed enriched for dosage alterations. This supports the hypothesis of Bailey et 
al. that the regions within duplicons are more likely to undergo genomic alterations. 
 Retrospectively, we have checked all 58 genes localised outside the duplicons, as 
identified in 2001, using the most recent assembly of the Human Working Draft (May 
2004). It appeared that 76% of these regions were still unflanked by intrachromosomal 
duplicons, including the regions containing DGKi and DAD1 genes. 
 Several factors will lead to an underestimation of the true number of alterations 
occurring between duplicons, and some of these may also explain why we did not find 
any deletions. First, the regions lacking single-copy sequences were excluded in this 
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study. It is reasonable to assume that these regions are more likely to undergo rear-
rangements based on their repetitive sequence content. These were not included, as the 
MAPH assay was based on copy number alteration of single-copy sequences. 
 Second, haplo-insufficiency of certain genes might not be compatible with life, or 
they may give a deleterious phenotype other than DD/CM. These alterations will not 
be detected in our study. This holds equally for the function-selected genes. Brewer et 
al.17 defined several regions that have never been involved in any deletion and those 
were thought to be potentially haplo-lethal. Of the 57 ‘Bailey’ regions tested, 10 were 
located within these possible haplo-lethal regions. These regions need to be tested by 
higher resolution methods, as the analysis of Brewer et al. was based on karyotypic ab-
normalities. Third, a substantial proportion of DD/CM could originate from genetic 
aberrations other than nonallelic homologous recombination. For example, point mu-
tations will not be detected using MAPH. 
 Fourth, the number of samples tested is rather small and the set of probes outside 
the duplicons is not random. In addition, the study cohort is already biased against 
rearrangements between duplicons, as any cases presenting with typical microdeletion 
syndrome-related features had already been diagnosed using cytogenetics tools. 
 Finally, it is possible that a part of the duplicons defined by Bailey et al. require ad-
ditional conditions before the obligate ‘repetitive breakpoints events’ will occur, result-
ing in copy number changes. These additional conditions could include a minimum 
length of 100% homology required for recombination, AT-rich sequences present on 
both sites of a recombination hotspots,18 or enrichment of Alu repeats within dupli-
cons.19 Further analysis needs to be performed to determine whether these conditions 
are present in the ‘Bailey’-defined duplicons. 
 A more clinical question concerns whether the imbalances found are disease-causing 
changes or benign polymorphisms. Alterations due to misaligned nonallelic homologous 
recombination should result in a deletion and a reciprocal duplication. In the majority 
of reciprocal deletion/duplication disorders, deletions were discovered before the duplica-
tion of the regions due to the fact that the techniques applied (usually FISH) were more 
amenable for deletion detection. To date, several duplications in regions involved in micro-
deletion syndromes have been identified in addition to the known deletions.20-23 The phe-
notype corresponding to the duplication is often milder than that related to the deletion. 
However, the copy number changes can also be associated with polymorphic variation.24 
 Due to the presence of >320 kb repeat structure on both sides of the Williams syn-
drome critical region, the existence of a reciprocal duplication of the Williams critical 
region was predicted,25,26 however, it has not been reported before. The patient with the 
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reciprocal duplication of the Williams critical region was diagnosed with craniosynos-
tosis and mild DD. The patient with the smaller duplication showed, in addition to 
craniosynostosis, multiple CM; however, his psychological development was normal. As 
the FKBP6 gene is the only gene in common and this gene is restricted to the male germ 
cells, it is reasonable to assume that the clinical overlap (craniosynostosis) is coincidental. 
 The clinical consequences of a duplication within the WBCR are currently un-
known. The fact that the imbalance is present in unaffected family members does not 
automatically mean that this is not pathological. Incomplete penetrance or multifactorial 
influences might cause variability of the phenotype. 
 It seems reasonable to assume that the de novo 17p11.2 duplication is responsible for 
the clinical features of case 3, as it is known that a duplication of the SMS critical region 
is associated with clinical features resembling those observed in our patient.23,27 
 The de novo duplication of 16p13.11 was seen in a boy with mild DD and learn-
ing disability. Since the father had similar learning problems, the significance of the 
duplication is questionable and this awaits confirmation from other patients. We note, 
however, that NUDE1 participates in a pathway that influences the neuronal migra-
tion during development of the central nervous system,28 which makes it an interesting 
candidate gene in this region. 
 Sebat et al.29 reported the screening of a total of 20 healthy individuals using the 
representational oligonucleotide microarray analysis (ROMA) technique. They found 
76 unique large-scale copy number polymorphisms. Among those, five probes on 
chromosome band 10q11.2 encompassing the full length of the PPYR1 gene were 
duplicated in one individual. This finding is in agreement with our finding of no 
less than four copy number changes in this gene, as it was altered in two unrelated 
patients (cases 5 and 6), one of their parents, as well as in a healthy control sample. 
In a subsequent study regarding genomic copy number differences in healthy indi-
viduals, 255 loci showing large-scale copy number variation (LCVs) were detected 
using array-CGH analysis.30 The only probe that overlapped one of the 255 suspected 
polymorphic clones contained a PPYR1 gene sequence. This clone (AL390716.27) 
was amplified in six individuals. Combining these findings in retrospect, it is possible 
that PPYR1 undergoes nonpathological or incompletely penetrant copy number varia-
tion. Two of the function-selected genes were localised within the suspected polymor-
phic clones (RYR3 within clone ACO11938.4; ERN1 within clone RP1189H15). The 
probes derived from both genes were not altered in our study population. This may 
well be due to our modest sample size, since most copy number variations detected 
by Iafrate et al. were present in only one or two (healthy) individuals. This also holds 
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true for the clones overlapping RYR3 and ERN1. In addition, a duplication seen with 
a single BAC clone might not encompass the entire clone length. 
 Recently, Sharp et al.31 also found a difference with regard to duplicons-flanked re-
gions and copy number variation, in agreement with our findings. In addition, 130 po-
tential copy number variation hotspots flanked by duplicons were tested for rearrange-
ments among 47 healthy individuals using a segmental duplicon BAC microarray. A 
total of 119 regions showed copy number alteration comprising 141 genes, including 
the P25, P29 and ADRBK2 genes, also present in our study. In all, 79 of the 130 copy 
number variation hotspots showed no alteration among this study population. It was 
suggested that these latter hotspots are excellent candidate regions to be associated with 
genetic disorders. Our study covers a fraction of these ‘hotspots’, which have thus been 
subjected to a first test for copy number alteration in relation to DD or CM. Using 
MAPH, we were able to identify three previously undescribed rearrangements, two 
duplications within WBCR and one duplication of chromosome region 16p13.11, of 
which the clinical relevance is uncertain at this moment. It will indeed be worthwhile 
to include these regions in further testing. 
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Note added in proof 
While this work was under review, another patient was described (Severe expressive-
language delay related to duplication of the Williams-Beuren locus, MJ Somerville et 
al. N Engl J Med 2005; 353:1694–1701, October 20, 2005) with a duplication of the 
WBS region. We have assessed the phenotype of our patient in the light of the reported 
clinical features (language deficiency but good spatial abilities). Considering the age of 
our patient, we could not assess the spatial abilities, but our patient did present with 
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Developmental delay (DD) affects ~3% of the general population and the underly-
ing cause remains unknown in about half of the cases. G-banded karyotyping is the 
most common approach for the detection of genomic alterations, however, despite its 
indisputable success, this tool has limited resolution, usually being unable to detect 
genomic changes <3–5 Mb. It is known that micro alterations that escape detection by 
classical cytogenetics contribute substantially to the etiology of DD (Flint et al., 1995; 
Vissers et al., 2003). This limitation has been partly overcome by fluorescence in situ 
hybridization (FISH) with a resolution of 5–500 kb, however, it has a limited possibil-
ity for multiplexing, for example, in most of the routine practice only 2–3 regions can 
be analyzed simultaneously. Therefore, candidate probes (especially for microdeletion 
syndromes) need to be selected a priori for FISH investigation, based on the patient’s 
phenotype. 
 Recent technological developments, such as array-based comparative genomic 
hybridization (array-CGH) (Pinkel et al., 1998; Antonarakis, 2001; Snijders et al., 
2001) and Multiplex Ligation-dependent Probe Amplification (MLPA) (Schouten et 
al., 2002), are efficient methods for screening for copy number imbalances in multiple 
genomic regions simultaneously. MLPA especially has already found its way into the 
diagnostic laboratories for several indications (e.g., BRCAI gene and NFI gene screen-
ing); however, the standard of practice for the assessment of developmental delay does 
not currently include MLPA and array-CGH testing. In this article, it is argued that 
both techniques are extremely valuable tools for the diagnostic setting in DD patients, 
and the implementation of both techniques should be considered. 
 Data regarding the robustness of both techniques have been provided previously 
(Price et al., 2005; Rooms et al., 2005). In the case of array-CGH, thousands of sites 
can be simultaneously investigated in one patient, allowing partial or total coverage of 
the genome. The number of targets that can be screened by MLPA is limited to <60 
loci per assay, however, 96 samples can be simultaneously tested at a cost less than one 
array-CGH hybridization. As MLPA analysis requires relatively little hands-on time 
(Table I), it is more suitable for the initial screening of large patient numbers. 
 To assess their value in clinical diagnosis, we have independently tested 58 devel-
opmentally delayed (DD) patients using both array-CGH and MLPA. This study was 
reviewed and approved by the Institutional Review Board of the Leiden University 
Medical Center, conforming to Dutch law and the World Medical Association Dec-
laration of Helsinki. The patients had, in addition to DD, either dysmorphic features 
or congenital malformations or both (DD ‘‘plus’’ patients). All patients had a normal 
karyotype and, where tested (the vast majority of the patients),had tested negative for-
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FragileX syndrome. The array-CGH results were partly reported elsewhere (Rosenberg 
et al., 2006) without the comparative analysis with MLPA. 
 The array used in the study contained ~3,500 large genomic insert clones spaced 
at 1 Mb intervals over the genome, meaning thattheresolution ofthearrays used is 
0.3–3 Mb. Array-CGH testing was performed as described by (Knijnenburg et al., 
2005). The clones were provided by the Wellcome Trust Sanger Institute (UK), and 
information regarding the full set is available at the Ensemble web site. 
 The MLPA probe design and assay was performed as described previously (White 
et al., 2004). It included a set of synthetic probes designed for 71 regions known to be 
frequently altered in DD patients (probe sequences are available on request). This set 
targets 42 chromosome ends (except for the p-arms of the acrocentric chromosomes), 
five pericentromeric regions on the q-arm of acrocentric chromosomes (the regions 
tested included the first gene-specific unique sequence near the centromere on the q-
arm) and 24 probes (Table II) containing microdeletion syndrome-relatedsequences.
The size of the probes used was between 75 and 125 bp, and the number of sites inves-
tigated by MLPA corresponds to ~2% (71/3,500) of all regions tested by array-CGH. 
 Seventeen alterations were detected by array-CGH analysis, of which 14 were verified 
using either FISH or MLPA (14/58 = 24%). (The MLPA probes were specifically de-
signed for confirming these alterations. They were not part of the screening set.) As 
far as was tested the remaining three changes could not be confirmed using FISH or 
MLPA. 
 MLPA analysis identified eight alterations, all of which were confirmed by FISH, 
MAPH or sequencing (8/58 = 14%). Table III provides an overview of the alterations 
found. The eight alterations found solely by array-CGH were all located in regions not 
Table 1.   A comparison of the man-hours and material required for both karyotyping 
and MLPA analysis. 
Karyotyping MLPA 
Number of samples performed per week 12 5 × 96 wells plate 
Total time before result per sample 32–40 hr 8 hra 
Materials needed Cell culture, reagents DNA reagents, probe set 
This table shows that MLPA is suitable for the screening of copy number variations in a large number of patients within 
relatively short time. Compared to karyotyping, this technique is much faster and requires less hands-on time. As it is 
also possible to analyze a part of a fragment run or use a DNA sequencer with less throughput capacity, it is not neces-
sary to wait for 96 patient samples requiring MLPA testing. 
aRecently, it was shown that MLPA analysis can be performed within 8 hr (Kalf et al. in preparation). 
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covered by MLPA probes. In contrast, the two alterations detected by MLPA only were 
too small to be detected by array-CGH analysis. One of these alterations was a point 
mutation near the ligation site of the MLPA probe, which disturbed the ligation and 
appeared as a deletion. The point mutation (that was never reported before) has been 
proven by bi-directional sequencing. It is a silent mutation, and it was also present in 
one of the parents. Therefore, it was considered to be a single nucleotide polymor-
phism (SNP). Although all MLPA probes have been designed outside the sequences 
containing known SNPs, theoretically, a low frequency SNP could be present at or 
near the ligation site. Therefore, it is necessary to confirm copy number variations by a 
second MLPA probe covering an adjacent sequence or by sequencing. 
 Of the eight alterations detected by MLPA, we considered six to be probably caus-
Table 2.  Overview of the microdeletion syndrome-related probes used by MLPA 
screening. 
Disorder Chromosome band Gene 
Alagille syndrome 20p12.2 JAG1 
Angelman syndrome 15q12 UBE3A 
Cat eye syndrome 22q11.1 CECR2 
DiGeorge syndrome 22q11.2 DGCR2 
DiGeorge syndrome 22q11.2 HIRA 
DiGeorge syndrome 22q11.2 TBX1 
DiGeorge syndrome 22q11.2 UFD1L 
DiGeorge syndrome like region 10p14 CUGBP2 
Extostosis 8q24 EXT1 
Jacobsen syndrome 11q25 HNT 
Miller–Dieker syndrome 17p13.3 LIS 1 
Mowat–Wilson syndrome 2q22 SIP1 
Prader–Willi syndrome 15q12 SNRPN 
RETT syndrome Xq28 MECP2 
Rubinstein–Taybi syndrome 16p13,3 CBP 
Smith–Magenis syndrome 17p11.2 RAI1 
Smith–Magenis syndrome 17p11.2 COPS3 
Smith–Magenis syndrome 17p11.2 DRG2 
Sotos syndrome 5q35 NSD1 
Trichorhinophalangeal syndrome 8q23.3 TRPS1 
William–Beuren syndrome 7q11.23 ELN 
William–Beuren syndrome 7q11.23 FKBP6 
Wolf–Hirschhorn syndrome 4p16.2 MSX1 
X-linked hydrocephalus Xq28 L1CAM 
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ative as the phenotype of the patients agreed with the clinical features described in lit-
erature for those chromosome alterations. All these rearrangements were also detected 
by array-CGH. In two of these six cases, however, we could not confirm that the rear-
rangement was de novo. Two of the eight alterations detected by MLPA are likely to be 
polymorphic variants, as they are also present in unaffected family members. 
 Nine of the fourteen confirmed rearrangements detected by array-CGH are prob-
ably pathogenic, four alterations might be polymorphic variants as they are present in 
unaffected family members. The clinical consequences of the remaining alteration are 
currently unknown, because the patients’ parents were unavailable for testing. This 
latest FISH confirmed array-CGH finding, which was not detected by MLPA, was lo-
cated near the chromosome end of the long arm of chromosome 10. The correspond-
ing ‘‘subtelomeric’’ MLPA probe in our study mapped proximal to the altered BAC. 
Based on the data on the human genome variation database, theregioninvolved might 
bepolymorphic. Moreover, the clinical features of the patient do not resemble those 
corresponding with previously described 10q chromosome end alterations (Waggoner 
et al., 1999). The sizes of the reported alterations, however, are larger than the one 
obtained in this study. 
Table 3. Copy number variations detected by two techniques independently.
Only by a-CGH Only by MLPA By a-CGH and MLPA Total 
Altered 11 2 6 19
Confirmed 8a 2b 6 16 















Deletion 2 3 1c  0 1d 0 2c 0 1c,e 10
Duplication 1 1 0 0 1d 0 1c 0 0 4
del./dup. 0 0 0 0 0 0 0 0 1d,e 1 
UT 0 0 0 0 0 0 1c 0 0 1
Confirmed total 3 4 1 0 2 0 4 0 2 16 
An overview of the results obtained by screening of 58 DD patients using array-CGH and MLPA. All rearrangements 
were not detected by routine karyotyping.
UT, unbalanced translocation.
a These regions were not covered by MLPA analysis.
b These alterations were too small to be detected by array-CGH.
c Alterations localized at the chromosome ends.
d Alterations present in regions related to micro-deletion syndromes.
e  (One of ) the patient’s parents were (was) unavailable for testing. The phenotype of the patient, however, resembles 
that described in literature. Therefore, this alteration is thought to be pathogenic.
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Figure 1.  Alternative diagnostic approach. 
This flow chart summarizes the alternative diagnostic approach for screening developmentally delayed patient samples. In 
this approach, karyotyping will only be requested for a selected group of samples: (1) Samples that had tested negative for 
MLPA (and array-based tool in the case of DD ‘‘plus’’ patients). (2) Samples for which information about the location of 
the structural rearrangement is essential for clinical practice. These include aneusomies for which a Robertsonian translo-
cation should be excluded (acrocentric chromosomes (#)), unbalanced translocations and some of the alterations detected 
by array-CGH. Chr. end abn.: chromosome end abnormality, DD ‘‘plus’’ patients are patients with dysmorphic features 
and/or congenital malformations in addition to DD. These patients are suggestive for chromosomal imbalances. 
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at least two MLPA probes per regions of interest
(instead of one as was used in this study) to limit
false positive and false negative results as much as
possible. Implementing microdeletion syndrome-
related regions and two probes per region will
increase the costs related to MLPA screening,
however, this will also reduce the necessity of
performing FISH for the detection of microdeletion
syndromes, and the need for additional confirmation
tests (with the exception of sequencing, see above).
It is obvious that balanced translocations and
inversions will not be detected using this or other
molecular techniques (unless they are specifically
designed to detect breakpoints). Also, for a propor-
tion of the sampleswith a positive outcome using the
initial MLPA screening, subsequent karyotyping
is essential for localization of these structural
rearrangements. These include, for example,
aneusomies for which Robertsonian translocations
have to be excluded. Based on these arguments,
karyotyping will maintain its essential role in a
diagnostic process, however it will only be imple-
mented for selected samples.
After MLPA testing, additional array-CGH can be
performed for patients with a clinical phenotype
suggestive for chromosomal alterations. Although
this will increase the cost, it will also increase the
number of copy number variations detected.
Array-based techniques are evolving rapidly.
Several reports have described the results of testing
developmentally delayed patients tested using a
3,000-clone array [Vissers et al., 2003; Tyson et al.,
2005; Menten et al., 2006; Rosenberg et al., 2006;
Shaw-Smith et al., 2006]. In addition, de Vries et al.
FIG. 1. This flow chart summarizes the alternative diagnostic approach for screening developmentally delayed patient samples. In this approach, karyotyping will
only be requested for a selected gro p of samples: (1) Samples that had tested neg tive forMLPA (and array-bas d tool in the case ofDD ‘‘plus’’ patients). (2) Samples for
which information about the location of the structural rearrangement is essential for clinical practice. These include aneusomies for which a Robertsonian translocation
should be excluded (acrocentric chromosomes (#)), unbalanced translocations and some of the alterations detected by array-CGH. Chr. end abn.: chromosome end
abnormality, DD ‘‘plus’’ patients are patients with dysmorphic features and/or congenital malformations in addition to DD. These patients are suggestive for
chromosomal imbalances.
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 The comparison between the screening results for detecting copy number varia-
tions using the different approaches shows the reliability and specific strengths of both 
techniques. In summary, using ~2% of the loci tested by array-CGH, MLPA detected 
50% (8/16) of all alterations. Three potentially pathogenic alterations were not de-
tected using MLPA, as they were localized outside the regions tested. 
 Based on the outcome of this parallel screening and costs considerations, we sug-
gest the following strategy for diagnostic purposes: when a patient presents with DD 
of unclear etiology and the G-banding karyotype is normal, the first screening will use 
MLPA for the commonly altered regions in DD patients (currently, chromosome ends 
and microdeletion syndrome-related regions). Subsequently, when MLPA is negative 
and the patient’s phenotype is suggestive of a chromosome abnormality, array-CGH 
follows. 
 Alternatively, the order of testing could be reversed. MLPA using subtelomeric 
probes is capable of detecting trisomies as well as the vast majority of the unbalanced 
translocations, both of which comprise a substantial part of the alterations diagnose-
dusing cytogenetic tools. Table I shows that MLPA requires less manpower (hence is 
cheaper) and is considerably faster compared to karyotyping, and thus, it seems more 
effective to use MLPA as an initial screening tool. In addition to the time-and cost-ef-
fectiveness, MLPA has a much higher resolution for detecting copy number variations 
compared to karyotyping, and therefore, this technique is capable of detecting copy 
number variations that remain undiagnosed using this cytogenetic tool. Applying 
MLPA testing first will even be more effective when a MLPA probe set encompassing 
the most frequent microdeletion related regions is added. In a diagnostic setting, it 
is preferable to have at least two MLPA probes per regions of interest (instead of one 
as was used in this study) to limit false positive and false negative results as much as 
possible. Implementing microdeletion syndrome-related regions and two probes per 
region will increase the costs related to MLPA screening, however, this will also re-
duce the necessity of performing FISH for the detection of microdeletion syndromes, 
and the need for additional confirmation tests (with the exception of sequencing, see 
above). 
 It is obvious that balanced translocations and inversions will not be detected us-
ing this or other molecular techniques (unless they are specifically designed to detect 
breakpoints). Also, for a proportion of the samples with a positive outcome using the 
initial MLPA screening, subsequent karyotyping is essential for localization of these 
structural rearrangements. These include, for example, aneusomies for which Robert-
sonian translocations have to be excluded. Based on these arguments, karyotyping will 
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maintain its essential role in a diagnostic process, however it will only be implemented 
for selected samples. 
 After MLPA testing, additional array-CGH can be performed for patients with a 
clinical phenotype suggestive for chromosomal alterations. Although this will increase 
the cost, it will also increase the number of copy number variations detected. 
 Array-based techniques are evolving rapidly. Several reports have described the 
results of testing developmentally delayed patients tested using a 3,000-clone array 
(Vissers et al., 2003; Tyson et al., 2005; Menten et al., 2006; Rosenberg et al., 2006; 
Shaw-Smith et al., 2006). In addition, de Vries et al. (2005) used an array with 32,000 
clones for the detection of copy number variations. Recently, SNP-based arrays have 
successfully been used to detect genome-wide copy number variations (Friedman et al., 
2006). These type of arrays have an even higher resolution than the array used in de 
Vries et al. Future comparative studies will help to determine which array platform is 
the most appropriate to implement. 
 In short, the alternative diagnostic approach would include MLPA for DD samples, 
with subsequent array-based testing (for DD ‘‘plus’’ patients that had tested negative 
for MLPA). Karyotyping could then be used to locate structural rearrangements for se-
lected cases and for samples that showed no alteration using MLPA (and array-CGH) 
(Fig. 1). In this way, the screening of DD samples will be more effective in relation 
to the probability of finding a disease-causing rearrangement, which will improve the 
basis for counseling. 
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The presence of highly homologous sequences, known as low copy repeats, predis-
poses for unequal recombination within the 22q11 region. This can lead to genomic 
imbalances associated with several known genetic disorders. We report here a devel-
opmentally delayed patient carrying different rearrangements on both chromosome 
22 homologues, including a previously unreported rearrangement within the 22q11 
region. One homologue carries a deletion of the proximal part of chromosome band 
22q11. To our knowledge, a ‘pure’ deletion of this region has not been described previ-
ously. Four copies of this 22q11 region, however, are associated with Cat eye syndrome 
(CES). While the phenotypic impact of this deletion is unclear, familial investigation 
revealed five normal relatives carrying this deletion, suggesting that haplo-insufficiency 
of the CES region has little clinical relevance. The other chromosome 22 homologue 
carries a duplication of the Velocardiofacial/DiGeorge syndrome (VCFS/DGS) region. 
In addition, a previously undescribed deletion of 22q12.1, located in a relatively gene-
poor region, was identified. As the clinical features of patients suffering from a dupli-
cation of the VCFS/DGS region have proven to be extremely variable, it is impossible 
to postulate as to the contribution of the 22q12.1 deletion to the phenotype of the 
patient. Additional patients with a deletion within this region are needed to establish 
the consequences of this copy number alteration. This study highlights the value of us-
ing different genomic approaches to unravel chromosomal alterations in order to study 
their phenotypic impact. 
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introduction 
The 22q11 region contains highly homologous regions known as low copy repeat 
(LCR) sequences. Despite the difference in size and organisation of these repeats, the 
overall sequence identity is 97–98% (Shaikh et al. 2000). It has been demonstrated 
that the presence of these LCRs can initiate misaligned (non-) allelic homologous re-
combination of the region flanked by these duplicons, resulting in a deletion and an 
obligate reciprocal duplication (McDermid and Morrow 2002; Bailey et al. 2002). 
As a result, 22q11 is associated with different genomic disorders (Table 1). The 
22q11 related disorders display a wide variety of clinical features, with no obvious 
correlation between the size of the genomic imbalance and the severity of the clinical 
characteristics. 
 The most common genetic disorder in this region is the Velocardiofacial syn-
drome/DiGeorge syndrome (VCFS/DGS) [MIM # 192430; MIM #188400], af-
fecting 1:4,000–6,000 individuals. This syndrome is caused by haplo-insufficiency 
of the 22q11.2 region. Over 90% of patients suffering from VCFS/DGS have a 3 
Mb deletion between LCR22-2 and LCR22-4 (Fig. 1), that share a particularly high 
degree of homology. The rest of the patients have a smaller rearrangement (1.5 Mb) 
with breakpoints located in LCR22-2 and LCR22-3a. Fluorescent in situ hybridisa-
tion (FISH) analysis is 100% accurate in detecting VCFS. However, the DGS pheno-
type can also be caused by other genetic (e.g. 10p13 deletion) or non-genetic causes 
(Robin and Sprintzen 2005). Most of the affected organs (thymus, (para)thyroid 
gland, outflow area of the heart) in VCFS/ DGS (Table 1) are derived from the third, 
fourth and sixth branchial arch in early development. Recently, it became apparent 
that VCFS/DGS are due to developmental deficiency of the endodermal pharyngeal 
pouches and the pharyngeal mesoderm, rather than (migration) defects of the neural 
crest cells (Graham 2003). As the TBX1 gene is strongly expressed in the branchial 
arches, it is assumed that mutations in this gene are responsible for the majority of 
the features of VCFS/DGS (Jerome and Papaioannou 2001; Lindsay et al. 2001; 
Mercher et al. 2001). 
 In 1999, the first report of the reciprocal duplication of the VCFS/DGS region 
was published. The phenotypic variability associated with the duplication of the 
VCFS/ DGS region emerged as a healthy mother and grandmother had the same du-
plication as the affected individual (Edelmann et al. 1999). Ensenauer et al. (2003) 
summarised the clinical characteristics of 13 patients with 22q11 duplications of 
variable sizes (3, 4, 6 Mb). More recently, the clinical features of another seven 
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Table 1. Overview of different 22q11 related syndromes.




Deletion of the 
22q11.2 region
DD, facial dysmorphisms (micrognathia, short philtrum and ear 
anomalies), cleft palate, cardiac outflow tract defects, Tetralogy 
of Fallot, nasal speech, hypocalcemia, thymic hypoplasia and 
behavioural problems (especially schizophrenia).
22q11.2 duplication 
syndrome
Duplication of the 
22q11.2 region
Extremely variable. Clinical features of these patients could show 
similarities with those described in VCFS/DGS [DD (± motor 
delay), poor growth, dysmorphic features, velopharyngeal 
malformation ± cleft palate, urogenital malformations, hearing loss) 
However, dysmorphic features and behavioural problems not related 
to the VCFS/DGS spectrum have also been described (see text).
Cat eye syndrome Quadruplication of 
the 22q11.1 region
Ocular coloboma, downslanting palpebral fissures, preauricular 
tags and/or pits, anal atresia with fistula, frequent occurrence of 
congenital heart and renal malformations and normal to near-
normal mental development.
DD developmental delay
Figure 1  Overview of three 22q11 related syndromes in relation to the location of the 
different MAPH and BAC probes (RP11-66F9, N25) used in this study. 
The size of the majority of the deletions within the VCFS/DGS regions is 3 Mb. The remaining deletions of this region 
encompass 1.5 Mb. The distal breakpoint of the duplications of the VCFS/DGS region is not always localised within 
LCR-4 (indicated by a dotted line) (Ensenauer et al. 2003). Different types of CES are depicted. This figure is based on 
Fig. 2 of McDermid and Morrow et al. (2002).
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22q11 duplication syndrome patients were described, showing a very wide range 
of clinical variability. Furthermore, the first triplication of 22q11.2 was described 
(Yobb et al. 2005). 
 The Cat eye syndrome (CES [MIM #115470]) has three different subtypes: CES 
type I, CES type IIa and CES type IIb (Fig. 1). The endpoint of CES type I colocalises 
with LCR-2 and consists of two extra copies of the CES region only. Patients with 
CES type IIa have four copies of the CES region combined with three copies of the 
VCFS/DGS region. CES type IIb consists of four copies of both the CES region and 
the VCFS/ DGS region. The endpoint of both CES type IIa and IIB is mapped to 
LCR-4 (McDermid and Morrow 2002). 
 So far, a deletion of the Cat eye critical region has never been reported. 
 In this report, we describe the clinical features of a patient with complex chromo-
some 22 rearrangements, including a previously undescribed familial deletion of CES 
region in one homologue and, a duplication of VCFS/DGS region of the other homo-
logue, in addition to a deletion of 22q12.1. These imbalances were characterised using 
different techniques: multiplex amplifiable probe hybridisation (MAPH), multiplex 
ligation-dependent amplification (MLPA), fluorescence in situ hybridisation (FISH), 
array-based comparative genomic hybridisation (array-CGH). 
clinical rePort 
The male patient was born by forceps delivery after an uneventful pregnancy. At birth, 
a cleft palate was diagnosed and he was reported to have a double set of teeth. The 
cleft palate was corrected by surgical treatment at the age of two and five. He attended 
special education because of hearing loss and moderate mental retardation. From his 
early adolescence onwards, he has been living in a support home. His further medical 
history included cataract and myopia. 
 At the time of evaluation in the clinical genetics department, this patient was 
52 years old (Fig. 2). Physical examination showed hypertonia with wooden move-
ments. His speech was slow and difficult to comprehend and he tended to avoid eye 
contact. He had a normal height of 172 cm (–1.5 SD), microcephaly (head circumfer-
ence 51.2 cm: –3.8 SD), round face with hypotonic expression, proptosis of the eyes, 
prominent simple ears, earpits on both sides and short fifth fingers. His heart tones 




Figure 2  Picture of the proband. 
Note the microcephaly, myotonic facial expression, the proptosis of the eyes and the prominent simple ears. [See ap-
pendix: colour figures.]
Figure 3.  The pedigree of proband III-1. 
A square symbol and an arrow mark the proband. The symbol (
at 1 Mb density over the full genome were produced in
the Leiden Technology Center (LGTC). The BAC set
used to produce these arrays was received from the
Welcome Trust Sanger Institute (UK), and information
regarding the full set is available in the genome browser,
Ensembl (http://www.ensembl.org/).
Tiling path array
The chromosome 22 tile path array and its hybridisation
and analysis were performed as described by Woodfine
et al. (2004).
Fluorescence in situ hybridisation (FISH)
The FISH experiments were performed by standard
procedures (Dauwerse et al. 1992).
The CES region specific BAC RP11-66F9 were visu-
alised using Alexa594 (green). For the identification of
chromosome 22, the telomere specific BACs LSI-ARSA
and RP11-3018K1 (22q13) (Flint and Knight 2003) was
used and visualised using FITC (green). The VCFS/
DGS region was tested by N25 Probe (Vysis). This
probe consists of N25 in red (SpectrumOrange).
Results
MAPH and MLPA
Multiplex amplifiable probe hybridisation analysis of
the index patients DNA revealed a deletion of probes
within the CES region, (CECR1 (GeneID: 51816),
CECR2 (GeneID: 27443), CECR6 (GeneID: 27439)
sequence) and a duplication of the probes containing
sequences within VCFS/DGS region (DGCR2 (GeneID:
9993), DGCR8 (GeneID: 54487), TBX1 (GeneID: 6899),
UF1DL (GeneID: 7353), HIRA (GeneID: 7290),
SERPIND1 (GeneID: 3053). The TUBA8 gene
(GeneID: 51807), localised between CECR and DGCR,
showed a normal copy number (Fig. 4).
It was not possible to test the patient’s parents;
however, we were able to test several other healthy
family members. The results are summarised in Fig. 3
and show that both siblings, two of their children and a
brother of the patients’ father carried the same deletion
in the Cat eye region as the index patient. The duplica-
tion of 22q11.2 was absent in all family members tested.
After verification of these findings with MLPA using
sequences of CECR2 gene and DGCR2 gene, the char-
acteristics of the genetic rearrangements of index patient
were refined by different techniques.
Array-CGH
Array-CGH using a 3500 BAC array was initially car-
ried out to define the length of each of the two rear-
rangements. However, this analysis revealed a third
chromosome 22 alteration, namely a deletion of 22q12.1.
The deleted area was localised about 25 Mb distal from
the 22q11.2 region, between BACs CTA-57G9 and
CTB-48E9. As this deletion was present in a relatively
gene-poor region, the chromosome 22-MAPH-probe set
did not contain a probe in this region. The duplication
of 22q11.2 and the deletion of chromosome 22q12.1
were not present in the healthy brother of the index
patient.
Fig. 3 The pedigree of proband
III-1. A square symbol and an
arrow mark the proband. The
symbol ) represents all five
unaffected family members with
a deletion of the CES region
80
) represents all five unaffected family members with 
a deletion of the CES region.
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Familial history 
The pedigree of the family is shown in Fig. 3. Familial history included two siblings 
with children and grandchildren, all of them healthy. The index patient’s father died 
at the age of 81 years of unknown causes. His mother died due to a cardiovascular ac-
cident at the age of 79 years. The overall familial history showed no other individuals 
with developmental delay, nor any other genetic disorders. 
Additional investigation 
Additional investigation showed a normal male karyotype and a normal number of 
CGG repeats of the FMR1 gene. FISH analysis was performed for the detection of a 
deletion of chromosome band 22q11.2 (using TUPLE1 probe) and for the detection 
of a deletion of 4p16.3 (Wolf–Hirschhorn syndrome) (using LSI-WHS probe). No 
rearrangements were detected. DNA testing for myotonic dystrophy type 1 showed 
normal CTG repeats on both alleles. 
materials and methods 
Patients 
This study was approved by the Institutional Review Board of the Leiden University 
Medical Center, conforming to Dutch law. All subjects or their representatives gave 
informed consent for DNA studies. 
MAPH and MLPA 
Multiplex amplifiable probe hybridisation was performed as described by White et al. 
(2002). The probe set used contained 19 probes from genes on chromosome 22 with 
approximately 1 Mb spacing, and ten additional genes in the 22q11 region. 
 A modified protocol of MLPA (Schouten et al. 2002) was performed as described 
by White et al. (2004). 
Array-comparative genomic hybridisation (array-CGH) 
The array-CGH procedures were performed as described (Knijnenburg et al. 2004). 
Briefly, slides containing triplicates of ~3,500 BAC DNA probes spaced at ~1 Mb 
density over the full genome were produced in the Leiden Technology Center (LGTC). 
The BAC set used to produce these arrays was received from the Welcome Trust Sanger 
Institute (UK), and information regarding the full set is available in the genome brows-
er, Ensembl (http://www.ensembl.org/). 
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Tiling path array 
The chromosome 22 tile path array and its hybridisation and analysis were performed 
as described by Woodfine et al. (2004). 
Fluorescence in situ hybridisation (FISH) 
The FISH experiments were performed by standard procedures (Dauwerse et al. 
1992). 
 The CES region specific BAC RP11-66F9 were visualised using Alexa594 (green). 
For the identification of chromosome 22, the telomere specific BACs LSI-ARSA and 
RP11-3018K1 (22q13) (Flint and Knight 2003) was used and visualised using FITC 
(green). The VCFS/ DGS region was tested by N25 Probe (Vysis). This probe consists 
of N25 in red (SpectrumOrange). 
results 
MAPH and MLPA 
Multiplex amplifiable probe hybridisation analysis of the index patients DNA re-
vealed a deletion of probes within the CES region, (CECR1 (GeneID: 51816), CECR2 
(GeneID: 27443), CECR6 (GeneID: 27439) sequence) and a duplication of the probes 
containing sequences within VCFS/DGS region (DGCR2 (GeneID: 9993), DGCR8 
(GeneID: 54487), TBX1 (GeneID: 6899), UF1DL (GeneID: 7353), HIRA (GeneID: 
7290), SERPIND1 (GeneID: 3053). The TUBA8 gene (GeneID: 51807), localised 
between CECR and DGCR, showed a normal copy number (Fig. 4). 
 It was not possible to test the patient’s parents; however, we were able to test several 
other healthy family members. The results are summarised in Fig. 3 and show that 
both siblings, two of their children and a brother of the patients’ father carried the 
same deletion in the Cat eye region as the index patient. The duplication of 22q11.2 
was absent in all family members tested. 
 After verification of these findings with MLPA using sequences of CECR2 gene and 
DGCR2 gene, the characteristics of the genetic rearrangements of index patient were 
refined by different techniques. 
Array-CGH 
Array-CGH using a 3500 BAC array was initially carried out to define the length 
of each of the two rearrangements. However, this analysis revealed a third chromo-
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some 22 alteration, namely a deletion of 22q12.1. The deleted area was localised about 
25 Mb distal from the 22q11.2 region, between BACs CTA-57G9 and CTB-48E9. 
As this deletion was present in a relatively gene-poor region, the chromosome 22-
MAPH-probe set did not contain a probe in this region. The duplication of 22q11.2 
and the deletion of chromosome 22q12.1 were not present in the healthy brother of 
the index patient. 
Chromosome-22-tiling-path array 
To map the breakpoints of the alterations at a higher level of resolution, the patient’s 
DNA and that of his brother were analysed on a chromosome-22-tiling-path array, 
as shown in Fig. 5. The sizes of the deletion and the duplication are 1.5 and 4.1 Mb, 
respectively. The transition of the deletion and the duplication within the 22q11 re-
gion maps to the LCR22-2. As the size of the duplication is larger than 3 Mb, the 
distal breakpoint of the alteration is not localised within LCR22-4, being localised 
more distally. The distal deletion on chromosome band 22q12.1 encompasses 2.3 Mb 
on chromosome band 22q12.1 and is not flanked by intrachromosomal LCRs. This 
region, however, is flanked by sequences that share high homology with sequences 
localised on other chromosomes. 
Chromosome-22-tiling-path array
Tomap the breakpoints of the alterations at a higher level
of resolution, the patient’s DNA and that of his brother
were analysed on a chromosome-22-tiling-path array, as
shown in Fig. 5. The sizes of the deleti n and the dupli-
cation are 1.5 and 4.1 Mb, respectively. The transition of
the deletion and the duplication within the 22q11 region
maps to the LCR22-2. As the size of the duplication is
larger than 3 Mb, the distal breakpoint of the alteration is
not localised within LCR22-4, being localised more dis-
tally. The distal deletion on chromosome band 22q12.1
encompasses 2.3 Mb on chromosome band 22q12.1 and
is not flanked by intrachromosomal LCRs. This region,
however, is flanked by sequences that share high homol-
ogy with sequences localised on other chromosomes.
Additional familial investigation using MLPA
showed that none of the family members with a 22q11
deletion carried the distal deletion.
Fluorescence in situ hybridisation (FISH)
Based on FISH studies on both metaphase and inter-
phase nuclei using FISH probes RP11-3018K1 and LSI-
ARSA (both corresponding to the subtelomeric region
of chromosome 22q), N25 (corresponding to the VCFS/


























Fig. 4 MAPH analysis of
chromosome 22. MAPH plot of
chromosome 22 revealing a
deletion of the CES region and
a duplication of the VCFS/
DGS region in the proband. A
probe covering 22q12.1 was not
included. The arrow indicates
the locus of the 22q12.1 deletion
























































Fig. 5 Chromosome 22 tiling
path array. a Tiling path array
analysis of the proband
revealed the deletion and
duplication of 22q11 sub-
regions and a distal deletion of
chromosome band 22q12.1. The
sizes of the rearrangements are
1.5, 4.1 and 2.3 Mb,
respectively. One BAC within
the VCFS/DGS region shows
an aberrant ratio. The cause of
this aberration is currently
unknown. b Tiling path array
analysis of the healthy brother
of the proband confirmed the
presence of the proximal 22q11
deletion but the absence of the
duplication of 22q11 and the
deletion of 22q12.1
81
Figure 4.  MAPH analysis of chromosome 22. 
MAPH plot of chromosome 22 revealing a deletion of the CES region and a duplication of the VCFS/DGS region in 




Tomap the breakpoints of the alterations at a higher level
of resolution, the patient’s DNA and that of his brother
were analysed on a chromosome-22-tiling-path array, as
shown in Fig. 5. The sizes of the deletion and the dupli-
cation are 1.5 and 4.1 Mb, respectively. The transition of
the deletion and the duplication within the 22q11 region
maps to the LCR22-2. As the size of the duplication is
larger than 3 Mb, the distal breakpoint of the alteration is
not localised within LCR22-4, being localised more dis-
tally. The distal deletion on chromosome band 22q12.1
encompasses 2.3 Mb on chromosome band 22q12.1 and
is not flanked by intrachromosomal LCRs. This region,
however, is flanked by sequences that share high homol-
ogy with sequences localised on other chromosomes.
Additional familial investigation using MLPA
showed that none of the family members with a 22q11
deletion carried the distal deletion.
Fluorescence in situ hybridisation (FISH)
Based on FISH studies on both metaphase and inter-
phase nuclei using FISH probes RP11-3018K1 and LSI-
ARSA (both corresponding to the subtelomeric region
of chromosome 22q), N25 (corresponding to the VCFS/
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Fig. 5 Chromosome 22 tiling
path array. a Tiling path array
analysis of the proband
revealed the deletion and
duplication of 22q11 sub-
regions and a distal deletion of
chromosome band 22q12.1. The
sizes of the rearrangements are
1.5, 4.1 and 2.3 Mb,
respectively. One BAC within
the VCFS/DGS region shows
an aberrant ratio. The cause of
this aberration is currently
unknown. b Tiling path array
analysis of the healthy brother
of the proband confirmed the
presence of the proximal 22q11
deletion but the absence of the
duplication of 22q11 and the
deletion of 22q12.1
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Figure 5.  Chromosome 22 tiling path array. 
A Tiling path array analysis of the proband revealed the deletion and duplication of 22q11 subregions and a distal dele-
tion of chromosome band 22q12.1. The sizes of the rearrangements are 1.5, 4.1 and 2.3 Mb, respectively. One BAC 
within the VCFS/DGS region shows an aberrant ratio. The cause of this aberration is currently unknown. B Tiling 
path array analysis of the healthy brother of the proband confirmed the presence of the proximal 22q11 deletion but 
the absence of the duplication of 22q11 and the deletion of 22q12.1.
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 Additional familial investigation using MLPA showed that none of the family 
members with a 22q11 deletion carried the distal deletion. 
Fluorescence in situ hybridisation (FISH) 
Based on FISH studies on both metaphase and interphase nuclei using FISH probes 
RP11-3018K1 and LSI-ARSA (both corresponding to the subtelomeric region of chro-
mosome 22q), N25 (corresponding to the VCFS/ DGS region) and RP11-66F9 (cor-
responding to the CES region), it was concluded that the deletion of the CES region 
and the duplication of the VCFS/DGS region are localised on different homologues of 
chromosome 22 (Fig. 6). 
discussion 
The complex rearrangement described here is, to our knowledge, the first report of a 
‘pure’ deletion (e.g. not as a part of an unbalanced translocation) located in the CES 
region. The question is whether this rearrangement is related to a specific phenotype. 
Haplo-insufficiency of the CES region was found among five healthy relatives of the 
index patient. In addition, the family study indicates that the patient’s father was an 
obligate carrier of the deletion of the CES region, as one of his brothers was a car-
rier of this deletion. A recent publication (Banting et al. 2005) showed that the vast 
majority of mice heterozygous for CECR2 gene mutations were normal and capable 
of reproduction, whereas mice homozygous for mutations in the CECR2 gene (corre-
spondingly located on chromosome band 22q11.1 in the human genome) had a high 
penetrance of exencephaly. They established that CECR2 plays a role in neurulation 
during embryogenesis. These results suggest that, although the CECR2 gene is essen-
tial during early development, a 50% decrease of gene dosage might not be associated 
with an aberrant phenotype. Although this data involves only one gene within the 
CES region, it is in accordance with our findings that a deletion in this region has no 
(obvious) phenotype and might therefore be present in the healthy population. In fact, 
the lack of clinical phenotype would explain the absence of reports on this deletion. 
Another reason for the lack of reported deletions of the CES region is that there is no 
commercial FISH probe available for this region, so it cannot be found ‘coincidentally‘ 
as the duplication of the VCFS/DGS region was detected (Edelmann et al. 1999). 
Furthermore, ascertainment bias might account for this deletion. People with a mild 
phenotype will not be tested using high resolution-or whole genome techniques. 
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Figure 6.  FISH analysis of chromosome 22. 
A A partial metaphase of the patient, hybridised with the telomere probe RP11-3018K1 (green; chromosome region 22q13), 
N25 (red; VCFS/DGS region) and RP11-66F9 (green; CES region). On the right chromosome, green signals of RP11-
3018K1 (telomeric side of chromosome 22) and a red signal N25 corresponding to the VCFS/DGS region are present; 
however, the signal of RP11-66F9 is lacking, indicating a deletion of the CES region. On the left chromosome, in addition 
to the green signals of RP11-3018K1, a red signal corresponding to the VCFS/DGS regions and a green signal correspond-
ing to the CES region are both present. These latest two signals are partly overlapping. On this chromosome, the signal of 
N25 is stronger than the signal on the right chromosome, suggesting a duplication of the VCFS/DGS region. These findings 
are confirmed by the result of the interphase nucleus depicted in part b of this figure. B The different chromosomes 22 are 
marked 1 and 2. The signal of LSI ARSA, corresponding to the telomeric side of chromosome 22, is indicated with a blue ar-
row. The red arrow indicates the N25 signal (corresponding to the VCFS/DGS region), which is duplicated in chromosome 
22 nr.1 (two red signals). The green arrow indicates the signal of RP11-66F9 (corresponding to the CES region). This signal 
is missing on chromosome 22 nr.2, demonstrating the deletion of the CES region. [See appendix: colour figures.]
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 Patients with duplication 22q11.2 syndrome show a wide variety of clinical features 
ranging from unaffected to severely affected individuals (Edelmann et al. 1999; Kriek 
et al. 2004; Yobb et al. 2005). Despite this, Ensenauer et al. (2003) described six clini-
cal features that are frequent among 22q11.2 patients. Five of these (cognitive deficit, 
poor growth, dysmorphic features, cleft palate and hearing loss) were present in our in-
dex patient. The most characteristic dysmorphic features for the duplication 22q11.2 
syndrome, however, such as superior placement of eyebrows, widely spaced eyes and 
downslanting of the eyes, were absent in our patient. Furthermore, our patient has 
several features (myotonic facial expression, proptosis of the eyes and a double set of 
teeth) that have not been described previously in other dup22q11.2 patients. Notably, 
the patients described by Ensenauer et al. (2003) show an ascertainment bias towards 
VCFS/DGS related features. All 653 patients included in this study were previously 
referred for 22q11 deletion screening using FISH on metaphase nuclei. In 2005, the 
clinical characteristics of another seven patients showing a duplication of the VCFS/
DGS region were summarised (Yobb et al. 2005). This group of patient has a partial 
ascertainment bias for VCFS/DGS related features. Five were detected using FISH for 
22q11 deletion screening, two were found by screening a cohort of 275 samples that 
was referred for fragile X screening. The clinical features of the latest two patients did 
not show similarity with VCFS/DGS spectrum. This last paper highlights the extreme 
variability of this alteration. 
 It is known that genetic factors localised outside the 22q11 region contribute to the 
variable clinical manifestations of 22q11 related alterations. It appeared that Fibroblast 
Growth Factor 8 (FGF8) mutant mice show close resemblance to the phenotype of 
del22q11.2 syndrome patients (Frank et al. 2002). Therefore, the FGF8 gene, localised 
in the ectoderm and endoderm of the developing pharyngeal arches, might contribute 
to the 22q11 features. Stalmans et al. (2003) argued, based on mouse experiments, that 
the vascular endothelial growth factor gene (VEGF gene) modifies the expression of 
the VCFS/DGS syndrome, especially the cardiovascular birth defects. These, or other, 
as yet unidentified, modifiers localised outside the 22q11 region could also contribute 
to the phenotype of 22q11 duplication cases. Phenotypic variability due to the pres-
ence of a so far unknown modifier of a rearrangement might also play a role in to the 
phenotype of the patients with a deletion of the CES region. 
 In short, the clinical features described can, in theory, be caused by the unique 
combination of the three copy number changes on chromosome 22. However, as the 
deletion of the CES region probably has no clinical consequences, there is no previous 
MR-related literature regarding the deletion of 22q12.1 and the contribution of 22q11 
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rearrangements could be altered by other factors, it is not possible to determine the 
isolated influence of the different genetic imbalances. 
 To date, only a few cases with a duplication of the VCFS/DGS region have been 
described. It is probable that the majority of these duplications have not been detected 
so far due to a combination of phenotypic diversity (mentioned above) and the dif-
ficulty of diagnosis. A good example of the second argument is the clinical report 
described here; our patient was tested for a possible deletion in the VCFS/DGS region 
using FISH on the metaphase cells and the duplication present in the same region 
could not be seen, as two signals were overlapping. To overcome these problems, one 
has to focus on applying techniques in a routine diagnostic setting that are capable of 
detecting both duplications and deletions, within the same assay. In this way, it will be 
possible to increase the number of patients with a genetic diagnosis and, in parallel, 
learn more about possible causes of clinical features as we have demonstrated in this 
study of 22q11 rearrangement. 
 Recent initiatives such as those of the Sanger Institute (www.sanger.ac.uk/
PostGenomics/decipher/) to create platforms for compiling molecular cytogenetic data 
from clinical genetic studies will hopefully provide a base for understanding the role 
of different DNA copy number alterations in genetic diseases. Collecting and under-
standing larger sets of data generated by different genomic approaches, as described 
here, will improve our ability to determine which copy number alterations contribute 
to abnormal phenotypes, and eventually result in a more consistent application of 
these techniques for genetic counseling. 
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Peters Plus syndrome is an autosomal recessive disorder characterized by anterior eye-
chamber abnormalities, disproportionate short stature, and developmental delay. After 
detection of a microdeletion by array-based comparative genomic hybridization, we 
identified biallelic truncating mutations in the b1,3-galactosyltransferase–like gene 
(B3GALTL) in all 20 tested patients, showing that Peters Plus is a monogenic, primarily 
single-mutation syndrome. This finding is expected to put Peters Plus syndrome on the 
growing list of congenital malformation syndromes caused by glycosylation defects. 
Peters Plus syndrome (MIM 261540) is an autosomal recessive disorder characterized 
by a variety of anterior eye-chamber defects, of which the Peters anomaly occurs most 
frequently.1 Other major symptoms are a disproportionate short stature, developmen-
tal delay, characteristic craniofacial features, and cleft lip and/or palate.1 
 To detect potential microrearrangements affecting the disease locus, we performed 
genomewide 1-Mb resolution array-based comparative genomic hybridization2 on ge-
nomic DNA of two brothers and four isolated patients who all received the clinical 
diagnosis of Peters Plus syndrome. In both brothers, two adjacent BAC clones (RP11-
95N14 and RP11-37E23) were found to be present in a single copy, representing an 
~1.5-Mb interstitial deletion on chromosome 13 (q12.3q13.1). MLPA (multiplex liga-
tion-dependent probe amplification) analysis was used to confirm the deletion and to 
better define its extent. The deletion was confirmed in both brothers and their mother 
and spans six genes (HSPH1, B3GALTL, LGR8, LOC196545, FRY, and the first 13 
exons of the BRCA2 gene). Two of these, LGR8 and BRCA2, are associated with hu-
man disease. Mutations in LGR8 cause testicular maldescent3; since both brothers had 
cryptorchidism, this may be related to their LGR8 haploinsufficiency. BRCA2 muta-
tions are associated with hereditary breast and ovarian cancer, and large genomic rear-
rangements are known to contribute to ~2% of the BRCA2 mutation spectrum.4,5 The 
brothers’ family history was positive for breast cancer in at least two deceased female 
relatives, in whom we established the presence of the deletion by interphase FISH on 
tumor material. Thus, this deletion constitutes a novel large BRCA2 rearrangement 
associated with familial breast cancer. 
 Since none of the six genes was an obvious candidate gene for Peters Plus syn-
drome, we sequenced the genes’ exons and flanking sequences in one of the affected 
brothers. A point mutation (c.1020+1GA) was detected in the b1,3-galactosyl-
transferase–like gene (HUGO Gene Nomenclature Committee symbol B3GALTL) 
within the donor splice site of exon 8. The same mutation was also present in the 
other brother and as a single copy in the father. We subsequently performed targeted 
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sequencing analysis for the presence of the c.1020+1GA mutation in an additional 
18 patients with Peters Plus from 15 families. Fourteen patients were Dutch whites, 
and the other patients were Turkish, British, Arab, or Indian. All had the salient fea-
tures of Peters Plus syndrome (table 1). We detected a homozygous c.1020+1GA 
mutation in 16 of the 18 patients. In the remaining two patients (Dutch siblings), 
only a single c.1020+1GA mutation was present (on the maternal allele). On se-
quencing the remainder of the gene, we detected a point mutation in intron 5 of 
B3GALTL (c.437+5GA) on the paternal allele. Of the 11 available parent sets, all 
were heterozygous for the mutation detected in their affected offspring. We then ex-
cluded the presence of the c.1020+1GA and c.437+5GA mutations in 455 chro-
mosomes of healthy Dutch individuals, by melting-curve analysis with specifically 
designed primer sequences (LightScanner HR96 [Idaho Technology]). Also, we 
investigated whether c.1020+1GA could be a founder mutation, by analyzing 
known intragenic B3GALTL SNPs in 18 of the homozygous patients. Seven patients 
(Italian, Turkish, English, and four Dutch) showed heterozygosity for at least one of 
the three informative SNPs (rs9315120, rs877103, and rs877104 [dbSNP]), which 
indicates that it is most likely a recurrent mutation, although some of the Dutch 
patients may have a common ancestor. The mutation is at the site of a potentially 
methylated CpG dinucleotide, which could explain its recurrence.6 
 A deleterious effect of the c.1020+1GA mutation on transcription is certain, 
since it alters a donor splice site that is predicted to produce a skip of exon 8 and 
an out-of-frame mRNA product. We verified this by RT-PCR on patient material 
(fig. 1D). The c.437+5GA mutation changes a highly conserved nucleotide and is 
predicted to affect splicing (Berkeley Drosophila Genome Project). To confirm this, 
we performed an RT-PCR on RNA isolated from lymphocytes from a patient with 
Peters Plus syndrome (c.1020+1GAmat/c.437+5GApat). The patient’s cDNA 
showed a skipped band, lacking exon 5, that results in an out-of-frame product. 
Notably, the expression of this band is much higher than that of the faint wild-type 
(WT) band, which is the product of the allele carrying the c.1020+1GA muta-
tion in exon 8 (fig. 1E). An explanation may be that the transcript lacking exon 8 is 
unstable. This theory is compatible with the fact that the individual who is hetero-
zygous for the c.1020+1GA mutation (fig. 1D [Het]), also shows a low expression 
of this product.
 B3GALTL contains 15 exons and spans 132 kb of genomic DNA. It is transcribed 
in a wide range of human tissues (dbEST Web site), in the form of two transcripts 






















































































































































































































































































































































































































































































































































































































































































































































































































































































Peters Plus Syndrome is caused by mutations in B3GALTL
Figure 1.  Overview of the location of the mutations in the B3GALTL gene and the 
results of the RT-PCR of RNA isolated from fibroblasts. 
A, Genes present in the 1.5-Mb deletion found in two brothers with Peters Plus syndrome. B, 15 exons of the B3GALTL 
gene, with the localization of the mutations. C, B3GALTL protein, which consists of a transmembrane region (TMR), a 
stem region (SR), and a catalytic domain (CD). Both mutations (c.1020 1GrA and c.437 5GrA) are located in the stem re-
gion. D, Result of the nested RT-PCR of exons 7–11 of the BGALTL gene, with RNA derived from myoblasts (WT), RNA 
from fibroblasts of a father heterozygous for the c.1020 1GrA mutation (Het), and RNA from fibroblasts of his affected 
son with c.1020 1GrApat/delmat (Hom). The patient shows a smaller band compared with the WT band, which indicates 
a skip of exon 8. Sequence analysis of this band is shown. The vertical line indicates the end of exon 7 and the beginning 
of exon 9. The RT-PCR of the father shows, in addition to the WT band, a skipped product with much less intensity. E, 
Result of the RT-PCR encompassing exons 4–7 of the BGALTL gene, with RNA derived from lymphocytes of a control 
individual (WT) and a patient with a c.1020 1GrAmat/c.437 5GrApat genotype (Het). In addition to a faint WT band, the 
patient shows a smaller product that lacks exon 5. The sequence analysis of this smaller band confirms the skip of exon 5. 
[See appendix: colour figures.]
regulation.7 Transcription has been shown to terminate at three different alternative 
polyA-addition sites, all in exon 15.7 The B3GALTL protein spans 498 aa and con-
tains a short N-terminal tail, a trans-membrane region (aa 5–28), a so-called stem 
region (aa 29–260), and a C-terminal catalytic domain (aa 261–498).7 On the basis 
of the sequence of its catalytic domain, the protein most closely resembles proteins 
from the GT31 family of beta-3 glycosyltransferases (CAZy [CarbohydrateActive 
enZymes Web site]). Both the c.1020+1GA and the c.437+5GA mutations in 
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B3GALTL are predicted to lead to a truncated product lacking the catalytic domain, 
since they are located in the putative stem region of the protein (fig. 1C).7 Thus, 
since all patients we analyzed have homozygous severely truncating mutations, it is 
expected that they have, effectively, full knockout mutations and lack any significant 
B3GALTL activity. Given this genetic homogeneity, there is a strikingly variable 
cognitive phenotype. Even within the group homozygous for the c.1020+1GA 
mutation, patients range from having normal secondary education to severe cogni-
tive impairment, which suggests that other factors modulate the phenotype. The 
brothers with the deletion of one of their alleles (c.1020+1GApat/delmat) have se-
vere cognitive impairment that is within the range of Peters Plus syndrome, and they 
have no structural malformations outside the Peters Plus spectrum. This indicates 
that hemizygosity for the genes HSPH1, LOC196545, and FRY, which have hith-
erto not been associated with human congenital malformations, did not produce a 
detectable phenotype. Figure 2 illustrates the facial phenotypes of four patients with 
Peters Plus syndrome. 
 B3GALTL is a putative glycosyltransferase that has not been previously associ-
ated with human disease or congenital malformations but has recently been shown 
to be over-expressed in thyroid oncocytic tumors.8 So far, we have not been able to 
verify a glycosylation defect in patients with Peters Plus syndrome; serum transferrin 
isoelectric-focusing studies in six of the current patients had normal results. We also 
Figure 2. Facial features of four patients with Peters Plus syndrome. 
Patients A and C are homozygous for the c.1020+1GA mutation. Patient B has the c.1020+1GAmat/c.437+5GApat 
genotype, and patient D has the c.1020+1GApat/delmat genotype. Note the Peters anomaly of the eyes, the long face, 
and the Cupid’s bow shape of the upper lip in all patients. Patients B and D have a repaired cleft lip and/or palate. 
Patient A is female; the rest are male. [See appendix: colour figures.]
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studied profiles of enzymatically released N-glycans by matrix-assisted laser-desorp-
tion-ionization time-of-flight mass spectrometry (MALDI-TOF MS) and high-pH 
anion-exchange chromatography (HPAEC) with electrochemical detection. No ob-
vious differences in overall N-glycosylation of serum proteins were observed (results 
not shown). However, these results do not exclude a glycosylation defect,9 and we are 
initiating further (functional) studies. 
 There are several hundred glycosyltransferases, predicted to be active in humans, that 
are involved in the posttranslational modification of proteins by the addition of specific 
oligosaccharide side chains (glycans), to form glycoproteins. Congenital disorders of gly-
cosylation are due to defects in the synthesis of the glycan moiety of glycoproteins or other 
glycoconjugates.10 Mutations in a number of glycosyltransferases have been associated with 
congenital malformation syndromes.10 Pending confirmation of the glycosylation defect, 
Peters Plus syndrome can most likely be added to this growing list. Anterior eye-chamber 
defects, such as Peters eye anomaly and glaucoma, are also described in Walker-Warburg 
syndrome and muscle-eyebrain disease,10,11 which suggests that adequate glycosylation 
plays a critical role in the formation of the anterior eye chamber.11,12 Interestingly, at least 
one Peters Plus- affected family in the present study has a documented history of glauco-
ma in confirmed mutation carriers. This raises the question of whether haploinsufficiency 
of – and possibly variations in – B3GALTL increases glaucoma susceptibility, which war-
rants further research. Finally, the present study emphasizes the value of genomewide array 
analysis in establishing the genetic basis of autosomal recessive disorders. 
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erratum
In the September 2006 issue of the Journal, in the article entitled “Peters Plus Syndrome 
Is Caused by Mutations in B3GALTL, a Putative Glycosyltransferase” by Lesnik Ob-
erstein et al. (79:562–566), because of the use of an incorrect reference sequence, the 
annotation of the mutations in the article is incorrect. On the basis of a coding DNA 
reference sequence (GenBank accession number NM_194318.2), the exon 5 splice-
site mutation should be described as c.347+5GA (not c.437+5GA), and the exon 
8 splice-site mutation as c.660+1GA (not c.1020+1GA). All variations identified 
in the B3GALTL gene have been collected in a new locus-specific sequence-variation 
database. The database has been registered at the Human Genome Variation Society 
and can be found at http:// chromium.liacs.nl/lovd/search.php?select_dbpB3GALTL. 
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Alpha thalassemia retardation associated with chromosome16 (ATR-16 syndrome) is 
defined as a contiguous gene syndrome resulting from haploinsufficiency of the a-
globin gene cluster and genes involved in mental retardation (MR). To date, only few 
cases have been described which result from pure monosomy for a deletion of 16p. In 
most of these cases the deletion was identified by densitometric analysis of Southern 
blot results or by Fluorescent In Situ Hybridization analysis, and these alterations have 
not been mapped in detail. In this study, we have fine mapped deletions causing a-
thalassemia within 2 Mb from the telomere of 16p by multiplex ligation-dependent 
probe amplification (MLPA). We have developed a rapid and simple test for high reso-
lution mapping of rearrangements involving the tip of the short arm of chromosome 
16 by incorporating 62 MLPA probes spaced approximately 10–200 kb over a region 
of 2 Mb from the telomere. One deletion of approximately 900 kb without MR was 
identified in addition to three de novo deletions varying between 1.5 and 2 Mb caus-
ing ATR-16 in three patients having mild MR and a-thalassemia. Two were found by 
chance to be ATR-16 because they were included in a study to search for telomeric 
loss in MR and not by hematological analysis. This would plead for more alertness 
when a persistent microcytic hypochromic anemia at normal ferritin levels is observed 
as suggestive for the ATR-16 syndrome. The region on chromosome 16p for which 
haploinsufficiency leads to the dysmorphic features and MR typical for ATR-16, has 
been narrowed down to a 800 kb region localized between 0.9 and 1.7 Mb from the 
telomere. 
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introduction 
Genomic deletions involving the a-globin gene cluster on chromosome 16p13.3 are 
the most common molecular cause of a-thalassemia (approximately 80–90% of cases) 
(Bernini and Harteveld 1998; Higgs 1993). Due to selective advantage, a-thalassemia 
carrier frequencies are high in areas endemic for malaria tropica. Less frequently a-
thalassemia is found in North-European Caucasians. Even more rare are mental retar-
dation (MR) syndromes in which the occurrence of a-thalassemia is merely a marker 
of the genomic defect. These syndromes are known as a-thalassemia MR syndromes 
ATR-X and ATR-16 (depending on the respective chromosomes involved) (Weatherall 
et al. 1981; Wilkie et al. 1990a, b). 
 ATR-X involves mutations of the X-linked ATRX gene, coding for helicase-2, a pu-
tative global transcriptional regulator (Cardoso et al. 2000, 1998; Gibbons and Higgs 
2000; Gibbons et al. 1992; Villard et al. 1997; Wilkie et al. 1991; Wilkie 1990b; 
Yntema et al. 2002). ATR-16 is characterized by the occurrence of large deletions in-
volving the a-globin gene cluster on chromosome 16p and is most likely a contiguous 
gene syndrome (Daniels et al. 2001; Flint et al. 1996; Horsley et al. 2001; Lamb et al. 
1993; Wilkie et al. 1991). At present molecular tests commonly used to identify dele-
tion types of a-thalassemia and ATR-16 are gap-PCR, Southern blot or fluorescent 
in situ hybridization (FISH) analysis (Daniels et al. 2001; Flint 1996; Gallego et al. 
2005; Lindor et al. 1997). However, the applicability of these techniques is limited 
to known deletions, may involve radio-activity, is dependent upon the hybridization 
probes available and may require time consuming and laborious cell culture to generate 
metaphase chromosome spreads. 
 Recently, we have developed an multiplex ligation-dependent probe amplification 
(MLPA) based assay to perform high resolution screening for unknown rearrange-
ments on chromosome 11p15.4 and in a 700 kb telomeric region of the short arm 
of chromosome 16 (16p13.3) causing b-and a-thalassemia, respectively. During the 
examination of 38 putative a-thalassemia carriers, we identified a single patient show-
ing a telomeric deletion without MR, for which the 3¢breakpoint could not be deter-
mined (- -GZ) (Harteveld et al. 2005). During this study we extended the MLPA assay 
to investigate a region of approximately 2 Mb involved in a-thalassemia and MR. A 
second patient was brought to our attention because of a persistent microcytic hypo-
chromic anemia without iron depletion. The patient showed MR and the parents were 
normal. Two patients were detected using multiplex amplifiable probe hybridization 
(MAPH) for the screening of genomic imbalances in the subtelomeric region among 
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mentally retarded patients. Only the telomeric probe associated with the telomere of 
16p appeared to be deleted, excluding unbalanced translocation in these patients. The 
results of this screening were verified by MLPA and FISH analysis. One of these pa-
tients has been previously described (P.V.) (Kriek et al. 2004). 
materials and methods 
Appropriate informed consent was obtained from all human subjects studied. 
Clinical report 
Case G.Z. 
Shortly after birth the patient had surgery for pylorus stenosis. He was regularly seen 
until the age of 4 because of persisting microcytic hypochromic anemia with normal 
iron levels. There was no developmental delay nor any other abnormalities related to 
the ATR-16 syndrome. The propositus was investigated for the first time at the age 
of 5 at the hematological and biochemical level together with his parents because of a 
suspected a-thalassemia. The father presented with normal hematological parameters, 
the mother and the patient both showed hematological abnormalities and an unbal-
anced hemoglobin chain synthesis ratio typical of a0-thalassemia carriership. At that 
time DNA analysis was not feasible. The patient was re-investigated in 2002 at the age 
of 30, when microcytic hypochromic anemia at normal ferritin was still present. The 
seven most common a-thalassemia deletions (– a3.7 ,– a4.2,–(a)20.5 ,- -MedI ,- -SEA , 
- -THAI ,- -FIL) were excluded at the molecular level by multiplex PCR (Chong et al. 
2000; Liu et al. 2000). Both mother and son had a normal school education and there 
was no indication for MR in these family members. 
Case H.N. 
H.N. is the third child of healthy, non-consanguineous parents. He was born after an 
uncomplicated pregnancy and delivery, with a birth weight of 3.1 kg. Directly after 
birth a short period of asphyxia was recorded, and was attributed to meconium-stained 
amniotic fluid (Apgar scores 3/6/9 after resp. 1, 5 and 10 min; pH cordblood 7.13). 
He made a quick recovery with an oxygen mask. He had a clubfoot on the left, for 
which he was operated on at the age of 1 year (lengthening of achilles tendon). 
 In infancy, he suffered from recurrent chest infections and asthma. His motor devel-
opment was delayed: sitting at the age of 10 months, crawling at the age of 18 months 
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and walking at the age of 23 months. He spoke his first words at the age of 18 months. 
At the age of 2 years and 6 months he was referred to the pediatric neurologist because 
of hypotonia, psychomotor retardation and speech delay. At the age of 3 years and 
8 months a severe delay in active language ability was reported. Subsequent testing 
showed mild MR (SON-IQ 58). 
 We first examined him at the age of 4 years and 8 months. He was able to con-
struct short sentences (three words) and went to a special school with an individual 
teaching program. By that time, mild anemia had become apparent. Physical exami-
nation showed the following: height 104 cm (–1 SDS), weight 17.5 kg (+1 SDS), 
head circumference 53 cm (0 SDS). He had nasal speech. His facial features showed 
downslanted palpebral fissures, mild hypertelorism, a broad nasal tip, small posteriorly 
rotated ears, a short neck with webbing, and a low trident posterior hairline. Apart 
from pectus carinatum, an operated clubfoot on the left, and a flat foot on the right, 
no other anomalies were noted (Fig. 1a). 
Additional investigations
Conventional chromosome analysis showed a normal male karyotype. Metabolic screen 
was negative. MRI of the brain showed an arachnoidal cyst in the right temporal lobe. 
As some features were consistent with Noonan syndrome, PTPN11 mutation analysis 
was performed, which resulted negative. 
Case P.V. 
This male patient was born after an uneventful pregnancy and delivery. He is the 
youngest of a family of three children to non-consanguineous parents. His sister died 
3 days postpartum due to severe complications at delivery resulting in asphyxia. There 
was no family history of either developmental delay or congenital malformations. In 
early childhood, the patient had several episodes of pneumonia, and was diagnosed 
with asthma at a later stage. Neuropsychological testing was performed at the age of 2, 
because of developmental delay and because his overall behavior was far from consis-
tent with his age. The patient started walking at the age of 30 months. He started to 
actively use language at the age of 5. He suffered from recurrent epileptic seizures at 
the age of seven that were treated successfully with Depakine. In addition, mild anemia 
was detected. 
 A physical examination at age 11, revealed a very outgoing boy. His height was 
144.5 cm (–1 SDS), his weight 29 kg (–2 SDS) and head circumference 52.3 cm (–1 
SDS). He showed mild dysmorphic features including high forehead, some periorbital 
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Figure 1. Three unrelated patients.
H.N. (a), P.V. (b) and F.T. (c) showing a mild mental retardation (IQ 50–60), a severe delay in active language ability, some 
typical facial features like downslanted palpebral fissures, mild hypertelorism, a broad nasal tip and small ears and a short 
neck with webbing, which is most pronounced in a and b. Patient H.N. and P.V. both show pectus carinatum. This was 
also observed for patient F.T. (not shown). H.N. also has an operated clubfoot on the left, while patient P.V.’s right foot is 
turned inside, the other foot showing a cafe´-au-lait spot. c Patient F.T. has a short neck and small ears. On the outer right a 
photograph is shown of the patient at age 11. The karyotype was normal in all patients and hematological analysis showed 
a persistent microcytic hypochromic anemia without iron deficiency [See appendix: colour figures.]
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fullness, microphthalmia, telecanthus, broad nasal bridge, posterior rotated ears, a flat, 
rather long philtrum, full lips and micrognatia (Fig. 1b.). He had an extra incisor. His 
trunk showed a mild pectus excavatum and two café au lait spots. Auscultation of the 
heart was normal. Hyperlaxity of the joints was observed. 
Conventional chromosome analysis at a resolution of 500 bands showed a normal male 
karyotype. Due to his behavior and some of the facial dysmorphism, FISH analysis for 
the Williams Syndrome Critical region was performed. No deletion was detected on 
chromosome band 7q11.23. No metabolic abnormalities were observed. 
Case F.T. 
F.T. was referred at the age of 30 years because of mild and persistent microcytic hy-
pochromic anemia. She was born at term after an uneventful pregnancy. Her birth 
weight was 2,600 g. APGAR score was reported as ‘low’ after 1 min but recovered to 
ten after 5 min (no direct data, home delivery). In infancy, it was noted that her de-
velopment was retarded in comparison to other children (e.g. first words after 2 years 
of age), but the parents declined further investigation at the time. Her behavior was 
reported as shy and dependant. She attended special education at the age of 6 and she 
is now employed in a program for people with a mental handicap. She lives in a sup-
port home. Furthermore, she plays the drums and enjoys horseback riding. She has no 
problems with her general health. Hearing and vision were normal. Family history was 
unremarkable, she had one healthy sister. 
 Physical examination at the age of 31 showed a height of 162 cm (–1.3 SD), head 
circumference 52.5 cm (–1.7 SD), elongated face with a flat midface and a prominent 
nasal bridge. The palpebral fissures of her left eye showed slight upslant. Her ears were 
rather small, and had a slight question mark configuration. In addition, she had some 
irregularity of teeth, marked micrognathia and retrognatia (Fig. 1c). On her palatum 
durum, two small bulbous lumps were present and she had hypertrophic gums. Her 
neck was short. A pectus excavatum was present. Internal screen was normal. Her hands 
are rather short with slight tapering of the fingers and bilateral fifth finger clinodactyly. 
On the feet, both halluces showed laterial deviation, the second digits were short and the 
fourth digits showed medial deviation. Her joint were rather stiff. She did not have any 
skin pigment aberrations. She has scarce body hair with normal scalp hair. 
Hematological analysis 
Blood samples of patients and parents were collected in vacutainers with EDTA as 
anticoagulant. Hematological analysis was carried out according to standard methods 
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(Dacie and Lewis 1991). The red cell indices were measured with a standard cell coun-
ter (Micros 60; ABX Diagnostics, Montpellier, France). A Brilliant Cresyl Blue stain-
ing was performed on the blood smear to identify HbH inclusion bodies according to 
a standard method (Dacie and Lewis 1991). Globin chain synthesis was performed for 
patient GZ and his parents according to standard procedures (Giordano et al. 1999). 
DNA was isolated according to standard procedures (Miller et al. 1988). 
Design of the MLPA assay 
In total, 62 MLPA probe pairs were designed covering a region of 2 Mb from the 
telomer of 16p13.3 to the PKD-gene. Of these, 35 were previously reported to detect 
(unknown) a-thalassemia deletions and rearrangements in a 700 kb region from the 
telomer of 16p to the MSLN gene (Harteveld et al. 2005). An additional 17 probe pairs 
were designed to extend the region covered by MLPA from the MSLN gene towards 
the PKD gene to screen for even larger rearrangements (Table 1, Fig. 2). Each primer 
pair contained common ends corresponding to either a HEX-labeled amplification 
primer (detection in green), a FAM labeled primer (detection in blue) or a ROX la-
beled primer (detection in red) to be analyzed simultaneously in the same fragment 
run on the ABI3730. Finally, ten primer pairs were designed for high resolution map-
ping of the breakpoints after initial screening for large deletions in three colors. The 
data were collected and ratios between normalized peak heights of the patient and the 
normal controls were presented in a single scatter plot for each patient. 
 The oligonucleotides were ordered from Illumina, Inc. (San Diego, CA, USA), 
synthesized in a salt-free environment (50 nmol scale) and used without further 
purification. For each probe pair the downstream primer was 5’phosphorylated to al-
low ligation. 
 The MLPA reactions were performed as described by Schouten et al. (2002) and 
White et al. (2004) in brief, approximately 200 ng of genomic DNA in a final volume 
of 5 ml was heated for 5 min at 98°C. After cooling to room temperature, 1.5 ml of 
the probe mix and 1.5 ml SALSA hybridization buffer (MRC-Holland, Amsterdam, 
The Netherlands) were added to each sample, followed by heat denaturation (2 min 
at 95°C), hybridization (16 h at 60°C). Ligation was performed by adding 32 ml of 
ligation mix at 54°C for 10 min, the reaction was terminated by 5 min incubation 
at 95°C. PCR amplification was carried out for 33 cycles in a final volume of 25 ml, 
adding the 5’ROX-labeled M13-Forward and M13-Reverse primer set to a final con-
centration of 100 nM. The second common primer set designed to fine map the dele-
tion breakpoint region between two MLPA probes of the first set, were amplified by 
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adding the 5’HEX-labeled MAPH-Forward and MAPH-Reverse primers to a final 
concentration of 100 nM. Products were separated by capillary electrophoresis on the 
ABI 3730 (Applied Biosystems) and data analyzed as described previously (Harteveld 
et al. 2005). 
results 
Hematological analysis 
All patients presented with a microcytic hypochromic anemia without iron deficiency 
(Table 2). Two were brought to our attention because of a suspected a-thalassemia 
(G.Z. and F.T.) after routine hematological investigation. The other two (H.N. and 
P.V.) were investigated at the hematological level after identifying the telomeric loss of 
16p as the only chromosomal abnormality causative for the observed MR. The patient 
G.Z. without MR and his parents were investigated at the hematological and bio-
chemical level. He and his mother showed microcytic hypochromic parameters and an 
unbalanced a/b-globin chain synthesis ratio indicative for a0-thalassemia carrier-ship 
Figure 2  Schematic presentation of short arm of chromosome 16 (16p13.3), showing 
a 2 Mb region from the telomere containing the a-globin gene cluster up to 
the TSC and PKD genes. 
The arrows and numbers represent the location of the probes. The deletions found by MLPA are shown as bars below 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.  Scatterplots showing the MLPA results of the patients G.Z. 
(a), P.V. (b), H.N. (c) and F.T. (d). The Y-axis represents the ratio peak height of patient divided by that of the normal 
control, the X-axis shows the chronological position of MLPA probes along the p-arm of chromosome 16.
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(a/b = 0.6). The father showed a completely normal hematology and balanced chain 
synthesis (a/b = 1.1). 
 The three patients with MR and a-thalassemia all have healthy parents presenting 
with normal hematological parameters (Table 2), supporting a de novo event. 
Molecular analysis 
Case G.Z. 
The MLPA probes 1–35 appeared to be deleted in this patient as shown in the previous 
study (Harteveld et al. 2005), indicating that the 3’breakpoint was located somewhere 
between the MSLN gene and the TSC gene, approximately 2 Mb from the telomere 
of 16p. Additional MLPA primer pairs designed in this study, revealed the deletion 
breakpoint to be localized between probe no. 37 and 40, which spans a region of ap-
proximately 100 kb (Fig. 3a). Two probes, no. 38 and 39 were designed to narrow the 
breakpoint region to 31 kb between positions 869,698 and 900,907. The deletion 
involves the telomeric region including the complete a-globin gene cluster but leav-
ing the SOX8-gene intact. According to the hematological analysis of the parents, the 
deletion is inherited from the mother, who presented with microcytic hypochromic 






















Propositus G.Z. M–31 12.7 5.84 70 22.1 31.6 53 2.8 + aa/-GZ 
Mother of G.Z. F–55 11.6 5.50 67 21.1 31.7 ND ND ND aa/-GZ 
Propositus P.V. M–11 10.5 4.66 69 22.4 32.2 29 2.9 + aa/-PV 
Father of P.V. M–49 15.1 5.05 89 29.8 33.3 20 3.1 – aa/aa 
Mother of P.V. F–48 13.7 4.34 91 31.6 34.6 13 2.7 – aa/aa 
Propositus H.N. M–5 10.3 4.75 71 21.7 30.6 74 2.7 + aa/-HN 
Father of H.N. M–41 14.0 4.90 89 28.5 32.0 35 2.7 – aa/aa 
Mother of H.N. F–40 12.9 4.62 87 28.0 32.0 50 2.9 – aa/aa 
Propositus F.T. F–30 10.6 5.14 74 20.8 28.2 56 2.6 ND aa/-FT 
Father of F.T. M–60 14.8 4.84 93 30.8 33.0 32 2.6 ND aa/aa 
Mother of F.T. F–60 15.0 4.72 95 31.9 33.6 39 2.6 ND aa/aa 
Sister of F.T. F–27 13.8 4.67 91 29.8 32.7 30 3.0 ND aa/aa 
ZPP Zinc Proto Porphyrin (lmol ZP/mol Heme), ND not determined 
+/– = Positive/negative Inclusion Bodies test
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anemia, similar to the propositus. Unfortunately, no DNA of the parents was available 
for MLPA analysis. No clinical phenotype other than a0-thalassemia seems to be as-
sociated with this deletion. 
Case P.V. 
During an initial screening, a telomeric deletion was observed extending to KIAA0683 
at position 1,495,758 (probe no. 51). Two probe pairs (nos. 52 and 53) were designed 
between the last MLPA probe pair deleted in this patient and the first still present 
(probe no. 54) to reduce the breakpoint region. Both probes 52 and 53 appeared to be 
involved in the deletion reducing the breakpoint region to 114 kb between positions 
1,615,979 and 1,730,426 (Figs. 2, 3b). This deletion of approximately 1.62–1.73 Mb 
causes monosomy for several genes including the SOX8-gene. No other chromosomal 
aberrations were found in this patient, neither at the cytogenetic level, by FISH analy-
sis, nor by MAPH analysis (Kriek et al. 2004). 
Case H.N. 
After an initial screening the deletion was found to involve a 1.8–1.93 Mb region from 
the telomere. An additional MLPA analysis using newly designed probe pairs 56–59 
identified the deletion breakpoint between probes 59 and 60, which limits the break-
point region to 15 kb between positions 1,913,923–1,928,982 (Figs. 2, 3c). 
Case F.T. 
Initially, the deletion length appeared similar to that of patient H.N.. Fine mapping 
using MLPA probe pairs 56–59 revealed the 3’breakpoint to be different. The break-
point is localized between probe pairs 58 and 59, which equal a deletion length of 1.9 
Mb from the telomere to position 1,880,277–1,913,866 (Figs. 2, 3d). This region is 
extremely rich in Alu repeats, which may have played a role in the mechanism leading 
to these large deletions. This also might explain the observed clustering of 3¢break-
points in patients F.T. and H.N. 
discussion 
In contrast to the ATR-X syndrome, ATR-16 does not present with a clearly defined 
phenotype. Sixteen cases have been described in literature and in most cases it was not 
clear whether the dysmorphic features were attributable to the monosomy for 16p 
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or to the additional chromosomal aberrations found in these patients (Brown et al. 
2000; Eussen et al. 2000; Gallego et al. 2005; Warburton et al. 2000; Wilkie 1990a). 
Only five patients (indicated as BA, TN, BO, IM and LIN in Fig. 2) were described 
with a clear monosomy for a telomeric deletion of 16p (Daniels et al. 2001; Fei et al. 
1992; Lamb et al. 1993; Lindor et al. 1997; Wilkie et al. 1990a). We present the high 
resolution mapping by MLPA of ATR-16 deletions in four Caucasian patients affected 
with microcytic hypochromic anemia without iron deficiency, due to a large deletion 
including the complete a-gene cluster. One patient (G.Z.) with a deletion of 870–900 
kb presented no dysmorphic features or MR, while three patients showing deletions 
ranging from 1.7 to 1.9 Mb presented with mild MR (IQ 50–60) and a variety of 
dysmorphic features. The samples have been checked for unbalanced translocations 
and partly for deletions/duplications in other parts of the genome, either using telo-
mere MLPA (Schouten et al. 2002; Kriek et al. 2004) for samples H.N. and P.V.) or 
a 1420-plex bead-based MLPA (for samples H.N. and F.T., Fan et al. 2006; Aten 
et al., in preparation). No other deletions/ duplications or unbalanced translocations 
were found in H.N., F.T. and P.V. other than the deletions at the tip of chromosome 
16p13.3 confirmed by MLPA analysis using the probes described in this manuscript. 
 The two patients, G.Z. and P.V., showing respectively the largest deletion with only 
a0-thalassemia and the smallest deletion clearly associated with the classical ATR16 
features, might give a better insight into the genes for which haploinsufficiency con-
tributes to the syndrome. Three cases - -BO,- -IM and - -LIN are known from the litera-
ture without additional chromosomal rearrangements besides the deletion causative of 
ATR-16 (Daniels et al. 2001; Fei et al. 1992; Lindor et al. 1997). These deletions are 
larger than the presently described case, which restricts the region for which monoso-
my seems to contribute to the ATR-16 associated phenotype to an approximately 800 
kb region between 0.9 and 1.7 Mb from the telomere of 16p. Approximately 14 genes 
and gene families of known function are located in this area. 
 The SOX8 gene is a member of the SOX (SRY-related HMG-box) family and encodes 
for a transcription factor involved in regulation of embryonic development and in deter-
mination of cell fate. The SOX8-protein is suggested to be involved in brain development 
and function and is strongly expressed in brain and less abundant in other tissues. There-
fore SOX8 is considered to be a good candidate gene for which haploinsufficiency may 
contribute to the MR phenotype seen in ATR-16 patients (Holinski-Feder et al. 2000; 
Pfeifer et al. 2000). However, MLPA analysis in several members of a Brazilian family 
without MR or dysmorphic features using the 62 probes showed a deletion of the tip of 
the short arm of chromosome 16 including SOX8 (manuscript in preparation). 
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 Other disease genes located in the 800 kb region deleted between G.Z. and P.V. 
are CACNA1H, GNPTG and CLCN7. These genes are associated respectively with 
childhood absence epilepsy, autosomal recessive pseudo Hurler polydystrophy and 
autosomal dominant Albers-Schonberg osteopetrosis type II (Cleiren et al. 2001; Li-
ang et al. 2007; Perez-Reyes 2006; Tiede et al. 2006). It is not clear, however, how 
haploinsufficiency would lead to the phenotypic features seen in ATR-16. Of the three 
patients described in this report, only one (P.V.) suffers from epilepsy, while the others 
do not. No other features typical for pseudo-Hurler or Albers-Schonberg disease are 
seen in the ATR-16 patients described. Members of a Tryptase precursor gene family 
(TPSG1, AB1, B2 and D1) are located between 1.21 and 1.26 Mb, and are believed to 
play a role in the pathophysiology of the polygenic disorder of asthma (Pallaoro et al. 
1999). Also in P.V. and H.N. asthma was reported, supporting the assumed involve-
ment of the Tryptase family genes. Of the other genes in this region, such as C1QTNF8, 
UBE2I, BAIAP3, IFT140, C16orf30 and CRAMP1L, only BAIAP3 is highly expressed 
in brain. This gene encodes a transmembrane protein, a member of the secretin recep-
tor family, which interacts with the cytoplasma specific angiogenesis inhibitor1 and 
may be involved in synaptic functions (Shiratsuchi et al. 1998). To determine how 
haploinsufficiency for these genes may be of influence on the intellectual development 
and variability of dysmorphic features seen in these patients, more deletions should be 
studied. 
 Some common features associated with ATR-16 include a severe delay in active 
language ability, downslant of the palpebral fissures, mild hypertelorism, a broad nasal 
bridge and small ears and a short neck with webbing. Most of these features are seen in 
two of our patients (P.V. and H.N.), who are considered monosomic for the telomeric 
deletion on chromosome 16p. On the other hand, patient F.T. who has a deletion 
length similar to H.N. shows much less pronounced dysmorphic features presumed to 
be characteristic for ATR-16, which subscribes the variability in expression of this syn-
drome. All patients have at least one common feature measurable at the hematological 
level, i.e. a0-thalassemia. Nevertheless only F.T. was recognized as a possible ATR-16 
syndrome at the hematological level, because of a persistent microcytic hypochromic 
anemia at normal ferritin levels. The other two patients (P.V. and H.N.) were identified 
by MAPH screening using subtelomeric probes and mapped in detail by MLPA in the 
present study. Because dysmorphic features associated with ATR16 are not always very 
specific, we would like to plead for incorporating a simple hematological test if ATR-
16 is suspected and, when positive, recommend a molecular screening using the 62 
MLPA probes as described in this study. 
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 Ultimately cloning of the breakpoint and subsequent sequence analysis is the only 
way to determine the nature of the deletion found, e.g. healed telomere break, inter-
stitial deletion or translocation to another non-coding subtelomeric region (with the 
loss of the area involved in ATR16) and this will be subject for future study. On the 
other hand MLPA is a strong diagnostic tool in determining whether a genomic region 
is deleted, the extent of the deletion and the location of breakpoints. Because MLPA 
employs standard technology operational in most diagnostic laboratories, it is highly 
suitable for rapid testing for these disorders, which are believed to be under diagnosed 
(Daniels et al. 2001; Wilkie et al. 1990a). 
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Molecular karyotyping by array-based techniques represents a giant leap forward com-
pared to microscopic metaphase banding. We compared the performance of four dif-
ferent array based platforms to identify and map the breakpoints in four patients with 
different interstitial 2p deletions, all localised within 2p16.1-p21. Currently, there are 
two main array formats, array-CGH and SNP-based. For array-CGH the probes used 
are (3K–32K) genomic clones or up to 244K oligonucleotides, with the size and num-
ber determining the resolution of analysis. SNP arrays, containing 10K–1000K loci 
have proven to facilitate, in addition to genome-wide association studies, the detection 
of deletions and duplications. The resolution of these arrays depends on the number of 
SNP loci present and on their distribution across the genome. 
 In this study, the platforms used include a 3K large genomic insert clone array, a 
44K (long oligo) microarray and two SNP- based arrays (250-500K, and 317K). Our 
analysis showed that the size of the 2p deletions varied, from ~10.6Mb in patient 1, 
to ~2.4Mb in patient 4. The minimum region of overlap of the deletions was ~1.3Mb 
encompassing 8 genes. The MSH6 gene was deleted in minimally three out of four 
patients, indicating that they have a 60-90% chance of developing colon carcinoma. 
No clear genotype/phenotype correlation emerged from the comparison of the four 
patients.
 Comparing cross-platform the breakpoint mapping gave similar results in the ma-
jority of cases. 
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introduction 
For decades trypsin Giemsa banding of metaphase spreads has been the standard di-
agnostic method to detect chromosomal rearrangements. The method has several ad-
vantages; all chromosomes are seen under the microscope, and individual cells can be 
karyotyped, permitting clonal analysis1,2 and the study of mosaicism. A major limita-
tion is the fact that due to the contraction of chromosomes during metaphase and the 
resolution of the light microscope, G banding is not capable of identifying rearrange-
ments smaller than 3-5 Mb. 
 Fluorescence in Situ Hybridization (FISH)3,4 partly overcomes this problem, allow-
ing direct testing for the presence, absence or amplification of specific genomic regions. 
This method is especially used for the confirmation of microdeletion syndromes and 
the analysis of potential subtelomeric rearrangements. FISH analysis can also be used 
for the detection of mosaicism to a very low level, depending on the number of cells 
analysed. However, it has several drawbacks, as detecting rearrangements using FISH 
analysis is only possible when cells are available, an obvious, specific phenotype is pres-
ent that is recognized by a specialist, and when a specific FISH probe exists. Finally, 
although multi-colour methodologies have been developed5,6,7 the number of loci that 
can be analysed simultaneously is limited. 
Recently, array-based technologies have been developed that provide both genome-
wide and high resolution analysis. In contrast to FISH, where fragments of DNA are 
labeled and hybridized to chromosome spreads, array-based approaches label genomic 
DNA, which is then hybridized to DNA spotted on a solid support, typically a glass 
slide. The size of the DNA probe and the number of probes on the array determine the 
resolution of analysis. 
 The first arrays used relatively large DNA fragments (~150 kb) isolated from Bac-
terial Artificial Chromosome (BAC) or P1 derived Artificial Chromosome (PAC) 
clones.8-10 A newer format uses oligonucleotide probes of 25 to 60 nt in length.11,12 
Due to the smaller size of these probes and the much larger number of loci analysed, it 
is possible to detect much smaller copy number variations (CNVs) with greater preci-
sion compared to those that can be revealed using BAC-PAC clone arrays. The 25-mer 
probe arrays were originally designed for SNP analysis. However, they were quickly 
used to estimate copy number changes by using both signal strength and allele scoring. 
Initial studies used the Affymetrix 10K array, which demonstrated the principle that 
the arrays could provide quantitative data.13 Subsequent work has taken advantage of 
144
Chapter 3
higher resolution chips, currently up to 500-1000K.14 In practice, these arrays have an 
effective resolution below 10 kilobases. However, despite their extremely high resolu-
tion, it should be noted that these tools can not be used to detect copy neutral rear-
rangements like translocations and inversions.
In this study, we have analysed four patients with different sizes of interstitial 2p dele-
tions, all localised within the chromosome region 2p16.1-p21. We have compared 
different platforms for identifying the deletions as well as their ability to define break-
points. In addition, we have collated and compared the clinical data of these patients. 
It appears that psycho-motor delay is the only common clinical feature that corre-
sponds to a deletion within this area.
methods
Array- Comparative Genomic Hybridisation (Array-CGH)
The array-CGH procedures were performed as previously described.15 The clones were 
provided by the Wellcome Trust Sanger Institute (UK), and information regarding the 
full set is available at the Ensembl web site.
 The array contained ~3500 large genomic insert clones spaced at ~1 Mb intervals 
over the genome, meaning that the resolution of the array varies between 0.2-3 Mb. 
Profiles were displayed by using the Log(2) ratio of test and reference sample. The 
thresholds were set at -0.3 and 0.3. BACs with a Log(2) ratio outside this interval were 
considered to be altered.15,16
Agilent microarray
Agilent Human Genome CGH Microarrays consist of ~44,000 60-mer oligonucle-
otide gene focused probes that span coding and non-coding sequences with an average 
spatial resolution of ~35 kb. Both genes with known function and hypothetical genes 
were included in the array. We used a loop-hybridisation design to analyse six DNA 
samples, including three patients with an interstitial 2p deletion. In a loop hybridisa-
tion design DNA sample 1 and 2 are differently labelled (Cy5 and Cy3, respectively) 
and subsequently hybridised on the same array. The second array includes DNA sam-
ple 2 and 3 that are labelled using Cy5 and Cy3, respectively. In this way, one sample 
is hybridised twice on an independent array in two different colors (= dye swap), en-
abling its own internal quality control. Arrays were hybridised according to the recom-
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mendations of the supplier (www.agilent.com). Data were analysed using the Agilent 
CGH Analytics 3.4 software with a moving averaging window of 1Mb. The size of the 
three different deletions was calculated using the Log(2) ratio. The thresholds were set 
at -0.3 and 0.3.
Affymetrix 500K Genechip
The Genechip Human Mapping 500K array set was used. The procedure was per-
formed as described in the Affymetrix GeneChip Human Mapping 500K Manual 
(http://www.affymetrix.com). The set comprises two SNP arrays contain ~250.000 
25-mer oligonucleotides each. Using this protocol, the human genome is cut by re-
striction enzymes (NspI and StyI); one restriction enzyme is used per array, enabling 
the analysis of 250,000 loci. The use of a second restriction enzyme is necessary for the 
analysis of another 250,000 loci. For data analysis, DNA-Chip Analyzer (dChip) soft-
ware (version release 02-16-06) was used.17,18 Regions of copy number gain and loss 
were detected using the hidden Markov model output of dChip. The thresholds for 
this platform were set between 1.6 and 2.4 using a linear scale, in where 2.0 represents 
two copies of a given locus.11,19
Illumina 317K beadchip
The Illumina humanhap 317K genotyping beadchip work up has been performed 
as suggested by the manufacturer (www.illumina.com). The SNP array consists of 
317,000 25-mer oligonucleotide probes. For data analysis, the beadstudio data analysis 
software provided by Illumina was used.
 In this platform, the regions for CNVs are detected based on the LogR ratio. This 
tool combines data of both heterozygosity (SNP call) and signal strength. The thresh-
olds were set at -0.3 and +0.3. In addition to the Log R ratio, the data analysis software 
also provides B allele frequency, Loss of Heterozygosity (LOH) and Copy number 
(CN) score. 
Patient samples
The four patient samples were gathered from the Netherlands (patient 1), Canada 
(patient 2), Brazil (patient 3) and Italy (patient 4), respectively. Two of them have been 
described previously.20,21
 The DNA of the patients was applied to each platform once, except for the Agilent 
array (due to the dye swap procedure). This study was approved by the Institutional 




Initial chromosome analysis of patient 1 did not reveal any abnormalities. However, 
by using both Multiplex Amplifiable Probe Hybridisation (MAPH)22 and 3K array-
CGH, it was possible to identify a deletion of chromosome region 2p16.2-p21. Retro-
spective analysis of the karyogram (G-banding) did detect the interstitial 2p deletion. 
The banding pattern of the short arm of chromosome 2 of this patient was compared 
to that of the previously described patient with a deletion within this region,20 and was 
found to be similar (data not shown).
 To study deletions in this region and their phenotypic consequences in more detail, we 
collected DNA from three additional patients with overlapping interstitial 2p deletions. 
These DNA samples were hybridised on four different array platforms to test the perfor-
mance of these platforms and to map the deletion breakpoints as precisely as possible.
Table 1. Overview of the BAC array results.
Intnl Clone name Chrom. Patient 1 Patient 2 Patient 3 Patient 4 
RP11-204D19 2     
RP11-24I5 2     
RP11-421J10 2     
RP11-27C22 2     
RP11-110G2 2     
RP11-1084a21 2     
RP11-436K12 2     
RP5-960D23 2     
RP11-19A8 2     
RP11-436L21b 2     
RP11-436L21 2     
RP11-460M2 2     
RP11-319N5 2     
RP11-5M9 2     
RP11-391D19 2     
RP11-389K20 2     
RP11-335O22 2     
RP11-7H13 2     
RP11-508L23 2     
RP11-30C22 2     
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Platform 1: 3K BAC array
A summary of the results obtained by array-CGH analysis is shown in table 1. The 
deletion of patient 1 closely resembles that of patient 2 although it extends one cen-
tromeric BAC further. The deletion of patient 4 is the smallest. The minimal region 
of overlap is defined by the telomeric breakpoint of patient 3 and the centromeric 
breakpoint of patient 4 and it is estimated to be 1.4 - 1.5 Mb.
Figure 1.  The result of patients using Agilent microarray platform.
(A) Due to the dye swap, the deletion is depicted in two colors resulting in a symmetrical profile pattern. All genes 
localized within the deleted region are visualized using the Agilent software tool. The deleted region of patient 3 (B) and 
patient 4 (C) are outlined by the dashed line and the dotted line, respectively. For the size of the deletion see table 2. 
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Platform 2: 44K Agilent Technologies microarray
At the time this study was performed, the Agilent 44K oligo array was the only Agilent 
array available, covering only gene-based sequences of the human genome. Three of 
the four interstitial 2p deletions were tested using this oligo array (figure 1). Patient 2 
could not be tested, as there was not enough material available. 
 Due to the loop-hybridisation set up (see Material and Methods) in combination 
with a dye swap, the samples were effectively analysed in two independent hybridisa-
tions. The analysis maps the proximal breakpoint of patient 3 to the region between 
the NRXN1 and the ASB3 genes, a large region (2.8 Mb) devoid of known genes. 
Consequently, the estimation of this breakpoint might be less accurate. The results of 
this platform agree with the outcome of the array-CGH. Deletion size varied, from a 
maximum in patient 1 (10.6 – 10.7 Mb) to a minimum in patient 4 (2.4 – 2.7 Mb) 
(table 2). The size of the minimum region of overlap calculated based on the Agilent 
data is 1.6 Mb.
Platform 3: Affymetrix 250K / 500K Genechip 
Three out of four patients were analysed using a 500K Genechip (patients 1, 2, 4). 
Patient 3 was analysed only by the 250K Genechip using the NspI restriction enzyme 
(figure 2). Interestingly, the sizes of the deletions calculated based on 250K analysis 
were comparable with those obtained from the combined data of both arrays (500K) 
(data not shown), indicating that for the calculation of large CNV the use of only one 
restriction enzyme can be sufficient. 
 The minimal region of overlap between the different interstitial deletions on chro-
mosome band 2p is 1.2 Mb (table 2). 
Platform 4. Illumina 317K beadchip
The results obtained for all four patients are depicted in figure 2. The results regarding 
the sizes are in agreement with the results obtained using the other 3 platforms (table 2). 
The minimal region of overlap, based on the results of the beadchip, is 1.4 Mb.
discussion
In this study, different high resolution genome wide screening platforms were com-
pared, including array-CGH using large insert clones, the long-oligo array of Agilent, 
the Affymetrix Genechip and the beadchip of Illumina. The genechip and the bead-
chip are SNP based arrays and they both use short-oligos. 
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Figure 2.  The interstitial 2p deletion of the four patients analysed by Affymetrix 
genechip (left) and the beadchip of Illumina (right). 
The deletions of the different patients are shown separately. Patient 3 was only analysed using 250K NspI genechip. A 
normal copy number of two is represented by a copy number between 1.6 and 2.4 for the Affymetrix genechip or by a 
LogR ratio between –0.3 and +0.3 for the beadchip of Illumina. The vertical lines represent the size of the largest dele-
tion. In general, the variation of the data points obtained by the beadchip is larger than that of the genechip. Especially 
in patient 3, the difference in variation is remarkable. [See appendix: colour figures.]
 Comparing across platforms, we found that the localisation of both proximal and 
distal breakpoints was largely in agreement (table 2). Nearly all BACs that showed 
2 copies did not have overlap with regions that were deleted according to the results 
obtained by the SNP arrays and vice versa. One exception was the proximal breakpoint 
in patient 3 in which BAC RP11-7H13 should have been deleted according to the data 
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obtained by two SNP platforms. Notably, an ‘aberrant’ Agilent result was present at 
the same breakpoint as was the ‘aberrant’ BAC (proximal breakpoint in patient 3). In 
fact, the breakpoint mapping of the two array-CGH platforms was similar (breakpoint 
at ~52.8Mb), as was the outcome of both SNP platforms for the proximal breakpoint 
of patient 3 (localised at ~53.6Mb)(table 2). This might be explained by the difference 
in probe density near the breakpoints localised by the different platforms (see also 
Results). This idea is strengthened by the fact that, based on in silico data of the 244K 
array, (an improved version of the Agilent array), the number of oligonucleotides lo-
calised near the proximal breakpoint of patient 3 was significantly increased; 25 probes 
were localised within the breakpoint interval determined by the 44K array. The num-
ber of ‘extra’ probes present at the rest of the breakpoints defined by the 44K array is 
5-10. 
 There is also some discrepancy between the outcomes of the two SNP platforms. 
In general, the data obtained using the beadchip showed more variation in all patients 
compared to that of genechip (figure 2). The maximum number of SNPs that were in 
discordance between the two SNP arrays was five (the distal breakpoint of patient 3) 
(figure 3). These five SNPs are in a genomic region covering more than 100 Kb. The 
number of data points for both SNP based arrays is similar at this breakpoint (based 
on the Ensembl database) (figure 3), indicating that both SNP platforms should be 
equally informative. We do not have a satisfactory explanation for this difference. The 
other differences in breakpoint mapping between the two SNP based tools included 
either only one or two SNPs (distal breakpoint of patient 2 and 4) or the differences 
in localisation of the breakpoints were very small (proximal breakpoint of patient 4; 
breakpoint mapping difference 7 kb). The observed difference in breakpoint mapping 
can be related to the use of different scoring algorithms that differ between platforms. 
This indicates that sequencing of the breakpoints is still needed to obtain information 
about the exact localisation of the breakpoint.
 Patient 1, 3 and 4 did not show any copy number alterations outside chromosome 
region 2p16.2-p21. Patient 2, however, had a deletion on chromosome band 6q22.31 
of ~1.2 Mb in size. This was identified using the BAC-array (BAC clone RP11-475J3) 
and the two SNP-based platforms. It has previously been found within the healthy 
population23 and there are no known genes within the deleted region. It is therefore 
thought to be a neutral variant.
Currently, there is no golden standard available to determine which platform is the 
most accurate. It might be argued that high density SNP genotyping would be the 
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most appropriate to implement for the screening copy number alteration, as this tool 
offers the simultaneous measurement of copy number changes and copy-neutral loss 
of heterozygosity (i.e uniparental disomy). On the other hand, the SNPs have been 
selected based on criteria such as heterozygosity, confirmation with Hardy-Weinberg 
equilibrium. Although these features are important for association studies, where SNPs 
need to be informative, they are less critical for copy number analysis where even 
spacing is more important. Indeed, many regions prone to rearrangements (e.g. du-
plicons) are lacking or are underrepresented on these arrays, as the associated SNPs 
did not meet the required quality criteria. This is in contrast to array-CGH in which 
the location of the oligonucleotides is not limited to known SNPs, and, therefore, it 
is possible to analyse regions of the genome where no validated SNPs are available.24 
Calculating the spacing between the consecutive data points per platform within chro-
mosome region 2p16.2-p21, shows that the median spacing of genechip was 2.40 kb, 
with a maximum of 65.10 kb, the median spacing of the beadchip was 4.57 kb (with 
a maximum of 71.85 kb) and finally, that of Agilent using the 244K was 9.85 kb (with 
Figure 3.  Overview of the distal breakpoints of patient 1 and patient 3 defined by Agi-
lent, the Affymetrix genechip and the beadchip of Illumina.
The deleted region is depicted in red, whereas regions showing two copies are depicted in green. A green circle repre-
sents the last data point that showed a normal copy of two. A red circle represents the first data point that showed a 
deletion. 
The number of data points per platform is comparable at the location of the distal breakpoint of patient 1 and 3. In 
patient 1, the breakpoint mapping of all platforms is concordant. In contrast, there is a huge difference in breakpoint 
mapping in patient 3. According to the results obtained by Agilent platform, the distal breakpoint of the deletion is 
located 290-260K outside the most distal point of the picture (47,92 Mb) (green and red arrow). The results of the 
Affymetrix platform show that the deleted region starts more proximally at ~48.03Mb (black arrow). The beadchip of 
Illumina defines the distal breakpoint of the deletion between these two points. [See appendix: colour figures.]
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a maximum of 47.40 kb). Thus, although the median spacing of Agilent is the largest 
(as it is gene-based), this platform might be the most valuable tool for investigating 
CNVs, depending on the genome region of interest (based on the maximum spacing 
of the three platforms).
 Indeed, a previous study24 has shown that in addition to the SNP-arrays, array-
CGH analysis is required to cover all CNV regions in the human genome, with at least 
one third of CNVs >50 kb otherwise being missed. New arrays of both Affymetrix and 
Illumina are closing this gap by combining both SNP- and non-SNP probes on one 
array.
 The beadchip has several clear advantages over the genechip, such as a higher SNP 
call rate, which is important when the expected size of the CNV is small. In our study, 
about 5-10%, sometimes even more, of all SNPs on the Affymetrix platform could 
not be scored (data not shown), resulting in a significant reduction of its resolution. 
Of course, the cause of such reduction might lie in a suboptimal quality of the DNA, 
however the identical DNA was used on the Illumina arrays. In addition, the genechip 
needed two arrays (this experiment) for a resolution comparable to that of the bead-
chip, which is especially of interest for the detection of small CNVs, and nearly all 
steps of the Illumina protocol can be automated. At the time these experiments were 
performed, only Illumina provided customer friendly software. Recently, however, 
software enabling easy calculation of the data generated by Affymetrix has become 
available, demonstrating the fast adaptation of products and application within this 
field. An important argument in favor of the genechip is the fact that they have started 
to validate these arrays to allow implementation in a diagnostic setting. 
Looking at the breakpoints of the four patients, it can be concluded that the deletion 
of patients 1, 2 and 4 includes both the MSH2 and the MSH6 genes. The distal break-
point of patient 3 is localised within or nearby (depending on the platform applied) 
the MSH6 gene; the MSH2 gene is not deleted in patient 3. This means that at least 
three out of four patients have a twenty fold increased chance of developing colon 
cancer or other Lynch syndrome-related tumors25 compared to the healthy population. 
For this reason, it is of high clinical interest to diagnose the breakpoints of interstitial 
2p deletions. However, when comparing the phenotype of the four patients (table 3), 
the only feature in common is mental retardation, which is a non-specific feature of 
nearly all chromosome anomalies. The lack of a common phenotype could be due to 




 The minimum region of deletion overlap is localised between the distal breakpoint 
of patient 3 and the proximal breakpoint of patient 4. This region is ~1.3 Mb in size 
and encompasses 8 genes, from MSH6 to FSHR. So far, this region was not found 
altered among healthy individuals.24 The FOXN2 gene, located between MSH6 and 
FSHR might be of interest in relation to the phenotype of the patients. It is known 
that deregulation of FOX family genes can lead to congenital disorders in addition to 
its involvement in several types of cancer. Furthermore, the FBXO11 gene coding for 
F-box protein family, might be involved in some of the developmental anomalies, as it 
related to phosphorylation-dependent ubiquitination. Mutations within the LHCGR 
and the FSHR genes are related to aberrant external and/or internal genital organs. No 
mutations with specific pathogenetic consequences have been reported for the remain-
ing two genes (CCDC128, STON1).
Recently, the whole genome of Nobel laureate Jim Watson was sequenced (http://
www.ncbi.nlm.nih.gov/Traces/trace.cgi), revealing as much as 600,000 single nucleo-
Table 3.  Overview of clinical features of the four patients with different sizes of inter-
stitial 2p deletions.
Patient 1 Patient 2 Patient 3 Patient 4
Localisation 2p16.2-p21 2p16.2-p21 2p16.3 2p16.3-p21
Cytogenetically visible Yes Yes No No
De novo Yes Yes N.D. Father not tested 
Age of examination 6, 13, 36 months 5, 13.6, 17 month 7 years 37 years
Psychomotor delay Present Present Present Present
Length Short stature (-2 
SD)
Tall stature 75th percentile Short stature
Weight 10th percentile 95th percentile 50-75th percentile > 97th percentile
Size of skull < 25th percentile Microcephaly 50th percentile. < 25th percentile




Turricephaly Brachycephaly with 
narrow forehead









ity with tendency to 
dislocation, 
High arched, narrow 
palate oblong face, 
large mouth, thin 
upper lip
Colon cancer Too young Too young Too young Yes
N.D.: not determined
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tide variants that had not been reported before. The cost involved of this project was 
substantial and therefore this way of screening the human genome is not applicable on 
large scale yet. It can be expected, however, that affordable sequence-based whole ge-
nome genotyping will become possible within the coming two years. As a result, SNP 
typing and array-CGH will be superseded fairly soon by next generation sequencing. 
The first step towards the implementation of genome wide sequencing in a diagnostic 
setting would be to type “harmless” variations in a large group of normal individuals, 
since on average 1 in 1000 nucleotide on the human genome of a healthy individual 
varies. In addition, screening large cohorts of affected individuals with well-defined 
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We are currently able to apply genome-wide screening tools with an unprecedented res-
olution to detect progressively smaller variants. It can be argued that this will improve 
the basis of genetic counselling significantly, as the probability of finding variants that 
may be related to the impairment of development and health in a patient will increase, 
and more information can be given about recurrence risks. It also enables us to verify 
assumptions that were made long before karyotyping and molecular diagnostic tools 
were invented. In these early days, geneticists have categorised large patient groups as 
having a multifactorial cause for their developmental delay. With the identification of 
variants that show a clearly detectable, but incomplete association with MR, one can 
now ‘prove’ on a molecular basis that the assumptions made were correct. 
 Although the identification of new variants is gratifying, it is accompanied by a 
progressively more difficult task for the people working in human and clinical genetics. 
After the introduction of karyotyping, a relatively small number of heteromorphisms 
(e.g. variants not related to human disease) were recognised and documented. This is 
in contrast to the current situation, where the number of variants with an unknown 
contribution to genomic disorders is huge. It has recently become clear that, by zoom-
ing in on the human genome using array-based platforms, variations exist at an un-
expectedly high frequency among healthy individuals; as much as 12% of the human 
genome show CNVs that are probably not related to any clinical feature (Redon et al. 
2006). 
 So, the more we learn about the human genome, the more we are confronted with 
questions about the implications of new findings. Does it involve a disease-causing 
alteration or is it a neutral variant? 
 In many reports the authors have only considered de novo variants to be causative. 
As soon as it became clear that one of the parents carried the same CNV, as the one 
detected in the affected child, it was thought to be a neutral variant. This is not always 
a correct assumption, as familial variants might be related to genomic disorders due 
to phenotypic variability (Ullmann et al. 2007), the presence of an autosomal reces-
sive disorder (chapter III-2), or related to a deletion of an imprinted region that may 
be silent in one parent and disease-causing in the next generation. To complicate the 
picture even further, genetic disorders can also originate by a combination of two or 
more variations inherited from two parents, where each of which alone will not result 
in disease (Klopocki et al. 2007) (Lupski 2007). In addition, we can expect that some 
of the regions showing CNVs among healthy individuals contribute to genetic disease. 
This would indicate that CNVs present in regions described in the Human Variation 
database are not always neutral variants. In contrast, as pointed out in chapter I-5, the 
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finding of a de novo variation in an affected individual does not automatically mean 
that the alteration is disease causing. All these observations impact greatly on genetic 
counselling and this also underlines the main drawback of using the new platforms, 
as we sometimes lack the knowledge to adequately inform the patient and the family 
of the consequence of any finding. To resolve this, it is of great importance to collate 
CNV data in databases that are accessible to everyone working in this field. Two of 
such databases are available at this moment (ECARUCA and DECIPHER). 
 New tools for genome analysis reach the diagnostic laboratory at a quick pace. As 
a result, one can consider several technical approaches to help diagnose the patient 
with mental retardation and / or congenital malformation. In chapter II-3, we pro-
posed a strategy in which MLPA covering the chromosome ends and regions related 
to micro deletions/ duplications should be used first, and if uninformative be followed 
by whole genome analysis. As pointed out by Rauch et al. (2006), this first step will 
detect an aberration in 5-20% of the MR patients, depending on the criteria used for 
selection. Since these rearrangements are also readily detected by currently available 
genome-wide screening tools (arrays), the use of these arrays as a first step now seems 
a more logical way to go, if it is possible to implement this in the diagnostic setting. 
Due to the necessity of guaranteeing Standard Operating Procedures in the diagnostic 
laboratories, it is often difficult to implement the most recent technologies that have 
proven to be efficient in a research setting. The rapid evolution of technology demands 
constant adaptation from both the clinician (who has to explain the outcome of the 
screening towards the patient) and the laboratory (validation and implementation of a 
new technique) in order to continue applying state of the art diagnostic methods.
 At this moment, there is no golden standard available for determining which ge-
nome-wide screening platform provides the most relevant data for diagnostic purposes. 
The advantages of both CGH array based screening and high-density SNP genotyping 
have been discussed in section I.6.3.5. A recent study (Redon et al. 2006) has shown 
that in addition to the SNP-arrays, array-CGH analysis is required to cover all CNV 
regions in the human genome, with at least one third of CNVs >50 kb otherwise being 
missed. New arrays of both Affymetrix and Illumina are closing this gap by combining 
both SNP- and non-SNP probes on one array. In addition, Nimblegen now has a 42 
M non-SNP array available enabling the detection of variants as small as 500 bps.
Although we already struggle to arrive at correct and comprehensive interpretation 




Recently, the whole genome of Nobel laureate Jim Watson was sequenced, revealing 
as many as 600,000 variants that had not been reported before. The cost involved of 
this project was substantial and therefore this way of screening the human genome is 
not yet applicable on large scale. It can be expected, however, that affordable sequence-
based whole genome genotyping will become possible within the coming 2-5 years. As 
a result, SNP typing and array-CGH will be superseded fairly soon by next generation 
sequencing. The first step towards the implementation of genome wide sequencing 
would be increasing the knowledge about “harmless” variations in a large group of 
normal individuals, since on average 1 in 1000 nucleotides in the genome of a two 
healthy individuals varies. In addition, screening large cohorts of affected individu-
als with well-defined clinical features is essential to be able to interpret this new data 
(Ropers et al. 2007). 
 The possibility of ‘reading’ the whole human genome at the nucleotide level will 
also provide information about susceptibility for diseases that are not related to the 
patients’ reason for consulting a specialist. This issue should be discussed with the 
patient or the parents during the counseling prior to genome-wide testing. One might 
choose to communicate only the variants that are thought to be causally related to the 
patients’ phenotype or those that are well known to have a great potential influence 
on the patients’ health (for example inactivation of tumor-suppressor genes). Two ex-
amples of alterations in tumor-suppressor genes detected after screening the human 
genome for MR-related CNVs are described in chapter III-2 and III-4. The patients 
in chapter II-2, carrying an interstitial 2p deletion, have a high chance of developing 
a HNPCC related tumor, as the deletion includes the MSH6 gene. In chapter III-4, 
the mother and the maternal grandmother of the two index patients with Peters Plus 
syndrome were found to have a 1.5 Mb deletion encompassing a part of the BRCA2 
gene. Despite the fact that both women already developed breast cancer, they are now 
confronted with a high recurrence risk and a moderate increased risk of developing 
ovarian cancer. These ‘side effects’ of screening can’t be avoided. However, a positive 
consequence of this knowledge is the fact that these patients can now be included in a 
screening program. 
 In summary, we can conclude that the plasticity of the genome creates a conun-
drum of Babylonic proportions. Nevertheless, it is expected that the implementation 
of new screenings technologies will give greater insight into a range of genetic diseases, 
and will hopefully lead to a better understanding of the many different causes of intel-






For decades, trypsin Giemsa banding of metaphase spreads has been the standard di-
agnostic method to detect chromosomal rearrangements. The method has several ad-
vantages; all chromosomes are seen under the microscope, and individual cells can be 
karyotyped, permitting clonal analysis (Caspersson, Lomakka, and Zech 1972; Yunis 
1976). A major limitation is the fact that due to the contraction of chromosomes dur-
ing metaphase, and the resolution of the light microscope, G banding is not capable of 
identifying rearrangements that are smaller than 3-5 Mb. 
 Fluorescence in Situ Hybridisation (FISH) (Landegent et al. 1985) (Ried et al. 
1990) partly overcame this problem, allowing direct testing for the presence or absence 
of a specific genomic region. This method is especially used for the identification of 
micro deletion syndromes and subtelomeric rearrangements. It has several drawbacks 
though, as detecting rearrangements using FISH analysis is only possible when an 
obvious, specific phenotype is present that is recognized by a specialist, and when 
a specific FISH probe is available. Multi-colour methodologies have been developed 
(Knight et al. 1997) (Engels et al. 2003), however, the number of loci that can be ana-
lysed simultaneously remains limited. 
 Assays for gene copy number or gene dosage have long been utilized in the clinical 
molecular genetic laboratories. For many years, Southern blotting analysis (Southern 
1975) followed by densitometry was the main assay available to assess for a small 
number of copy number variations. The development of real-time Polymerase Chain 
Reaction (PCR), Multiplex Amplifiable Probe Hybridisation (MAPH) (Armour et al. 
2000) and Multiplex Ligation-dependent Probe Amplification (MLPA) (Schouten et 
al. 2002) allowed more widespread analysis of gene dosage. MAPH and MLPA are 
PCR-based methods to simultaneously determine the copy number of a large set, cur-
rently up to 60, of different chromosomal loci. The advantage of MAPH/MLPA com-
pared to other techniques, such as FISH, is that the resolution of detection is limited 
only by the size of the probes used (100-500 bp) and it facilitates the parallel screening 
of several tens of patients at many different loci in one experiment. 
 Chapter II-1 describes the use of MAPH probe sets covering different genomic 
loci, including subtelomeric regions, regions involved in microdeletion syndromes and 
a set of genes evenly spread through out the rest of the genome. Using these probe sets, 
184 mentally retarded patients were screened. Results included the detection of rear-
rangements in subtelomeric and pericentromeric regions, as well as several interstitial 
alterations, indicating that submicroscopic alterations with a higher frequency were 
not limited to the ends of the chromosomes. 
 In Chapter II-2, a MAPH assay was designed containing exon-specific single copy 
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sequences from within a selection of the 169 regions flanked by duplicons that were 
identified, at a first pass, in 2001. Subsequently, the frequency of chromosomal re-
arrangement among patients with mental retardation (MR) and/or congenital mal-
formations (CM) was determined. The same study population was tested for rear-
rangements in regions with no known duplicons nearby, using a set of probes derived 
from function-selected genes. As expected, the alteration frequency per unit of DNA 
is much higher in regions flanked by duplicons (fraction of the genome tested: 5.2%) 
compared to regions without known duplicons nearby (fraction of the genome tested: 
24.5%). Thus, the data supported the emerging hypothesis that regions flanked by 
duplicons are enriched for copy number variations.
 Recently, technologies have been developed that provide both genome-wide and 
high resolution analysis. The first arrays used relatively large fragments of DNA (~150 
kb) isolated from mainly Bacterial Artificial Chromosome (BAC) (Solinas-Toldo et al. 
1997; Pinkel et al. 1998; Snijders et al. 2001). A newer format uses oligonucleotide 
probes of 25 to 60 nt in length. Due to the smaller size of these probes and the much 
larger number of loci analysed, it is possible to detect much smaller copy number varia-
tions (CNVs) compared to the variations that can be revealed using BAC-PAC clone 
array. The 25-mer probe arrays were originally designed for use in genome-wide SNP 
analysis, for linkage and association studies. As successive arrays have provided ever 
increasing coverage, currently up to 500-1000K, they were quickly used to estimate 
copy number changes by using both the signal strength and SNP score. The 60 nt oligo 
based arrays give stronger signal intensity and CNVs can therefore be detected using 
solely the signal intensity.
 To assess the value of MLPA and array based techniques in clinical diagnosis, 58 
developmentally delayed (DD) patients with a normal karyotype were independently 
tested with both array-CGH and MLPA. The results are described in chapter II-3. It 
shows that both methods are effective and represent an improvement to classical and 
molecular cytogenetics, as currently applied. Considerations balancing cost-efficiency 
and complexity promote a format where MLPA screening precedes array-CGH analy-
sis. In addition, an alternative screening strategy, encompassing MLPA testing prior 
to karyotyping for unselected samples is described. However, at this moment, whole 
genome array analysis has become affordable, making MLPA analysis as a first step not 
necessary anymore.
 Chapter III-1 highlights the value of using different genomic approaches to un-
ravel chromosomal alterations and their phenotypic impact. Albeit was possible to 
identify a previously unreported rearrangement within the 22q11 region, e.g. a dele-
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tion of the proximal part of chromosome band 22q11. It is argued that a deletion in 
this chromosome band is unrelated to the phenotypic trait seen in the index patient. 
The other chromosome 22 homologue carries a duplication of the Velocardiofacial/Di-
George syndrome (VCFS/DGS) region. In addition, a previously undescribed deletion 
of 22q12.1, located in a relatively gene-poor region, was identified.
 Chapter III-2 describes the identification of the gene involved in Peters Plus syn-
drome. This shows how the application of new techniques leads to the identification 
of the pathogenetic mutations of this autosomal recessive syndrome.
 Chapter III-3 shows that MLPA testing is capable of fine mapping the breakpoints 
of different interstitial 16p deletions. As the clinical features are not very distinctive, 
the screening of the ATR-16 region in patients presenting with mild to moderate MR 
and microcytic hypochromic anemia with normal ferritin levels is proposed.
 Finally, four platforms (a 3 K BAC clone array, a 44 K microarray and two SNP- 
based arrays (250-500K, and 317K) have been compared for their ability to identify 
the breakpoints in four patients with different sizes of interstitial 2p deletions, all lo-
calised within 2p16.1-p21(chapter II-4). All platforms identified the deletion and the 
results were comparable cross-platform. 
 It is evident that the genome-wide high resolution arrays provide an enormous 
improvement of the resolution of chromosome analysis. However, preliminary studies 
indicate that the extent of ‘normal’ copy number variation in the human genome may 
amount to at least 12 % (Redon et al. 2006). This percentage is still rather small com-
pared to the number of variants that will be revealed using next generation sequencing. 
This sequence-based whole genome genotyping of a patient will soon be possible on 
a large scale. Consequently, the problem we are now facing with CNVs based on the 
outcome of array screening will be amplified substantially. Collecting data of sequence 
variation in very large groups of healthy individuals as well as of well-characterised 
patients will be needed to understand the results in the near future. 







In 1956 werd door Tjio en Levan het correcte aantal chromosomen in een menselijke 
cel gepubliceerd (n = 46). Op basis van deze bevinding werd een techniek ontwikkeld 
om chromosomen nader te onderzoeken; karyotypering met behulp van de de lichtmi-
croscoop (Caspersson, Lomakka, and Zech 1972; Yunis 1976). Een andere belangrijke 
doorbraak was de ontdekking van de Fluorescent In Situ Hybridisation (FISH) techniek 
(Ried et al. 1990; Landegent et al. 1985). Dit maakte het mogelijk om gericht relatief 
kleine veranderingen in het erfelijk materiaal van de mens te identificeren. Het werd 
echter duidelijk dat deze microscopische technieken beperkingen kennen, arbeidsin-
tensief en kostbaar zijn. De belangrijkste beperking is dat veranderingen in het erfelijk 
materiaal kleiner dan 5-10 miljoen bouwstenen (= megabasen=Mb) zonder duidelijke 
specifieke klinische kenmerken bij een patiënt niet kunnen worden gediagnosticeerd. 
In de afgelopen jaren is een scala aan moleculaire technieken ontwikkeld met een ho-
gere resolutie in vergelijking met karyotypering. Aanvankelijk gaven multicolour en 
multiprobe FISH uitkomst, echter deze technieken zijn niet in staat om veranderingen 
in het erfelijk materiaal kleiner dan ~2 Mb op te sporen (figuur 3). Southern blotting 
(Southern 1975) en Pulse field gel electrophoresis (PFGE) (van Ommen et al. 1986; 
Den Dunnen et al. 1987) zijn wel in staat deze submicroscopische veranderingen te de-
tecteren, echter zij zijn arbeidsintensief en hebben een lage doorvoersnelheid. In 2000 
en 2002 werden, respectievelijk, Multiplex Ampliable Probe Hybridisation (MAPH) 
(Armour et al. 2000) en Multiple Ligation-dependent Probe Amplification (MLPA) 
(Schouten et al. 2002) technieken geïntroduceerd. Deze, op kwantitatieve PCR-geba-
seerde, technieken zijn in staat om met een zeer hoge resolutie (overeenkomend met 
de probe lengte ~100-500 baseparen) meerdere plaatsen op het genoom te testen op de 
aanwezigheid van kopie-verschillen bij 96 patiënten in één reactie. 
 Hoofdstuk II-1 en hoofstuk II-2 beschrijven twee studies waar gebruik is gemaakt 
van de MAPH techniek. De MLPA techniek is in deze studies gebruikt voor de verifi-
catie van de gevonden veranderingen. In hoofstuk II-1 worden de ‘chromosoom-eind’ 
en interstitiële veranderingen (verandering binnen het chromosoom) samengevat, die 
gevonden zijn na het testen van 184 patiënten met een verstandelijke beperking. Ruim 
4% van deze studiepopulatie had een verandering aan het einde van de chromosomen. 
Een onderverdeling in patiënten met een verstandelijke beperking met en zonder aan-
vullende dysmorfe / aangeboren afwijkingen resulteerde in de conclusie dat de kans op 
het vinden van veranderingen aan het einde van de chromosomen het grootst is bij pa-
tiënten met aanvullende afwijkingen. Deze bevinding is in overeenkomst met data uit 
de literatuur. Daarnaast werd met een relatief klein aantal geteste interstitiële gebieden 
(n = 112, inclusief gebieden die gerelateerd zijn aan microdeletie syndromen), zeven 
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veranderingen gedetecteerd. Dit bevestigde het idee dat het voorkomen van submi-
croscopische veranderingen in het erfelijk materiaal niet beperkt is tot de uiteinden van 
de chromosomen, maar dat overal langs de armen van de chromosomen afwijkingen 
kunnen ontstaan.
 Hoofdstuk II-2 beschrijft de bevindingen van het testen van stukken genoom die 
geflankeerd worden door segmentale duplicaties. Dit zijn stukken erfelijk materiaal 
met een zeer hoge homologie (volgorde van de bouwstenen zijn vrijwel gelijk), waar-
door ongelijke paring gevolgd door ongelijk ‘overstappen’ tot kopie-verschillen kunnen 
leiden (figuur 2A). Op basis van onze bevinding kon geconcludeerd worden, overeen-
komend met de data uit de literatuur, dat kopie-verschillen vaker voorkomen tussen 
deze zogenaamde homologe gebieden dan elders in het genoom. 
 Ondanks dat MAPH, maar vooral MLPA momenteel wordt toegepast in meer-
dere, vooral Europese, diagnostische laboratoria voor het opsporen van veranderingen 
in vele verschillende genen, zijn zij niet in staat om genoom-breed te screenen op de 
aanwezigheid van mogelijke kopie-verschillen. Array-gebaseerde technieken (BAC-, 
oligo- en SNP arrays) zijn wel in staat om in één proef het gehele erfelijk materiaal van 
een patiënt te testen, waarbij de resolutie afhangt van wat aangebracht is op de array. 
De resolutie van deze technieken neemt steeds verder toe. Recent zijn SNP-gebaseerde 
opsporingstechnieken beschikbaar gekomen. Dit maakt het niet alleen mogelijk om 
naar kopie-verschillen te zoeken, maar ook naar verlies van heterozygositeit (diversiteit 
in het erfelijk materiaal) of naar niet-Mendeliaanse overerving te kijken. Gezien het 
feit dat het toepassen van karyotypering en genoombrede technieken met een hoge 
resolutie aanvankelijk relatief duur waren, is in hoofdstuk II-3 een alternatieve ma-
nier van testen voorgesteld. Deze houdt in dat met behulp van MLPA, de plaatsen op 
het erfelijk materiaal getest worden, waarvan bekend is dat ze frequent veranderingen 
laten zien (bij een bepaalde studiepopulatie), alvorens genoombreed getest wordt. Ka-
ryotypering wordt alleen verricht voor een geselecteerde patiëntengroep die bij MLPA 
en genoombrede technieken geen verandering liet zien of voor het uitsluiten van een 
Robertsoniaanse translocatie (versmelting tussen de centromeren van twee chromoso-
men, die geen functionele korte arm hebben). Ondertussen zijn de kosten van array 
onderzoek substantiëel gedaald, waardoor de MLPA stap vóór het uitvoeren van array 
gebaseerde technieken niet meer noodzakelijk is.
 Op basis van de resultaten die beschreven staan in hoofstuk III-1 kan geconclu-
deerd worden dat verschillende technieken, zoals MAPH/MLPA-, FISH analyse en 
array gebaseerde technieken, elkaar aanvullen in plaats van dat ze ‘concurrenten’ zijn. 
In dit hoofdstuk wordt duidelijk dat de verschillende aspecten van een gecompliceerde 
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herrangschikking op een chromosoom slechts gedefiniëerd kon worden door het toe-
passen van meerdere technieken. Deze complexe herrangschikking bleek te bestaan uit 
een deletie en een duplicatie in het 22q11 gebied op twee verschillende chromosomen 
22, gecombineerd met een tweede deletie die verderop op de lange arm van het chro-
mosoom was gelocaliseerd. Daarnaast werd op basis de bevindingen in deze studie 
beargumenteerd dat een deletie dichtbij het centromeer van chromosoom 22 (het Cat-
eye syndroom gerelateerd gebied), waarschijnlijk niet gerelateerd is aan een klinisch 
beeld.
 In hoofdstuk III-2 beschrijven wij hoe de toepassing van een hoge resolutie tech-
niek (array-CGH) heeft geleid tot de identificatie van de oorzaak van het Peters Plus 
syndroom, een zeldzame ernstige aandoening. Dit is de eerste autosomaal recessieve 
aandoening die is opgelost door toepassing van array-CGH.
 Hoofdstuk III-3 beschrijft het inzoomen van een gebied op de korte arm van chro-
mosoom 16 dat verantwoordelijk is voor het ATR-16 syndroom (Alpha Thalassemie 
Retardatie syndroom, waarvan de oorzaak op het 16e chromosoom is gelegen). Met be-
hulp van 3 kleuren MLPA werd het ATR-16 gerelateerde gebied nader gespecificeerd. 
Aangezien de klinische kenmerken van de ATR-16 patiënten weinig specifiek zijn, 
wordt aangeraden om bij een patiënt met een verstandelijke beperking en bloedar-
moede een eenvoudig hematologische test te laten verrichten. In geval van een micro-
cytaire hypochrome anemie (specifieke vorm van bloedarmoede) met een normaal ijzer 
gehalte kan gericht moleculair diagnostisch onderzoek (MLPA) naar ATR-16 worden 
aangevraagd.
 De toepassing van vier hoge resolutie technieken voor de identificatie van de breek-
punten in vier verschillende patiënten met overlappende deleties op de korte arm van 
chromosoom 2 is beschreven in hoofdstuk III-4. De resultaten van de verschillen-
de technieken waren vergelijkbaar. Door de toepassing van de nieuwe hoge resolutie 
technieken wordt de resolutie van de chromosoom analyse sterk verbeterd. Echter, de 
eerste publicaties benadrukken het frequente voorkomen van kleine kopie-verschillen 
bij gezonde mensen (Iafrate et al. 2004; Sebat et al. 2004; Redon et al. 2006). Met 
behulp van array-CGH en SNP arrays werd vastgesteld dat geveer 12% van het hu-
mane genoom ‘onschuldige’ kopie-verschillen kan bevatten. Dit is nog maar een klein 
deel van de variatie die in het humane genoom wordt aangetroffen bij vergelijking op 
sequentie-niveau. Recent is de volgorde van de bouwstenen van het erfelijk materiaal 
van één persoon gepubliceerd, namelijk die van de Nobelprijswinnaar James Watson. 
Dit onderzoek leverde 600.000 niet eerder gerapporteerde veranderingen op. Dit illu-
streert dat genoombreed sequencen (het bepalen van de volgorde van het gehele erfelijk 
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materiaal van de mens) het probleem van de interpretatie van de resultaten bij men-
sen met een aandoening exponentiëel zal vergroten ten opzichte van de ‘onbekende’ 
veranderingen waar we nu mee geconfronteerd worden. Het is daarom van zeer groot 
belang om eerst veel kennis op te doen over de variaties in het erfelijk materiaal bij 
grote groepen gezonde mensen en daarnaast over variaties die voorkomen in patiënten 
met een goed gedefiniëerd klinisch beeld (Ropers 2007).
 Bij vele patiënten wordt nu een oorzaak gevonden voor hun verstandelijke beper-
king, waar dit vroeger niet mogelijk was. Om echter alle gegevens, die door de nieuwe 
technieken beschikbaar komen, goed te interpreteren, is veel werk nodig. Uiteindelijk 
kan onze kennis van het menselijke genoom zodanig toenemen dat wij per bouwsteen 
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N.B.:   Please, send this form as attachment to 
 K.Szuhai@lumc.nl and M.Kriek@lumc.nl
Patient for MAPH and/or Array-CGH screening
Date of birth: …… / …… / ……..
DNA number /Isolation number: D..   / …. D1. ……………
Gender: M / F
Severe developmental delay   YES / NO
Mild developmental delay YES / NO
Dysmorphic features: YES / NO
Please, list:
(Multiple) Congenital Abnormalities (MCA) YES / NO 
Please, list
Heart defects present: YES / NO
Positive family history: YES / NO
If yes, please specify
Consanguinity:  YES / NO
Perinatal onset growth retardation: YES / NO
Previously tested for:
• Karyotyping:  YES / NO P-number:
• Fragile X YES / NO
• microdeletion syndrome YES / NO
Outcome:
MAPH screening :  YES / NO
CGH screening:  YES / NO 





p. 14 and 15
A. Part of the long arm of the right chromosome is missing. The loss of genomic material is called a deletion. 
B.  A part of the short arm of the chromosome is present twice (right). This extra material is called a duplication. As 
the duplicated region is localised within the chromosome, this duplication is called an interstitial duplication.
C.  The amount of genetic material in part C of this picture is similar to the unaffected left chromosome. However, 
a part of the chromosome is inverted. As the centromere is localised within the invertion, this situation is called a 
pericentromeric inversion.
D.  Again the amount of genetic material is normal, however, a part of the information of the dark grey chromosome 
has been transported to the light grey chromosome and vice versa. This is called a balanced translocation.
E.  Non allelic homologous recombination. The two alleles of a chromosome contain regions that are highly homolo-
gous (e.g. segmental duplications, low copy repeats or duplicons). The presence of these segmental duplications 
can result in misalignment of these regions and subsequently in non allelic homologous recombination. The green 
arrow shows the origin of a duplication of the region present between two highly homologous regions, whereas the 
red arrow indicates the origin of a deletion.
F. In this situation a part of the left chromosome is inserted in another chromosome. This is called an insertion.
Figure 1. Deletion, duplication, inversion and balanced translocation. 




Figure 3.  Current standard 
cytogenetic 

















Figure 4. Identification of the parental origin of an allele. 
A. Different VNTR lengths in both parents present on a specific region in the human genome. B.
B.  One of the children has the identical combination of VNTR lengths as one of its parents. Uniparental disomy (of 
genetic material from the parent with identical VNTR lengths) or a deletion present at the allele inherited from 
the ‘other’ parent should be considered. Picture derived from www.geninfo.no.
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Figure 1.  Results of case 3. 
The plots correspond to the MAPH results showing (A) a deletion of the DRG2 gene, two normal copies of COPS3A 
(RAI1 not present), and the MLPA results; and (B) a deletion of RAI1, a deletion of DRG2, and a normal ratio of 
COPS3A. (C) The additional FISH analysis using the LSI-SMS probe specific for the Smith Magenis chromosomal 
region shows a normal signal on the short arm of only one copy of chromosome 17. 
Case 3
This boy was seen by a clinical specialist at the age of
2.5 years for his psychomotor retardation and joint hyper-
flexibility. Physical examination showed few dysmorphic
features (a tent shaped mouth), hypotonia, and hypermobi-
lity. MAPH analysis revealed a de novo deletion within
chromosome band 17p11.2 corresponding to the Smith-
Magenis syndrome (SMS) region, using a probe for the DRG2
gene (LocusLink: 1819). The more distally located COPS3 gene
(LocusLink: 8533) showed two copies (fig 1a). Additional
MLPA testing showed that the RAI1 gene (LocusLink: 10743)
was also deleted in this patient (fig 1b), and FISH analysis
(probe LSI-SMS) verified the deletion of part of chromosome
band 17p11.2 (fig 1c). Recently, three dominant frameshift
mutations in RAI1 have been identified in three patients with
phenotypic characteristics of SMS but no cytogenetically
detectable deletion of chromosome band 17p11.2.18 The
authors argue that mutations in RAI1 are responsible for
most of the characteristic features of SMS and that further
variation is caused by hemizygosity of the other genes in the
chromosome region.
Case 4
This male patient showed at the age of 12 years a mild
learning disability, a low voice, a disproportionally short
stature (height 22 SD, span 23 SD for height, sitting height
20.5 SD, head circumference 22 SD), limited elbow
extension, a permanently extended, inflexible fifth digit of
both hands with a ram’s horn shaped nail and hypotrophy of
the hypothenar muscles (fig 2), and a short broad great toe
on both feet. The hand x ray revealed short metacarpals I and
V, short distal phalange V, and a delay of bone maturation. In
this patient, a de novo deletion of 4q34.1 was detected and
confirmed by FISH (probe RP11-475B2). Analysis with a
more distally located MAPH probe at chromosome band
4q35.1 showed that this latter region was still present,
indicating an interstitial rearrangement. Additional FISH
experiments using different BAC probes limited the deletion
to a maximum of 3 Mb (data not shown).
Patients with an interstitial 4q deletion have been
described with a range of features, depending on the
proximal and distal breakpoints of the deletion.19 As it is
known that fifth finger anomalies and short stature are
found in patients with an interstitial deletion of 4q including
4q34,20 as well as in patients with a terminal deletion of 4q, it
is possible that the genes responsible for these features are
located within this region.
Figure 1 The plots correspond to the MAPH results showing (A) a
deletion of the DRG2 gene, two normal copies of COPS3A (RAI1 not
present), and the MLPA results; and (B) a deletion of RAI1, a deletion of
DRG2, and a normal ratio of COPS3A. (C) The additional FISH analysis
using the LSI-SMS probe specific for the Smith Magenis chromosomal
region shows a normal signal on the short arm of only one copy of
chromosome 17.
Figure 2 The right hand of case 4 showing a short, inflexible fifth digit
with a ram’s horn shaped nail and hypotrophy of the hypothenar
muscles.
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Figure 3.   Facial dysmorphism 
of case 6. 
Note the microcephaly, ptosis of the left eye, 
flat philtrum, and thin upper lip. 
chaPter iii-1 
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Figure 2  Picture of the proband. 
Note the microcephaly, myotonic facial expression, the proptosis of 




Figure 6.  FISH analysis of chromosome 22. 
A A partial metaphase of the patient, hybridised with the telomere probe RP11-3018K1 (green; chromosome region 22q13), 
N25 (red; VCFS/DGS region) and RP11-66F9 (green; CES region). On the right chromosome, green signals of RP11-
3018K1 (telomeric side of chromosome 22) and a red signal N25 corresponding to the VCFS/DGS region are present; 
however, the signal of RP11-66F9 is lacking, indicating a deletion of the CES region. On the left chromosome, in addition 
to the green signals of RP11-3018K1, a red signal corresponding to the VCFS/DGS regions and a green signal correspond-
ing to the CES region are both present. These latest two signals are partly overlapping. On this chromosome, the signal of 
N25 is stronger than the signal on the right chromosome, suggesting a duplication of the VCFS/DGS region. These findings 
are confirmed by the result of the interphase nucleus depicted in part b of this figure. B The different chromosomes 22 are 
marked 1 and 2. The signal of LSI ARSA, corresponding to the telomeric side of chromosome 22, is indicated with a blue 
arrow. The red arrow indicates the N25 signal (corresponding to the VCFS/DGS region), which is duplicated in chromo-
some 22 nr.1 (two red signals). The green arrow indicates the signal of RP11-66F9 (corresponding to the CES region). This 





Figure 1.  Overview of the location of the mutations in the B3GALTL gene and the 
results of the RT-PCR of RNA isolated from fibroblasts. 
A, Genes present in the 1.5-Mb deletion found in two brothers with Peters Plus syndrome. B, 15 exons of the B3GALTL 
gene, with the localization of the mutations. C, B3GALTL protein, which consists of a transmembrane region (TMR), a 
stem region (SR), and a catalytic domain (CD). Both mutations (c.1020 1GrA and c.437 5GrA) are located in the stem re-
gion. D, Result of the nested RT-PCR of exons 7–11 of the BGALTL gene, with RNA derived from myoblasts (WT), RNA 
from fibroblasts of a father heterozygous for the c.1020 1GrA mutation (Het), and RNA from fibroblasts of his affected son 
with c.1020 1GrApat/delmat (Hom). The patient shows a smaller band compared with the WT band, which indicates a 
skip of exon 8. Sequence analysis of this band is shown. The vertical line indicates the end of exon 7 and the beginning of 
exon 9. The RT-PCR of the father shows, in addition to the WT band, a skipped product with much less intensity. E, Result 
of the RT-PCR encompassing exons 4–7 of the BGALTL gene, with RNA derived from lymphocytes of a control individual 
(WT) and a patient with a c.1020 1GrAmat/c.437 5GrApat genotype (Het). In addition to a faint WT band, the patient 




Figure 2. Facial features of four patients with Peters Plus syndrome. 
Patients A and C are homozygous for the c.1020+1GA mutation. Patient B has the c.1020+1GAmat/c.437+5GApat 
genotype, and patient D has the c.1020+1GApat/delmat genotype. Note the Peters anomaly of the eyes, the long face, 
and the Cupid’s bow shape of the upper lip in all patients. Patients B and D have a repaired cleft lip and/or palate. 





Figure 1. Three unrelated patients.
H.N. (a), P.V. (b) and F.T. (c) showing a mild mental retardation (IQ 50–60), a severe delay in active language ability, 
some typical facial features like downslanted palpebral fissures, mild hypertelorism, a broad nasal tip and small ears and 
a short neck with webbing, which is most pronounced in a and b. Patient H.N. and P.V. both show pectus carinatum. 
This was also observed for patient F.T. (not shown). H.N. also has an operated clubfoot on the left, while patient P.V.’s 
right foot is turned inside, the other foot showing a cafe´-au-lait spot. c Patient F.T. has a short neck and small ears. On 
the outer right a photograph is shown of the patient at age 11. The karyotype was normal in all patients and hemato-




Figure 2  Schematic presentation of short arm of chromosome 16 (16p13.3), showing 
a 2 Mb region from the telomere containing the a-globin gene cluster up to 
the TSC and PKD genes. 
The arrows and numbers represent the location of the probes. The deletions found by MLPA are shown as bars below 




Figure 1.  The result of patient 1 using the Agilent microarray platform. 
(A) Due to the dye swap, the deletion is depicted in two colors resulting in a symmetrical profile pattern. All genes 
localized within the deleted region are visualized using the Agilent software tool. The deleted region of patient 3 (B) and 




Patient 1; 317 K beadchip 
Patient 2; 317 K beadchip 
Patient 3; 317 K beadchip 
Patient 4; 317 K beadchip 
Patient 1; 500 K genechip 
Patient 2; 500 K genechip 
Patient 3; 250 K genechip 
Patient 4; 500 K genechip 
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Figure 2.  The interstitial 2p deletion of the four patients analysed by Affymetrix 
genechip (left) and the beadchip of Illumina (right). 
The deletions of the different patients are shown separately. Patient 3 was only analysed using 250K NspI genechip. A 
normal copy number of two is represented by a copy number between 1.6 and 2.4 for the Affymetrix genechip or by a 
LogR ratio between –0.3 and +0.3 for the beadchip of Illumina. The vertical lines represent the size of the largest dele-
tion. In general, the variation of the data points obtained by the beadchip is larger than that of the genechip. Especially 









Figure 3.  Overview of the distal breakpoints of patient 1 and patient 3 defined by Agi-
lent, the Affymetrix genechip and the beadchip of Illumina.
The deleted region is depicted in red, whereas regions showing two copies are depicted in green. A green circle repre-
sents the last data point that showed a normal copy of two. A red circle represents the first data point that showed a 
deletion. 
The number of data points per platform is comparable at the location of the distal breakpoint of patient 1 and 3. In 
patient 1, the breakpoint mapping of all platforms is concordant. In contrast, there is a huge difference in breakpoint 
mapping in patient 3. According to the results obtained by Agilent platform, the distal breakpoint of the deletion is 
located 290-260K outside the most distal point of the picture (47,92 Mb) (green and red arrow). The results of the 
Affymetrix platform show that the deleted region starts more proximally at ~48.03Mb (black arrow). The beadchip of 
Illumina defines the distal breakpoint of the deletion between these two points. 
